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This dissertation is the result of research that was carried out at the Laboratory of Clinical 
Pharmacology and Therapeutics, Faculty of Medicine, University of Lisbon, and at the 
Joaquim Ferreira Lab (Farmacologia Clínica), Instituto de Medicina Molecular, Lisboa, 
Portugal.  
The overarching goal of this series of projects was to increase the knowledge and emphasize 
the importance of oral anticoagulants, particularly in conditions such as atrial fibrillation (AF). 
The projects were directly supervised of Professor Joaquim Ferreira (Head of the Laboratory 
of Clinical Pharmacology and Therapeutics, and Clinical Pharmacology Unit) and Professor 
Fausto Pinto (Head of the Cardiology Department at CHLN (Centro Hospitalar Lisboa 
Norte), Head of the CCUL (Centro Cardiovascular da Universidade de Lisboa), and Dean of 
the Faculty of Medicine, University of Lisbon. 
This dissertation is written in English, with an extended summary in Portuguese, as predicated 
in Regulamento de Estudos Pós-graduados da Universidade de Lisboa published in Diário da República, 
2.ª série - N.º 57 - 23 de Março de 2015, as well as the rules for presentation of PhD dissertation 
thesis of Faculdade de Medicina da Universidade de Lisboa  
 
This dissertation is divided into six chapters: an introductory chapter; an elaboration of the 
original research projects, organized into four chapters corresponding to the main fields of 
clinical pharmacology at a population level (pharmacoepidemiology; drug safety aspects such 
as comparative effectiveness research focusing on safety and pharmacovigilance; and 
pharmacoeconomics); and a final chapter with discussion and conclusions applying to the 
body of work. 
Each individual research project has a Background, Methods, Results, and Conclusions, which 
are discussed in the end of each chapter. 
Regarding the specific chapter contents, the first chapter is an overall introduction to the 
principles of thrombosis, oral anticoagulants, the main indications for oral anticoagulation, 
principles of population clinical pharmacology, an identification of gaps in the evidence 





The second chapter presents an overview of the pharmacoepidemiology of oral 
anticoagulants. This includes quantitative elements, namely the proportion of patients treated 
with oral anticoagulants, using atrial fibrillation as the reference therapeutic indication, and 
qualitative elements, namely a measure of disease control, and an evaluation of prescription 
patterns among Portuguese patients, particularly using Vitamin K Antagonists (VKA). The 
prescription of oral anticoagulants in Portugal was assessed over time in order to determine 
the impact of non-vitamin K antagonist oral anticoagulants (NOACs). 
 
In the third chapter, the safety issues (both bleeding and non-bleeding adverse events) of 
NOACs and VKA were scrutinized through systematic reviews and meta-analyses of 
randomized controlled trials. Tolerability and acceptability (drug discontinuation) were 
additionally evaluated in this comparative effectiveness/safety chapter. 
 
In the fourth chapter the safety of oral anticoagulants from a pharmacovigilance perspective 
were appraised. The safety evaluation of the oral anticoagulants was not restricted to the 
controlled setting (RCTs) but also included ‘real world’ observational research. The data 
presented in this chapter come from spontaneous reports of adverse drug reactions with oral 
anticoagulants in Portugal were analyzed in order to complement the evaluation from the 
RCTs. 
 
The fifth chapter presents a pharmacoeconomic analysis of oral anticoagulants, with AF as the 
reference condition in terms of burden, cost, and cost-effectiveness of the different oral 
anticoagulants. 
 
In the sixth and final chapter, the findings and their implications for clinical practice and 
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Oral anticoagulant drugs are essential in the treatment and prevention of thromboembolic 
events in certain prothrombotic conditions. Atrial fibrillation is the most prevalent arrhythmia, 
and is the main indication for chronic oral anticoagulation due to its thrombotic 
complications. Vitamin K antagonists (VKA) were until recently the only therapeutic options 
of this class in Portugal, namely in the form of warfarin and acenocoumarol. Despite proven 
efficacy, VKAs have a large pharmacodynamic variability owing to multiple potential 
interactions with food and other drugs. The development of the non-vitamin K antagonist 
oral anticoagulants (NOACs; apixaban, dabigatran, edoxaban, and rivaroxaban) increased the 
therapeutic armamentarium for anticoagulation. NOACs act directly by blocking thrombin or 
factor Xa, and exhibit an antithrombotic effect at least as effective as VKAs. Since the myriad 
of interactions found with VKAs are absent in NOACs, the anticoagulant effect is predictable, 
and does not require serial evaluations of hemostasis, making NOACs more convenient for 
patients and clinicians. Thus, it is reasonable to expect that NOACs may be prescribed often 
than VKAs. However, the approval of NOACs was based on phase III randomized controlled 
trials (RCTs), which are seldom planned to evaluate the safety of interventions. Additionally, 
NOACs are costlier than VKAs, raising the question of whether these new anticoagulants 
promote health gains at a sustainable cost to the Portuguese society. Therefore, it is important 
to better characterize the oral anticoagulants with a focus on NOACs in the population-level 
clinical pharmacology, namely pharmacoepidemiology, safety aspects of the oral 
anticoagulants (comparative safety and pharmacovigilance) and pharmacoeconomics. 
 
OBJECTIVES 
The aim of this dissertation was to improve the knowledge related to the oral anticoagulants in 
the four main fields population-level clinical pharmacology: pharmacoepidemiology, 
comparative effectiveness/safety, pharmacovigilance, and pharmacoeconomics. 
 
Specific objectives: 
1) Pharmacoepidemiology: To assess the state of oral anticoagulation in Portugal, in 
terms of proportion of non-anticoagulated patients, the quality of anticoagulation, and 





2) Comparative effectiveness/safety research: To evaluate the safety of NOACs, based 
on clinical trials’ data, in terms of bleeding and non-bleeding adverse events, as well as 
the overall tolerability and acceptability of the drugs. 
3) Pharmacovigilance: To identify adverse events related to oral anticoagulants most 
frequently reported to Pharmacovigilance Units in Portugal. 
4) Pharmacoeconomics: To assess the cost and burden of AF in Portugal, and the relative 
cost-effectiveness of oral anticoagulants in Portugal. 
 
METHODS 
To achieve the objectives, the following research projects were conducted: 
1) Pharmacoepidemiology: A systematic review and meta-analysis of all published studies 
in Portugal assessing the prescription/use of oral anticoagulant therapy in patients 
with AF; 
A retrospective observational study of a cohort of patients treated with VKAs for 
assessment of anticoagulation control quality through the Rosendaal Time in 
Therapeutic Range (TTR); 
A retrospective observational study of national outpatient prescribing oral 
anticoagulants, with characterization of the number of boxes sold and Defined Daily 
Dose (DDD, a standardized measure of the World Health Organization) prescribed 
for each group of drugs. 
2) Comparative effectiveness/safety research: Systematic review and meta-analyses based 
on aggregated data of phase III RCTs of NOACs compared to VKAs, for bleeding 
events, overall tolerability, and acceptability; and NOACs compared to all available 
comparators for non-bleeding adverse events. The data were pooled using a random-
effects model, and expressed as relative risk (RR) with a confidence interval of 95% 
(95%CI). 
3) Pharmacovigilance: A retrospective observational study of spontaneous reports related 
to oral anticoagulants, received by the National Pharmacovigilance System in Portugal. 
4) Pharmacoeconomics: A study concerning the cost of illness and burden of AF, and a 
cost-effectiveness study of oral anticoagulants in Portugal for AF were performed. To 
the burden of disease assessment, disability-adjusted life years (DALYs) related to the 
AF were estimated, as well as both the direct (inpatient and outpatient) and indirect 
(lost productivity) associated costs. To evaluate the cost-effectiveness, a Markov 




gains associated with NOACs were estimated and weighed through the Incremental 
Cost Effectiveness Ratio (ICER), which evaluates the cost of each Quality-Adjusted 
Life Years (QALY) gained for a given intervention in relation to the control 
intervention (VKAs and all NOACs). 
 
RESULTS 
1) About 60% of patients with AF in Portugal were not treated with oral anticoagulants, 
and oral anticoagulation with VKAs had a suboptimal control with a mean TTR of 
61%, according with the single-centre retrospective study. Since the introduction of 
NOACs in the Portuguese market, the number of pack and DDD of oral 
anticoagulants prescribed increased significantly, this rise being due to NOACs. 
Currently the NOACs as pharmacological group have most of the market share of oral 
anticoagulants. 
2) In the pooled safety data from phase III RCTs, NOACs were associated with a 
decreased risk of major bleeding (RR 0.72; 95% CI: 0.61 to 0.84; 12 RCTs), fatal 
bleeding (RR 0.52; 95% CI: 0.65 to 0.41; 12 RCTs) and ICH (RR 0.43; 95% CI: 12.36 
to 12.51; 11 RCTs) compared to the VKA. Regarding major gastrointestinal, 
intraocular, and pericardial bleeding, there was no increase in the risk of these events. 
The NOACs are not associated with liver injury (RR 0.93; 95% CI: 0.75 to 1.15; 26 
RCTs) or severe renal impairment (RR 0.93; 95% CI: 0.82 to 1.05; 7 RCTs). Similarly, 
there was no increased risk of infections or insomnia. 
The overall risk of serious adverse events was significantly decreased by NOACs 
compared to VKAs (RR 0.96; 95% CI: 0.94 to 0.98; 5 RCTs). The results for 
acceptability (drug discontinuation) were heterogeneous. However, for most NOACs 
the risk of treatment discontinuation due to drug-related or patient-related reasons 
were not increased compared to the VKAs in AF patients. 
3) The Pharmacovigilance study data showed that most the reported adverse events were 
related to NOACs (78%). About 25% of these events were related to bleeding and 
10% related thromboembolic events. The annual number of notifications has been 
increasing, but when adjusted to the degree of drugs exposure, the peak incidence was 
in 2012, with a subsequent decrease. 
4) AF has an important burden in Portugal contributing to the yearly loss of 23084 
DALYs and expenses of 141 million € (57% in direct costs and 43% in indirect costs). 





thromboembolic events in non-valvular atrial fibrillation. In the presented model, 
apixaban was shown to be cost-effective compared to warfarin (ICER €5529/ QALY) 
and dabigatran (ICER €9163/QALY), and dominant compared to rivaroxaban.  
 
CONCLUSIONS 
The proportion of patients receiving oral anticoagulant treatment is increasing in Portugal, 
mostly due to NOACs. These drugs have an acceptable safety profile, with an improvement of 
the risk of fatal and serious bleeding events, particularly intracranial hemorrhage, without 
substantial increase in other non-bleeding events, including hepatic, renal, or infectious. The 
risk of adverse events is generally lower, and most NOACs do not show an increased risk of 
discontinuation. Although most adverse events reported to the National Pharmacovigilance 
system are associated with the NOACs, the number of events since the increase in drug 
exposure has declined. 
Atrial fibrillation, the main indication for oral anticoagulation, has an important burden, with 
costs related to the disease that account for about 0.1% of gross domestic product of 
Portugal. The NOACs use for stroke prevention in AF is cost-effective compared with VKAs. 
 
 









Os anticoagulantes orais são essenciais no tratamento e prevenção de eventos 
tromboembólicos. A fibrilhação auricular (FA) é a arritmia mais prevalente e constitui a 
principal indicação para anticoagulação oral crónica para prevenção das suas complicações 
tromboembólicas. Até recentemente, os antagonistas da vitamina K (AVK), representados em 
Portugal pela varfarina e pelo acenocumarol, eram as únicas opções entre os anticoagulantes 
orais. Apesar da sua comprovada eficácia, verifica-se uma grande variabilidade no efeito 
farmacodinâmico devido às múltiplas interacções com outros fármacos e com os alimentos. O 
desenvolvimento e aprovação dos anticoagulantes orais independentes da vitamina K 
(NOACs; apixabano, dabigatrano, edoxabano e rivaroxabano) aumentaram as opções 
terapêuticas entre os anticoagulantes orais. Estes novos fármacos bloqueiam directamente a 
trombina ou o factor Xa e apresentam um efeito antitrombótico pelo menos tão eficaz como 
os AVK. Uma vez que o seu efeito anticoagulante é previsível, sem a multiplicidade de 
interacções que os AVK possuem, os NOACs não necessitam de avaliações seriadas da 
coagulação, sendo mais convenientes para os doentes e profissionais de saúde. Por estes 
motivos, é expectável que os NOACs venham a ser mais prescritos. Contudo a aprovação dos 
NOACs baseou-se nos ensaios clínicos controlados e aleatorizados (RCTs) de fase III, que 
raramente são planeados para avaliar a segurança das intervenções. Adicionalmente estes 
fármacos têm um preço superior aos AVK, pelo que é essencial determinar se esta nova classe 
de anticoagulantes orais condiciona ganhos em saúde a um custo sustentável para a sociedade 
portuguesa. 
Logo, é importante caracterizar os anticoagulantes orais com especial interesse nos NOACs 
nas principais áreas da farmacologia clínica a nível populacional: farmacoepidemiologia, 
aspectos relacionados com a segurança dos fármacos (segurança comparativa e 
farmacovigilância) e farmacoeconomia. 
 
OBJECTIVOS 
O principal objectivo desta dissertação foi melhorar o conhecimento sobre os anticoagulantes 
orais nas quatro principais áreas da farmacologia clínica populacional: farmacoepidemiologia, 







1) Farmacoepidemiologia: Avaliar o estado da anticoagulação oral em Portugal, em 
termos de proporção de doentes não-anticoagulados, a qualidade da anticoagulação e 
evolução do padrão de prescrição. 
2) Efectividade/segurança comparativa: Avaliar a segurança dos NOACs, baseada em 
dados de ensaios clínicos, no que diz respeito a eventos hemorrágicos, não 
hemorrágicos e tolerabilidade global, assim como a aceitabilidade destes fármacos. 
3) Farmacovigilância: Identificar os eventos adversos relacionados com os 
anticoagulantes orais mais frequentemente reportados às Unidades de 
Farmacovigilância de Portugal. 
4) Farmacoeconomia: Avaliar o custo e a carga da FA em Portugal e o estudo 
comparativo de custo-efectividade dos anticoagulantes orais em Portugal. 
 
MÉTODOS 
Para o cumprimento dos objectivos foram executados os seguintes projectos: 
1) Farmacoepidemiologia: Revisão sistemática com meta-análise de todos os estudos 
publicados em Portugal que avaliaram o uso ou prescrição de anticoagulantes orais em 
doentes com FA; 
Estudos observacional retrospectivo de um coorte de doentes tratados com AVK, 
para avaliar a qualidade do controlo da anticoagulação através do parâmetro Time in 
Therapeutic Range (TTR) estimado através do método de Rosendaal. 
Estudo observacional retrospectivo da prescrição nacional de anticoagulantes orais em 
ambulatório, com caracterização do número de caixas vendidas e Doses Diárias 
Definidas (DDD: Defined Daily Dose, uma medida padronizada da Organização 
Mundial de Saúde) dispensadas para cada grupo de fármacos. 
2) Efectividade/segurança comparativa: Revisões sistemáticas com meta-análise dos 
RCTs de fase III comparando os NOACs com os AVK, para eventos hemorrágicos, 
tolerabilidade global e aceitabilidade, e dos NOACs com todos os comparadores 
disponíveis para os eventos adversos não-hemorágicos. Os dados foram agregados 
utilizando o método de efeitos aleatórios e expressos em risco relativo (RR) com o 
intervalo de confiança de 95% (IC95%). 
3) Farmacovigilância: Estudo observacional retrospectivo das notificações espontâneas 
relacionadas com os anticoagulantes orais, recebidas pela Sistema Nacional de 




4) Farmacoeconomia: Estudo de custo e carga da FA e estudo de custo-efectividade 
relativa dos anticoagulantes orais em Portugal. Para a carga da doença foram estimados 
os anos de vida ajustados à incapacidade (disability-adjusted life years: DALYs) 
relacionados com a FA, os custos directos (internamento e ambulatório) e os custos 
indirectos (perda de produtividade) associados. Para avaliação do custo-efectividade 
relativa dos NOACs comparativamentes com os AVK foi utilizado um modelo de 
Markov com características ajustadas a Portugal. Foram ponderados os custo e ganhos 
em saúde, e a sua ponderação através do Incremental Cost Effectiveness Ratio (ICER), que 
avalia o custo de cada QALY ganho para uma determinada intervenção em relação à 
intervenção de controlo, que foram os AVK. 
 
RESULTADOS 
1) Até recentemente, 60% dos doentes com FA em Portugal não estavam tratados com 
anticoagulantes orais. Os dados do controlo da anticoagulação oral com AVK 
revelaram um controlo subóptimo com um TTR médio de 61%. Desde a introdução 
dos NOACs no mercado Português, o número de caixas e DDD de anticoagulantes 
orais aumentaram significativamente à custa destes fármacos. Actualmente os NOACs 
como grupo farmacológico têm a maioria da quota do mercado dos anticoagulantes 
orais. 
2) Em relação aos dados de segurança agregados dos ensaios clínicos, os NOACs 
estiveram associados a uma diminuição do risco de hemorragia major (RR 0.72, 95%CI: 
0.61 to 0.84; 12 RCTs), hemorragia fatal (RR 0.52, 95%CI: 0.41 to 0.65; 12 RCTs) e 
hemorragia intracraniana (RR 0.43, 95%CI: 0.36 to 0.51; 11 RCTs), comparativamente 
com os AVK. Em relação aos riscos de hemorragia digestiva major, intraocular e 
pericárdica, não houve aumento significativo destes eventos.  
Os NOACs não estão associados a lesão hepática (RR 0.93, 95%CI: 0.75 to 1.15, 26 
RCTs) ou lesão renal grave (RR 0.93; 95%CI: 0.82 to 1.05; 7 RCTs). De igual forma 
não houve aumento do risco de insónia ou infecções. 
O risco global de eventos adversos graves foi significativamente reduzido pelos 
NOACs comparativamente com os AVK (RR 0.96; 95%CI: 0.94 to 0.98; 5 RCTs). Os 
resultados para a aceitabilidade (descontinuação do fármaco) foram heterogéneos. No 
entanto para a maioria dos NOACs o risco de descontinuação terapêutica por motivos 
relacionados com os fármacos ou com o doente, não esteve aumentado 




3) Os dados do estudo de farmacovigilância demonstraram que a maioria dos eventos 
adversos notificados estavam relacionados com os NOACs (78%). Cerca de 25% 
desses eventos foram hemorrágicos e 10% tromboembólicos. O número anual de 
notificações tem vindo a aumentar, mas quando ajustadas ao grau de exposição dos 
fármacos, verificou-se um pico de incidência em 2012, com sucessiva diminuição 
desde então. Não foram identificados eventos não-expectáveis. 
4) Em Portugal, a FA apresenta uma carga importante, contribuindo para a perda anual 
de 23084 DALYs e custos aproximados de 141 milhões € (57% em custos directos e 
43% em custos indirectos).  
Os NOACs mostraram ser custo-efectivos comparativamente com os AVK para a 
prevenção de eventos tromboembólicos na FA não-valvular. No modelo apresentado, 
o apixabano mostrou ser custo-eficaz em relação à varfarina (ICER €5529/QALY) e 
ao dabigatrano (ICER €9163/QALY), e dominante em relação ao rivaroxabano.  
 
CONCLUSÕES 
A proporção de doentes tratados com anticoagulantes orais tem vindo a aumentar, 
essencialmente devido aos NOACs. Estes fármacos têm um perfil de segurança globalmente 
aceitável com redução do risco de eventos hemorrágicos fatais e graves, particularmente a 
hemorragia intracraniana, sem aumento substancial de outros eventos não-hemorrágicos, 
nomeadamente hepáticos, renais ou infecciosos. O risco de eventos adversos é globalmente 
inferior e a maioria dos NOACs não apresenta risco de descontinuação aumentado. Embora a 
maioria dos eventos adversos reportados ao Sistema Nacional de Farmacovigilancia esteja 
relacionado com os NOACs, o número de eventos ajustados ao aumento da exposição aos 
fármacos tem vindo a diminuir. 
A FA, principal indicação terapêutica para anticoagulação oral, tem um carga importante e 
custos que correspondem aproxidamente a 0.1% do Produto Interno Bruto de Portugal. O 
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1.1. Hemostasis and coagulation 
 
Thrombosis is a homeostatic and hemostatic essential process that leads to the formation of a 
clot plug that disables the leakage of blood from disrupted vessels. 
Hemostasis leads to the formation of a thrombus and is the results of the concerted actions of 




Figure 1: Physiologic hemostatic responses to vascular injury. 
 
 
The physiology of coagulation may be explained by two models: the coagulation cascade 
model; and the cell-based model. 
 
The classic coagulation cascade model is depicted in the Figure 2 and has three pathways: an 
extrinsic pathway, an intrinsic (or contact) pathway, and a final common pathway. 
The final common pathway starts with the conversion of the factor X to its active form (Xa). 
Factor Xa, factor V and calcium establish the prothrombinase complex. At this point it is 
estimated that one molecule of Xa in the prothrombinase complex leads to the formation of 
1000 thrombin (IIa) molecules1, from prothrombin (II). Thrombin leads to increased platelet 
aggregation1 and builds a plug of fibrin (activating the fibrinogen), furthermore promotes the 
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stability of the thrombus through the activation of XIII (to XIIIa) which covalently binds the 
fibrin molecules. Thrombin also promotes the activity of other coagulation factors (both from 
extrinsic and intrinsic pathways), inhibits the endogenous fibrinolytic system, and it is likely to 
have a role in inflammation/immunity2. 
Extrinsic pathway activation relies on the exposure of tissue factor (TF), which is 
constitutively expressed by vascular smooth muscle cells and adventitial fibroblasts, to factor 
VIIa in order to constitute the TF/VIIa complex, a major player in the activation of the 
common pathway by the formation of Xa factor. 
The intrinsic pathway is classically described as the coagulation process activated by the 
exposure of negatively charged surfaces to plasma. This trigger leads to the formation of a 
complex kininogen and prekalikrein and factor XII with the sequential activation of the 
factors XII, XI, IX. Factor IXa and its cofactor VIIIa form the tenase which activates the 
factor X into Xa for the final common pathway. 
 
 





The cell-based model is more contemporary, and undertakes the artificial division and step-
wise fashion of understanding of the coagulation process. This model takes into account the 
role of platelets in the process and considers all the pathways of the classical classification to 
CHAPTER I: OVERALL INTRODUCTION 
 
 13 
occur (almost) simultaneously. The cell-based model is characterized by the following phases: 
initiation, amplification, and propagation (Figure 3) 3,4. 
 
In the initiation, the complex TF/VIIa activates small amounts of factors IX, and X. The Xa 
and the available Va constitute the prothrombinase that activate of small amounts of 
prothrombin.  
The amplification phase is characterized by the prothrombotic effects of prothrombin: platelet 
activation and release of factor V from alfa-granules; splits factor VIII from von Willebrand 
factor and activates it to VIIIa, thus leading to an increased downstream of the coagulation 
process with the activation of tenase (IXa from initiation, Va and VIIIa from amplification). 
The propagation phase is characterized by a thrombin burst and requires that tenase complex, 
and prothrombinase complexes assemble in the platelet surface and generate further Xa and 
thrombin. At this stage, fibrinogen is converted to fibrin and stabilized through factor XIIIa.  
 
 
Figure 3: The cell-based model of coagulation. 
 
 
These endogenous procoagulant routes are counteracted and regulated by the intrinsic 
anticoagulant processes in order to prevent the continuous coagulation and to maintain de 
homeostasis. The main interveners are the antithrombin, thrombomodulin, protein C and S, 
tissue factor pathway inhibitor (TFPI), and the endogenous fibrinolytic system. 
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Antithrombin, a circulating glycoprotein produced by the liver, binds to free and biologically 
active coagulation factors, and in larger extent to thrombin (IIa). Tenase and prothrombinase 
complexes are not adequately inhibited by antithrombin. Thus, antithrombin is thought to be 
important to limit the coagulation process to the site of vessel injury. 
Thrombomodulin, a molecule expressed by endothelial cells, increases the rate of activation of 
protein C and its assembly with free protein S. Together protein C and S inhibit the factors 
VIIIa and Va, either free or as components of tenase and prothrombinase complexes, respectively. 
TFPI is inhibits the formation of Xa factor (with protein S), and in the presence of large 
amounts of factor Xa, acts as a negative feedback modulator of the tissue factor pathway 
inhibiting the TF-VIIa complex. 
The endogenous fibrinolytic system breaks down fibrin from clots through plasmin. Plasmin 
cleaves fibrin into fibrin degradation products. Thrombin inhibits the fibrinolytic system 
 
These mechanisms are impaired in some patients, leading thus to hemorrhagic or 
prothrombotic conditions. Prothrombotic conditions may require anticoagulant drugs to 
dissolve thrombus (e.g. venous thromboembolism) or to prevent thrombus formation (e.g. 
atrial fibrillation). 
 
Anticoagulant drugs may be classified according to the administration route: parenteral or oral. 
Parenteral anticoagulants include direct and indirect agents. Heparins (unfractioned and low-
molecular weight) and fondaparinux are indirect agents as they require antithrombin and 
enhance the antithrombotic effect of this molecule. Direct parenteral anticoagulants inhibit 
specific coagulation factors without any further mediator. Bivalirudin and argatroban interfere 
with thrombin, and factor Xa is inhibited by otamixaban. 
 
Due to the non-invasive nature of the administration route, oral anticoagulants are preferred 
for patients requiring medium- or long-term anticoagulation. 
Oral anticoagulants are nowadays classified as Vitamin K Antagonists (VKA) or Non-Vitamin 
K Antagonists Oral Anticoagulants.  
Vitamin K Antagonists include some drugs but in Portugal only warfarin and acenocoumarol 
are available. 
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As occurs with any new drug, anticoagulants are developed and studied in humans after their 
commercialization. Thus, it is important to further understand the principles of clinical 
pharmacology that mostly influence the approval and use of anticoagulants in the clinical 
practice. 
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1.2. Oral anticoagulants  
Oral anticoagulants’ classification can be divided into two classes according to the mechanism 
of action, i.e. if they depend or not of Vitamin K for the anticoagulant effect. 
 
1.2.1. Vitamin K Antagonists 
 
The Vitamin K Antagonists were, until recently, the only available oral anticoagulants. 
Nowadays there are different VKA (warfarin, acenocoumarol, phenprocoumon, fluindione), 
however only two of them are marketed in Portugal, warfarin (Varfine®) and acenocoumarol 
(Sintrom®). 
 
VKAs were discovered in North America in the first quarter of the 20th century, when cattle 
started to become with a hemorrhagic illness during a period of deep economic crisis. The 
responsible for this illness was a specific hay, the sweet clover hay, which becomes infected by 
fungi such as Penicillium, when it becomes more humid. Such conditions allowed the 
transformation of coumarin to dicoumarol, which given to the cattle led to hemorrhagic signs 
2 weeks after the ingestion, ending deadly in a period of 1-2 months 5,6. The coumarin 
derivatives were extensively studied in the Wisconsin University by the Wisconsin Alumni 
Research Foundation (WARF) and one them was found to be particularly hemorrhagic for rat 
poisoning purposes with a faster onset of action compared to dicoumarol6. This drug was 
named WARFarin, commercialized in the United States as Coumadin® when clinical 
applications were discovered, and worldwide spread afterwards.  
 
Vitamin K Antagonists can be classified as Coumarins or Indione derivatives. Warfarin, 
acenocoumarol and phenprocoumon are Coumarin derivatives. Fluindione and fenindione are 
Indadione derivatives. In Portugal, only warfarin and acenocoumarol are marketed. 
 
Vitamin K Antagonists inhibit the Vitamin K epoxide reductase complex subunit 1 
(VKORC1) (Figure 4). Vitamin K in the reduced form is a cofactor in the physiologic 
carboxilation of some coagulation factors produced in the liver such as II, VI, IX, C, protein 
C and S. VKAs inhibit the reduction of vitamin K and the substrate remains in the oxidized 
form disabling the adequate carboxylation of the referred factors through gamma-glutamyl 
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carboxylase (that requires reduced Vitamin K as a cofactor). Hence, coagulation factors are 




Figure 4: Mechanism of action of VKA (warfarin). 
 
 
Warfarin is a racemic mixture of R- and S-warfarin, but the anticoagulant effect is 
predominantely caused by S-warfarin.  On the other hand, the anticoagulation effect of 
acenocoumarol mainly depends on the R-enantiomer despite of S-enantiomer being more 
active due to its short half-life (1.8 h) compared to R-acenocoumarol (>6h)7,8.  
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The metabolism is mainly hepatic through CYP2C9 and the excretion remains majorly renal. 
The main pharmacologic properties of warfarin and acenocoumarol are depicted in Table 1. 
 
 










Warfarin 5 mg 100% >99% CYP2C9 40 h Renal 
(metabolites) 




* in Portugal; other countries may have pills with other dosages 
 
 
VKAs pharmacodynamics are not linear, i.e. the administered dose may not be proportional to 
the anticoagulants effect, due to many clinical and genetic factors. The International 
Normalized Ratio (INR) is the measure used to evaluate the anticoagulant effect of VKAs. 
INR is a standardized method that uses the prothrombin time (time to clot formation after 
adding calcium and a thromboplastin to citrated plasma) and adjusts the laboratory result 
according to the thromboplastin used, in order to get uniform results irrespectively of the used 
method (INR = [prothrombin time/mean of normal prothrombin time]International Sensitivity Index of 
Thromboplastin). 
 
According to indication, patients are required to maintain in a range of INR values (mostly 
between 2.0-3.0). Therefore, regular INR checks should be scheduled, in order to change 
VKA dose whenever the INR value is out of the therapeutic range. When patients reach a 
stable period (same dose and therapeutics INR values) follow up and INR checks can be done 
monthly. Patients out of therapeutic range require more evaluations. 
 
Up to 50% of the variability of warfarin maintenance dose may be attributed to genetic 
variation/polymorphism of CYP2C9 and VKORC112-14. However, baseline clinical conditions, 
acute illness and drug-drugs interactions play an important role on the inter-individual and 
intra-individual variability of the anticoagulants effect. 
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Due to previously mentioned reasons the response to VKAs has an important inter-individual 
and intra-individual variability. Patients are required to maintain as possible the maximum of 
time within therapeutic range, however it is not frequent. 
The most disseminated method to adequately estimate time in therapeutic range is the linear 
interpolation method of Rosendaal which assumes a linear variation of INR values between 
visits. It is accepted that a good quality of anticoagulation control is obtained when TTR>68-
70%. Lower values of TTR (≤58-65%) are deemed to disclose an absence of protective effect 
of VKA compared to other treatments15.  
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1.2.2. Non-vitamin K antagonist oral anticoagulants 
(NOACs) 
 
The Non-Vitamin K Antagonists Oral Anticoagulants include the approved drugs apixaban, 
dabigatran and rivaroxaban, and edoxaban (awaiting evaluation for reimbursement by the 
national regulatory agency). This group was initially known as New/Novel Oral 
Anticoagulants and the acronym NOACs stood still. Some years after the development and 
approval of some of these drugs, they are no longer considered to be new or novel. Some 
claimed that these drugs should be called as Direct Oral Anticoagulants (DOACs) or Target-
specific Oral Anticoagulants (TSOACs)16,17. In this thesis the acronym NOACs (from Non-
Vitamin K Antagonists Oral Anticoagulants) was conserved as it reflects the differences 
compared to the previous established oral anticoagulants (VKA) 18.  
NOACs selectively inhibit specific coagulation factors: dabigatran inhibits thrombin/IIa, Xa is 
inhibited by apixaban, edoxaban and rivaroxaban. 
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Table 2: Pharmacologic properties of NOACs 
 Apixaban Dabigatran Edoxaban Rivaroxaban 
Prodrug No Yes No No 
Mechanism of 
action 
Xa inhibitor IIa inhibitor Xa inhibitor Xa inhibitor 
Bioavailability 50% 3-7% 62% 66-100% 
Time to plasma 
peak  
1-4 hours 2 hours 1-2 hours 2-4 hours 
Half-life 12 hours 12-17 hours 9-11 hours 5-13 hours 
P-Glycoprotein 
transportation 











Minor CYP3A4  No Minor CYP3A4  CYP 3A4 and 
CYP2J2  
Renal clearance 27% 80% 35% 50% 
Doses for AF 
and VTE 
5 mg or 2.5 mg bid 150 mg or 110 
mg bid 
20 mg or 15 mg od; 
15 mg bid in the 
first 3 weeks of 
VTE treatment with 
anticoagulants 





















Kg; use of 
potent P-gp 
inhibitors  
* Dabigatran’s indication for 110 mg dose was retrieved from EU label. 
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Table 2 details some pharmacologic properties of NOACs 19,20. 
 
Their oral route and absence of regular hemostatic parameters evaluation represent an 
evolution of anticoagulant treatment compared to parenteral anticoagulants such as Low-
Molecular-Weight Heparin and VKA, respectively. 
 
NOACs were approved by the regulatory agencies based on the findings of large randomized 
clinical trials (RCTs) showing that NOACs are at least non-inferior to control (VKA or low 
molecular weight heparins (LMWH) or aspirin). Atrial fibrillation represents the condition of 
the majority of candidates for NOACs use, and considering the reimbursement of the 
dabigatran, rivaroxaban and apixaban (the NOACs reimbursed in Portugal) for that condition, 
it is expected that the number of patients treated with these drugs will exponentially rise.  
 
Antidotes specific for NOACs are also in development in order to further increase the 
healthcare and outcomes in bleeding patients. Idarucizumab is a humanized antibody fragment 
that binds to dabigatran and neutralizes its effect21,22. The first studies look promising although 
more data are required to ensure safety. Andexanet alfa is an antidote for Xa inhibitors and 
thus has the capacity to reversal the anticoagulant effects of apixaban, edoxaban and 
rivaroxaban23-25. Phase III study in patients treated with rivaroxaban is ongoing (ANNEXA-R 
trial, NCT02220725), while it is still just planned for edoxaban. The first phase III results for 
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1.3. Main indications for oral anticoagulation  
 
Oral anticoagulants prevent the formation of thrombi, and when thrombus or thrombi exist, 
these drugs prevent their expansion and also contribute to their resolution along with 
endogenous fibrinolysis. 
Overall, oral anticoagulants are licensed for the prevention of stroke and other 
thromboembolic events in atrial fibrillation and in patients with prosthetic heart valves; 
prevention and treatment of venous thromboembolic disease. Other indications correspond to 
rare diseases such as antiphospholipid syndrome or pulmonary arterial hypertension26, while in 
patients heart failure with low left ventricular ejection fraction no anticoagulant treatment 
should be prescribed in the absence of other indications27. 
 
The VKA treatment and INR target depends on the prothrombotic condition. In most 
conditions the INR target is 2.5 (range 2.0-3.0), but it can be higher in mechanical heart valves 
with additional clinical risk factors (Table 3). 
 
Table 3: INR target according to indication. 
Indication INR range or target 
Atrial Fibrillation 2.0-3.0 
Mitral stenosis with AF, thrombus or LA 
diameter>55mm* 
2.0-3.0 
Bioprosthetic valves in sinus rhythm 2.0-3.0 
Mechanical heart valves Medtronic Hall, St. Jude Medical, Carbomedics 
AVR: 2.5 (+0.5)* 
Bjork-Shiley and bileaflets: 3.0 (+0.5)* 
Omniscience, Starr Edwards: 3.5 (+0.5)* 
Venous thromboembolism 2.0-3.0 
Left ventricular thrombus 2.0-3.0 
* Suggested by the ACCP guidelines 
** In the presence of risk factors for thrombosis such as AF; mitral, pulmonary or tricuspid valve replacement; 
enlarged left atrium; spontaneous echo contrast; mitral valve gradient; or LV systolic dysfunction 
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NOACs were tested in many prothrombotic scenarios. These drugs were overall approved for 
non-valvular AF, treatment and prevention of VTE recurrence, thromboprophylaxis after 
elective hip or knee arthroplasty, and rivaroxaban 2.5 mg twice daily was approved for 
secondary prevention in patients in acute coronary syndromes (Table 4). 
 
Table 4: Main trials of NOACs according to indication and control group. 
Indication Main trials Control Approval by EMEA 
Non-valvular AF 
suitable for VKA 
Apixaban: ARISTOTLE 
Dabigatran: RE-LY 
Edoxaban: ENGAGE AF 
Rivaroxaban: ROCKET AF 
VKA Yes 
Non-valvular AF in 
patients unsuitable for 
VKA 




patients with MHV 
Dabigatran: RE-ALIGN (phase 
II RCT)* 
VKA No 
VTE treatment and 




COVER II, RE-MEDY 
Edoxaban: Hokusai-VTE 
Rivaroxaban: EINSTEIN trials 
VKA±LMWH Yes 
VTE prophylaxis after 
hip or knee arthroplasty 




Edoxaban: STARS trials 
Rivaroxaban: RECORD trials 
LMWH Yes 
VTE prophylaxis in 








Rivaroxaban: ATLAS ACS-2 
TIMI 51 
Placebo Only rivaroxaban 2.5 mg 
* Nearly 30% of the patients with mechanical heart valves had AF or atrial flutter. 
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1.3.1. Atrial fibrillation 
 
Atrial fibrillation, due to incidence, prevalence, and requirement of life-long anticoagulation in 
most of the patients, represents the condition owing the most important share of patients 
treated with oral anticoagulants. Therefore, atrial fibrillation was the target condition for most 
of the evaluations regarding the pharmacoepidemiology, safety and relative cost-effectiveness 
of oral anticoagulants. 
 
AF is an important risk factor for stroke and it is the most frequently determined mechanism 
for ischemic stroke.28,29  Over 15% of strokes are due to AF and they are generally more severe 
than those not related with AF.30,31 Stroke attributable to AF is associated with a 30-day 
mortality of 25% and one-year mortality of 50%.30 These patients have longer hospital stays 
and greater use of health resources compared to non-AF stroke patients.32,33 
 
This a cardiac arrhythmia characterized by the absence of organized atrial electric activity and 
subsequent atrial contractility. This leads to a blood stasis in the atrial chambers prone to 
thrombus formation in the atria and these thrombi are the cause of stroke in 2/3 of patients 
with AF34. 
 
The approach and management of AF patients require an accurate clinical and 
electrocardiographic diagnosis, and should further include the adequate assessment of 
symptoms, impact in quality of life and concomitant comorbidities. 
Treatment is mainly based on anticoagulant drugs (when indicated), choosing rate or rhythm 
control strategies, and optimization of comorbidities’ treatment. 
 
Oral anticoagulation is recommended for all patients with AF except those with very low 
thromboembolic risk. Patients with valvular AF (with significant mitral stenosis or mechanical 
heart valves) have a high thromboembolic risk, and should be treated with VKA (the only trial 
with NOACs in patients with mechanical heart valves – RE-ALIGN - showed increased risks 
of thromboembolic and hemorrhagic risks). Patients with non-valvular AF, require 
thromboembolic risk stratification. The CHA2DS2-VASc score allows the determination of the 
annual risk of thromboembolism (Table 5). Patients with CHA2DS2-VASc≥2 (annual risk of 
thromboembolic events ≥2%) should be anticoagulated. 
 




Table 5: Components of thromboembolic risk stratification score CHA2DS2-VASc. 
Clinical feature Points 
Congestive heart failure 1 
Hypertension 1 
Age (≥75 years) 2 
Diabetes 1 
Stroke or systemic 
embolism 
2 
Vascular disease 1 
Age (65-74 years) 1 
Sex category (female) 1 
 
 
Antithrombotic drugs in AF 
Stroke and systemic embolism are the main complications of AF. 
VKA were appraised in many trials in AF patients. VKA reduced the risk stroke compared to 
the absence of antithrombotic drugs and antiplatelet drugs. The pooled results of 6 RCTs with 
2900 patients determined a significant 64% stroke risk reduction with VKA compared to 
controls, and compared to antiplatelet drugs the dimension of stroke risk reduction was 22% 
(8 trials with 4876 patients).35 In comparative trials VKA had a pooled 39% reduction in 
stroke risk compared to antiplatelet drugs (12 trials with 12963 patients).35 A post-hoc analysis 
of Stroke Prevention in Atrial Fibrillation (SPAF) trials suggested that VKA reduces stroke 
risk, generally due to cardioembolic events, while acetylsalicylic acid mostly decreased the non-
cardioembolic strokes in AF patients.34 
The efficacy of VKA in AF was also stated in ACTIVE-W trial, where VKA reduced the risk 
of stroke compared to double antiplatelet therapy (acetylsalicylic acid and clopidogrel), with 
similar major bleeding risk.36 
 
More recently, NOACs challenged VKA, and stroke/systemic embolism risk was at least non-











Table 6: Pivotal trial of NOACs versus VKA in non-valvular AF 








18 201 patients 
with non-valvular 
AF 
18 113 patients with 
non-valvular AF 
21 105 patients 
with non-valvular 
AF 
14 264 patients with 
non-valvular AF 
Type of AF 
























significant mitral valve 
stenosis, prosthetic 
heart valves 
Mean age 70 years 72 years 71 years 73 years 
Mean CHA2DS/ 
CHA2DS2-VASc 
2.1 2.1 N/A 3.47 










Stroke and Systemic 
Embolism 
Mean TTR in 
VKA arm 






150 mg: 0.65 [0.52-
0.81]; 
110 mg: 0.90 [0.74-
1.10] 
60 mg: 0.87 [0.73-
1.04]; 






150 mg: 0.75 [0.58-
0.97]; 
110 mg: 1.13 [0.89-
1.42] 
60 mg: 1.00 [0.83-
1.19]; 







150 mg: 0.93 [0.81-
1.07]; 
110 mg: 0.80 [0.70-
0.93] 
60 mg: 0.80 [0.71-
0.91]; 
30 mg: 0.47 [0.41-
0.55] 
1.04 [0.90-1.20] 
* For ARISTOTLE and RE-LY the estimates are for ischemic and uncertain type of stroke. 
** Major bleeding defined according to ISTH. 
CI: Confidence Interval; HR: Hazard Ratio. 
 
 
In patients deemed to be unsuitable for VKA, acetylsalicylic acid has been taken as a valid 
option.37 Double antiplatelet therapy has shown to decrease the risk of major cardiovascular 
events, particularly stroke, but major bleeding rates were significantly higher.38 Thus the trend 
for adding clopidogrel on top of acetylsalicylic acid depends on individual 
ischemic/hemorrhagic assessment. More recently, AVERROES study (that was prematurely 
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halted due to the significance of differences found) showed that apixaban was superior to 
acetylsalicylic acid in the prevention of stroke or systemic embolism, without increasing the 
major bleeding risk.39 
Patients with mitral stenosis have been excluded from trials and NOAC treatment cannot be 
recommended for these patients with increased embolic risk. 
Patients with mechanical heart valves (with or without AF) are also considered out of the 
scope of NOACs due to the high thromboembolic risk retrieved from the phase II RCT RE-
ALIGN with dabigatran40. Labile inflammatory and prothrombotic post-operative state, 
because of platelet activation and tissue factor release from surgery, were suggested as possible 
explanations41,42. Therefore, NOACs are not indicated for valvular AF, particularly those with 
'mechanical and rheumatic mitral valvular AF', also termed MARM-AF, because patients with 
other forms of native valvular disease and bioprosthetic valves were already included in the 
main trials, and there was no safety warning regarding these conditions42. 
 
Atrial fibrillation in Portugal 
The management of stroke risk factors should be taken seriously, particularly in Portugal 
where stroke is a significant cause of morbidity and mortality surpassing the coronary heart 
disease.43 
 
The FAMA study provided a deeper insight about atrial fibrillation in the Portuguese 
population. In this cross-sectional study, a representative sample of the Portuguese population 
(≥40 years-old) with more than 10 000 individuals was screened with ECG for AF. The 
prevalence of AF was 2.5% (10.4% in patients with ≥80 years old), but only 1.6% of the 
individuals were aware to have this condition. Among patients aware of their condition, only 
38% were treated with anticoagulants.  
 
The FAMA study has brought knowledge about the prevalence of AF which is estimated to 
exist 121000 patients with this condition in Portugal. Nevertheless, data about anticoagulation 
in Portuguese patients are scarce and should be further evaluated. 
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1.4. Clinical pharmacology approach of oral 
anticoagulants 
 
1.4.1. Principles of Clinical Pharmacology – Population 
applications 
 
Clinical Pharmacology studies all aspects that relates drug development and human use 44. 
According to the Aronson’s manifesto for clinical pharmacology, the operational definition of 
this discipline includes four systems:  
Two basic “bench” tools of human pharmacology: 
Core human pharmacology; 
Core applied pharmacology; 
Two clinical / “bedside” applications of pharmacology: 
Individual application of clinical pharmacology; 
Population application of clinical pharmacology; 
 
Core human pharmacology is closely related to the study of receptors, enzymes, transporters 
and autacoids, while core applied pharmacology overviews the cell pharmacology, drug 
metabolism, pharmacogenetics and pharmacokinetics44. . 
 
The practical clinical fields are those required and most often evaluated for the approval of 
drugs and establishment of policies, as well as for drugs prescription and use in daily practice 
patients. While individual applications of clinical pharmacology study clinical toxicology, 
adverse reactions, drug interactions, drug monitoring and the practical aspects of drugs 
therapy in the individual patients, population applications have 4 main fields: 
Pharmacoepidemiology, Comparative effectiveness/safety research, pharmacovigilance and 
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The population applications are essential for the clinical practice as these provide and appraise 
evidence about interventions that may improve healthcare outcomes. The use and translation 
of the population applications to the individual clinical practice is provided by Evidence Based 
Medicine and Healthcare policies (approval, reimbursement) (Figure 6). 
 
 
Figure 6: Interaction between population and individual applications of Clinical Pharmacology 






In this dissertation, the research projects followed these four main areas of population clinical 
pharmacology, which considers pharmacoepidemiology, safety aspects in clinical trials 
(comparative safety reseach) and in the ‘real world’ (pharmacovigilance), and 
pharmacoeconomics. 
 





Pharmacoepidemiology is widely defined by the World Health Organization as the study of 
the use and effects/side-effects of drugs in large numbers of people with the purpose of 
supporting the rational and cost-effective use of drugs in the population thereby improving 
health outcomes45. Although this definition may overlap with other domains, the prescription 
and use of drugs in populations is still exclusive of Pharmacoepidemiology. 
Pharmacoepidemiology of oral anticoagulants aims to identify the patterns use of oral 
anticoagulants. In this regard the proportion of patients requiring anticoagulation that are 
treated with these drugs (using AF as the model of disease) is a performance measure of 
healthcare delivery, that should be assessed. This is particularly relevant because the use of oral 
anticoagulants, including NOACs, is very heterogeneous due to obstacles related to 
physicians, patients, and financial status46. As previously seen, not all oral anticoagulants are 
similar, and VKA require dose changing when the INR is out the therapeutic range. Another 
measure of adequacy of drug use, particularly VKA, is the Time in Therapeutic Range (TTR), 
i.e. the time in percentage that patients stay within the therapeutic range. 
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1.4.3. Comparative effectiveness and safety research 
 
The basis for the evaluation of the individual and population applications of drugs is the 
Evidence-Based Medicine (EBM). According to David Sackett, EBM relies on the 
conscientious, explicit, and judicious use of the best evidence to making decisions about the 
care of individual patients, taking into account the individual clinical expertise and the best 
available external clinical evidence from systematic research.47 It aims to optimize the decision-
making according to three major components the physician (with his knowledge and 
experience), the interventions/drugs (and their systematically retrieved evidence – CER data), 
and patients’ values and preferences. 
 
Thus, CER aims to generate and synthetize evidence that evaluates the effectiveness, benefits 
and harms of therapeutic interventions, diagnostic test, or healthcare frameworks.48 The 
synthetized data is deemed to help patients, healthcare personnel and policy makers to make 
informed decisions at the individual and population levels.48  
Data synthesis can have multiple sources, but currently the gold-standard for the evaluation of 
interventions are the systematic reviews and meta-analysis (Figure 7). 
 
 
Figure 7: Evidence-based Medicine pyramid of publication types. 
 




Systematic reviews of randomized controlled trials and meta-analyses are used to synthetize 
the data efficacy and safety. These are used to address and support the efficacy of oral 
anticoagulation in atrial fibrillation35 and to dismiss the routine use of oral anticoagulants in 
patients with heart failure and sinus rhythm27. 
 
It is well established that RCTs are the most robust study design to investigate causality of 
therapeutic interventions and therefore they are positioned at the top of evidence hierarchies. 
However, RCTs are majorly powered for efficacy outcomes and pivot trials aim to produce the 
necessary evidence for drug approval (and reimbursement). The methodological caveats of 
RCTs, in particular the fact that they are rarely designed to evaluate safety, made them 
susceptible to limitations that may hamper their ability to fully characterize drug-related 
harms49. Among other reasons, by increasing the power to detect differences between groups, 
systematic reviews with meta-analysis of RCTs focusing on drug safety and tolerability are 
partially capable to overcome this limitation. Furthermore, they are particularly relevant before 
massive post-marketing use of a new drug (a stage where no real big world data is still 
available) as they generate the best evidence to evaluate safety and tolerability at this early 
stage. 
  
Safety evaluates the freedom from harm or damage resulting from adverse reactions or 
physical, psychological, or behavioral abnormalities that occur as a result of drug use.50 
The main safety concerns potentially raised by oral anticoagulants are related to bleeding 
complications, which are direct pharmacodynamics consequences of anticoagulants. 
Nevertheless, other adverse events such as liver injury, particularly after recent history of the 
oral IIa inhibitor ximelagatran post-marketing withdrawal due increased risk of liver injury51,  
and other possible off-target effects must be scrutinized in order ensure the primum non nocere 
principle for a safe drug prescription.  
The safety and efficacy of any chronic treatment, anticoagulation included, strongly depends 
on patients’ tolerability and adherence to the medication. 
 
 





Pharmacovigilance relies on the detection, assessment, understanding and prevention of 
adverse effects or any other drug-related problem.52  
In oral anticoagulants, particularly after the licensing of NOACs, the post-marketing stage is 
crucial to screen for adverse events and to improve the awareness of the safety in a non-
selected population, in opposition to clinical trials. Pharmacovigilance uses methods that can 
raise alerts through safety signals detection, which can be important for unexpected or rare 
adverse events. For example, a pharmacovigilance study has raised a warning regarding the 
existence of the risk of eosinophilia and systemic symptoms associated with fluindione (a 
VKA marketed in France).53 Other firstly unsuspected adverse events related with VKA, are 
also target of studies such as osteoporosis or vessels calciphylaxis. 
Furthermore, clinical trials are performed for ‘short-term’ outcomes, while the safety of using 
of new drugs for longer periods remains unknown.  
 
 





Economic/Pharmacoeconomic evaluations provide information for healthcare decision-
makers, allowing optimal allocation of limited resources. In order to pursuit the impact of oral 
anticoagulants in the society, a burden of disease and cost of illness of atrial fibrillation and 
cost-effectiveness studies of oral anticoagulants were performed.  
 
Burden of disease is estimated by the means of quality-adjusted life-years (QALYs) lost or 
disability-adjusted life years (DALYs), which is a measure of the years of health lost due to 
disease or premature death. QALYs are the product of life expectancy combined with a 
measure of the quality of life-years remaining. It accounts for non-fatal morbidities and their 
contribution to premature death. QALYs expresses lost health in time units, concealing the 
years-loss due to disability and period between death and standardized average life expectancy 
(years of life lost because of premature mortality).   
QALYs lost or DALYs were calculated through standard methods,23,25 with coefficients of 
disability that range from 0 (healthy) to 1 (full disability or death).26 
The cost of atrial fibrillation included both direct and indirect costs.  
Direct costs included hospitalization and ambulatory-related expenditures. Hospitalizations 
were derived from database of National Health Service (NHS) with diagnosis-related groups 
(DRGs). Outpatient care resource use was estimated by a geographically representative expert 
panel of various specialists. 
Indirect costs assume that atrial fibrillation and related complications may disable patients for 
work and this brings a loss of economic value. 
 
The relative cost-effectiveness and cost-utility approach of oral anticoagulants looked for the 
projection of anticoagulants impact in ‘real world’ conditions. The outcomes are the 
incremental costs, life-years gained, incremental QALYs and incremental cost-effectiveness 
ratio (ICER). ICER is calculated through the ratio of the difference in the cost between 
interventions and the difference in the outcomes, such as stroke, intracranial hemorrhage and 
mortality. ICER provides the cost that, on average, the intervention needs to obtain additional 
success (life years gained or QALY). For example, a ICER of €1000/QALY reflects additional 
cost with an intervention required to gain 1 QALY.  
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This is of paramount importance in the evaluation of interventions that provide health 
benefits but are more expensive than the available options. ICER determines the investment 
that it is required to gain standardized health units, such as incremental life-year gained or 
incremental QALY. In Portugal the limit usually taken to be acceptable for funding new 
health technologies (cost-effectiveness threshold / willingness to pay limit) is €20000/QALY. 
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1.5. Gaps in the evidence  
 
Oral anticoagulants are efficacious in the many conditions, and NOACs overcome VKA 
regarding some unmet medical/patient needs. NOACs showed to be at least as efficacious as 
VKA in regards to stroke prevention in atrial fibrillation (as well as in VTE treatment; Table 
4) leading to the approval, and thereby increasing the therapeutics options for these 
conditions. 
 
Before the beginning of this project, the status quo of anticoagulation in Portugal was not well 
defined. Publications from other countries suggest that many patients were undertreated or 
were not adequately controlled with VKAs. In Portugal, the data about the proportion of 
patients that were anticoagulated were very scarse and underpowered, and the quality of 
control of VKA in Portuguese patients using standardized methods (such as Rosendaal 
method) was unknown. Due to their overall characteristics, NOACs are attractive and the 
control of anticoagulation would no longer be a problem, and it would be interesting to study 
whether simple indicators such as the prescription of anticoagulants would improve. 
 
It is well established that RCTs are the most robust study design to investigate causality of 
therapeutic interventions and therefore they are positioned at the top of evidence hierarchies. 
However, RCTs are majorly powered for efficacy outcomes and pivot trials aim to produce the 
necessary evidence for drug approval. The methodological caveats of RCTs, in particular the 
fact that they are rarely designed to evaluate safety, made them susceptible to limitations that 
may hamper their ability to fully characterize drug-related harms49. Thus powered data of 
NOACs safety and tolerability from RCTs are required before massive post-marketing use of 
a new drug (a stage where no big ‘real world’ data is still available), as well as information from 
the national drug safety surveillance as a complement of safety evaluations from clinical trials. 
 
Although oral anticoagulants are the few interventions that modulate the prognosis of atrial 
fibrillation, nothing was known about the impact of this prothrombotic disease of reference, 
in the society in terms of disability-adjusted life years (a measure of disease burden) and costs, 
and whether NOACs are cost-effective in the Portuguese society. 
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1.6. Objectives  
 
 
This project aimed to fulfil some gaps of current available evidence about oral anticoagulation, 
particularly in atrial fibrillation, as well as the need to further improve the knowledge about 
NOACs (particularly regarding safety issues, as individual trials are unpowered for such 
evaluation) and their effectiveness and costs in Portugal. 
In the research projects, whenever adequate, atrial fibrillation was considered the condition of 
reference of a prothrombotic disease requiring anticoagulation, although other conditions 
were also evaluated when it was methodological conceivable to increase the power and 
robustness of data. 
 
In order to improve and to explore the limitations and areas of uncertainty about oral 
anticoagulants/NOACs, this dissertation provided research studies that approach all main 
fields of the population applications of clinical pharmacology, and whose objectives were: 
 
Chapter II [Pharmacoepidemiology]: To evaluate and quantify the use of oral anticoagulants 
drugs in Portugal; 
Chapter III [Comparative effectiveness/safety research]: To assess the overall safety of 
NOACs regarding bleeding, and non-bleeding adverse events and the impact in drug 
discontinuation; 
Chapter IV [Pharmacovigilance]: To appraise the landscape of oral anticoagulants 
pharmacovigilance in Portugal; 
Chapter V [Pharmacoeconomics]: To evaluate the socio-economic impact of atrial fibrillation 
(as a representative prothrombotic condition requiring anticoagulation) and NOACs in 
Portugal. 
 
To achieve the proposed objectives, research projects were performed using the following 
methods: systematic reviews and meta-analyses, observational studies, burden of disease and 







Pharmacoepidemiology of  oral 
anticoagulants: trends in 
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2.1. The prevalence of Portuguese patients with 
atrial fibrillation treated with oral anticoagulation 
 
BACKGROUND 
Atrial fibrillation (AF) is the most common arrhythmia in clinical practice, with an estimated 
prevalence of 2.5% in the Portuguese population aged 40 and over according to the FAMA 
study. The prevalence increases with age, reaching 6.6% in the group aged 70 and over and 
10.5% in those aged 80 and over 54. 
In the FAMA study, a third of patients with AF were not aware that they had the condition. 
As AF can remain silent until complications occur 55,56, clinical screening is indicated for 
individuals aged 65 or over 57. The main complications of AF are thromboembolic events, 
particularly stroke. For prevention of such events oral anticoagulation therapy is 
recommended in patients with thromboembolic risk factors 57. 
The aim of this review was to estimate the prevalence of oral anticoagulant therapy in patients 




Systematic review of observational studies performed in Portugal that enrolled patients with 
AF or atrial flutter and reported the proportion of anticoagulated patients were included. 
Studies on specific populations or on specific interventions such as AF ablation were excluded 
since inclusion of patients who are not representative of the general AF population would 
introduce bias. 
 
MEDLINE, the Index of Portuguese Medical Journals and SIBUL (the Bibliographic Catalog 
of the Integrated Library System of the University of Lisbon) were searched. The search 
included review of the references lists of the studies and literature reviews found, but did not 
include abstracts of posters or oral communications at congresses. 
 
The results of the individual and pooled studies were expressed in percentages (prevalence) 
and 95% confidence intervals (CI). Inverse-variance weighting was used to aggregate the 
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results of each study. As considerable heterogeneity between studies was expected, the 
random-effects model of DerSimonian and Laird was used by default 58. 
In a separate analysis, estimates of prevalence were calculated as a function of the 
environment of the study (community or hospital). 
 
RESULTS 
Seven studies were included for analysis 54,59-64. Their main characteristics are shown in Table 7.  
 
Three studies were cross-sectional 54,59,63 and four were longitudinal (three retrospective cohort 
studies 60-62  and one prospective cohort study 64). Three studies were conducted in the general 
community 54,59,62,63 and four in a hospital environment 60-62,64. These studies enrolled a total of 
891 AF patients eligible for oral anicoagulation. Sample size ranged between 21 and 261 
individuals, most of them elderly (mean age varying between 77 and 85.5 years) and thus 
generally at high thromboembolic risk. Three studies included patients with significant valve 
disease or mechanical valves: in Jorge et al., 29% of the population had at least moderate valve 
disease or mechanical valves 62, in Ascenção et al., 20% had mitral stenosis 59, and in Dores et 
al., 6% of the population had valvular AF 61. Thromboembolic risk stratification was 
performed using the CHADS2and CHA2DS2-VASc scores and the risk categories proposed in 
the 2006 American College of Cardiology/American Heart Association/European Society of 
Cardiology (ACC/AHA/ESC) guidelines65. Two studies did not report using any risk 
stratification tools 54,60. 
 
The main source of possible bias was the lack of representativeness of the sample – some 
studies were performed exclusively in a hospital environment or analyzed patient subgroups.  
 
The meta-analysis of the results reveals that the prevalence of oral anticoagulant therapy in 
Portuguese patients with AF is 40% (95% CI: 32–48%), higher in community-based (45%; 
95% CI: 37–52%) than in hospital-based studies (36%; 95% CI: 24–48%), although this 
difference was without statistical significance (p=0.20). These results are presented in Figure 8.  
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AF is an important public health issue, particularly in Portugal, since it is a risk factor for 
stroke, a significant cause of morbidity and mortality in this country 43.  There is solid evidence 
that oral anticoagulation reduces the risk of thromboembolic events. Use of vitamin K 
antagonists is associated with a significant reduction of 64% in relative risk for stroke.35  
Despite the evidence and the recommendations concerning the reduction of thromboembolic 
risk in AF patients with this therapy, a significant proportion of the population at risk is not 
anticoagulated – about 40%. The level of oral anticoagulation prescription in these patients is 
an indication of the quality of health care, and there is an obvious need for change. 
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Vitamin K Antagonists (VKA) such as warfarin, acenocoumarol and phenpromcom are widely 
prescribed oral anticoagulant drugs. The main indications are atrial fibrillation (AF), valvular 
prosthesis, venous thromboembolism and intracavitary thrombus. These drugs’ efficacy and 
safety depends on International Normalized Ratio (INR) monitoring. The absence of standard 
dosages of VKA turns imperative to perform serial INR tests and make dosages adjustments 
when the results are out of the range. 
INR levels above and under pretended values are associated to increased risk of hemorrhagic 
and thromboembolic events, respectively 66,67. Time in therapeutic range (TTR) is a measure of 
quality of anticoagulation and lower values are related to adverse events 68. TTR knowledge is 
important to identify the current standard of anticoagulation care and establish new goals. 
Additionally, TTR is an important input to determine the cost-effectiveness of new oral 
anticoagulants 69. 
The most comprehensive published data about TTR in Portuguese patients comes from RE-
LY study. This trial included Portuguese patients and mean TTR for overall Portuguese 
centres was 61% 70,71. 
TTR data retrieved from randomized controlled trials may overestimate those from real 
world72. In order to estimate TTR, a retrospectively review of patients charts from a single-




Study design and setting 
We conducted a retrospective cohort study of patients treated with vitamin K antagonists 
followed in Cardiology Anticoagulation Clinic a Portuguese single-centre from January 2011 
to July 2013, in order to determine the TTR of the centre. We obtained Institutional Board 
and Ethics Committee approval for this study. 
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Participants, variables and statistical analysis 
We identified all patients treated with vitamin K antagonists followed in Cardiology 
Anticoagulation Consultation. Patients’ data were retrieved from Consultation database which 
contains the all INR records obtained in the visits. All patients were submitted to nurse led 
INR checking using CoaguCheck® XS system and follow-up was made according to INR 
value, and hospital protocol or physicians preferences. 
For analysis, we included patients whose target INR was between 2.0 and 3.0 (patients with 
INR targets between 2.5 to 3.5, including patients with mechanical heart valves were 
excluded). To better characterize the quality of long-term anticoagulation all patients under 2 
months of follow-up tests or <6 INR tests were excluded 73. We have characterized the 
demographic and clinical characteristics of the population. For each patient we evaluated all 
available INR values to calculate the individual TTR according to the Rosendaal method 74.  
Patients were clustered into subgroups according to the reason/indication for anticoagulation: 
non-valvular AF; valvular AF; venous thromboembolic disease; and others.  
The primary outcome was the TTR, a continuous outcome. Secondary outcomes were: 1) 
TTR < 60%, a marker of poor quality in the control of INR 68,75; 2) time under therapeutic 
range (INR < 2.0); 3) time over therapeutic range (INR > 3.0); 4) time with increased 
thrombotic risk (INR < 1.5); 5) time with increased hemorrhagic risk (INR > 4.5). 
All analyses were conducted using SPSS software version 9.1. Statistical summary measures 
such as arithmetic mean and median were used to characterize the population. Standard 
deviation (SD) and interquartile range were used to evaluate data dispersion. Multivariate 
logistic regression analysis was performed to identify risk factors for TTR < 60%, at a 
significance level of 0.05. Chi-square test was performed for the comparison of dichotomic 
data across groups. One-way ANOVA was used to evaluate differences between TTR across 





We found 501 patients treated with VKA with target INRs between 2.0 and 3.0, with their 
INR recorded in the database between January 2011 and July 2013. About 377 patients had 
the minimum required follow-up/number of tests to meet the inclusion criteria. 
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The mean age was 71 years, and 59.4% of the patients were male. Most of the patients had 
non-valvular AF (72.4%), while valvular AF (19.1%) and venous thromboembolic disease 
(3.4%) were less common. The population’s average CHA2DS2-VASc was 3.58. 
Patients were followed for a mean period of 471 days, having performed on average 17 INR 
tests per year each patient. The average time between two tests was 25.4 days. 
Table 8 shows the main characteristic of the population. 
 
Table 8: Clinical characteristics of included patients. 
Characteristics Population (N = 377) 
Age – years  
Mean (SD) 71.0 (10.4) 
Median (IQR) 72.0 (66–79) 
Female sex – no. (%) 153 (40.6) 
Previous stroke or transient ischemic attack – no. (%) 56 (14.9) 
Heart failure – no. (%) 160 (42.4) 
Diabetes mellitus – no. (%) 101 (26.8) 
Hypertension - no. (%) 253 (67.1) 
Vascular Disease History – no. (%) 122 (32.4) 
Indication for anticoagulation  
Non-valvular AF 273 (72.4) 
Valvular AF 72 (19.1) 
Venous thromboembolism 13 (3.4) 
Others 19 (5.1) 
CHA2DS2-VASc  
Mean (SD) 3.58 (1.62) 
Median (IQR) 3 (2–5) 













The mean TTR was 60.3% (SD 19.3%) and the median 63% (interquartile range 47.9-74.8%). 
About 44.3% of the patients evaluated have a mean TTR < 60%, and are at increased risk of 
thrombotic and hemorrhagic events. 
The female gender was the only characteristic that was significantly associated to poor 
anticoagulation control (TTR < 60%) in the multivariable regression analysis with an odds 
ratio 1.73 and 95% confidence interval 1.14-2.62 (p = 0.01). 
The average percentage of time that patients remained above (INR > 3.0) and below the 
target INR (INR < 2.0) was 16.5% and 23.2%, respectively. Patients were at high risk of 
bleeding (INR > 4.5) 1.7% of the time, and at high thrombotic risk (INR < 1.5) 4.7% of the 
follow-up period. Figure 9 and Figure 10 illustrate these results. 
 
Non-valvular AF was the most prevalent indication for anticoagulation. The mean CHA2DS2-
VASc was 3.65 (SD 1.58). In this cluster of patients, the average TTR was 59.3% (SD 19.8%) 
and the median was 61.8% (interquartile range 47.4-73.7%). These patients were on average 
23.4% of the time below therapeutic range (INR < 2.0), and 17.3% of the time over INR 3.0. 
The mean percentage of time with high thrombotic risk (INR < 1.5) was 5.3%, and 1.7% of 
the time patients were at high risk of bleeding. 
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There were no significant differences in average TTR between the different indications for 
VKA treatment (p = 0.18). The proportion of patients with low anticoagulation control also 
was not different across conditions (p = 0.53). Table 9 shows the mean TTR and the 
proportion of TTR < 60% according to the main indication for anticoagulation. 
 
 
Table 9: Mean Time in Therapeutic Range (TTR) according to main indication for anticoagulation. 
Population Mean TTR 
(SD) 
TTR < 60% (%) Patients Average follow-up 
(years) 
Non-valvular AF 59.3% (19.7%) 128 (46.7%) 274 1.27 
Valvular AF 64.0% (18.6%) 29 (40.3%) 72 1.44 
Venous 
thromboembolism 
54.6% (24.4%) 5 (38.5%) 13 1.18 













The Rosendaal TTR of this population of anticoagulated Portuguese patients was 60.3% 
during a mean follow-up of 1.3 years. Forty-four percent of this population had a TTR < 
60%. When out of therapeutic range, patients were more commonly prone to prothrombotic 
risk due to the higher percentage of time with INR < 2.0. This means that an important 
proportion of patients are at increased risk of major adverse events 68,75,76. 
Applying the data to those retrieved from randomized controlled trial, in centres with TTR of 
60-61%, NOACs tend to be safer and/or more effective than VKA.  
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2.3. Prescription of anticoagulants in Portuguese 





Oral anticoagulation is the mainstay in the prevention or treatment of some prothrombotic 
conditions. In prevalent conditions such atrial fibrillation (AF), oral anticoagulation with VKA 
showed a stroke risk reduction superior to 50% .77 Despite their demonstrated efficacy in 
clinical trials, the use of these drugs has consistently been reported as suboptimal as previously 
shown.78  
Recently, new pharmacological options have been developed with the same therapeutic goals. 
The non-vitamin K antagonist oral anticoagulants (NOACs) are considered at least as 
effective as VKAs, with lower risk of intracranial hemorrhage,79 without needing laboratory 
monitoring of international normalized ratio (INR). In Portugal, NOACs (dabigatran and 
rivaroxaban) were firstly widely used in 2010 with the reimbursement for the prevention of 
venous thromboembolism in patients undergoing hip or knee arthroplasty, and in 2011 the 
indication of NOACs was expanded to stroke prevention in non-valvular AF. In August 2014, 
three of these NOACs (apixaban, dabigatran and rivaroxaban) were approved for 
reimbursement under the National Health Service (NHS) for AF patients.  
Overall oral anticoagulants prescription may be considered a marker of care in prothrombotic 
conditions, and the advantages of NOACs preclude an increase in the prescription of oral 
anticoagulants. Therefore, we aimed to evaluate the trends in the prescription of oral 












We conducted an observational retrospective descriptive analysis of Portuguese landscape on 
the prescription of oral anticoagulants in the ambulatory care. In this study, drugs 
use/consumption was used as a proxy of prescription and we used these terms 
interchangeably. 
 
Data sources and outcomes reported 
Data from prescriptions were retrieved through the Portuguese National Authority of 
Medicines and Health Products (INFARMED) and IMS Health Portugal. 
Data from Infarmed were used to analyse yearly data of the counting packs of oral 
anticoagulants sold from 2010 (year of reimbursement and wide use NOACs) to 2015, and the 
daily defined doses (DDD) as defined by the World Health Organization (WHO) from 2010 
until the first trimester of 2016. Data from IMS Health were obtained through IMS dataview 
and reported all sells-in of oral anticoagulants in terms of counting packs and counting units 
(pills) in the last 4 years (from February 2012 until February 2016) by months. 
 
Data management 
We obtained data for the use of oral anticoagulants currently used in ambulatory care. These 
were grouped according to active substance in accordance with their WHO Anatomical 
Therapeutic Chemical (ATC) classification and afterwards according to their mechanism of 
action: VKA - B01AA; NOACs - B01AE07, B01AF01, B01AF02). Parenteral anticoagulants 
(e.g. heparins) or other oral anticoagulants not commercialized (e.g. edoxaban) were excluded.    
As packs can have different presentations and units can have different doses, the daily defined 
doses were used to standardize the data. DDD is a statistical measure of drug consumption, 
defined by the WHO (http://www.whocc.no/atc_ddd_index/?code=B01A), and is the 
assumed average maintenance dose per day for a drug used for its main indication in adults. 
Atrial fibrillation is deemed to be the main indication for oral anticoagulation, and in 2016 the 
DDD for NOACs were updated in order to reflect this, with a 10 mg DDD for apixaban, 300 
mg for dabigatran, and 20 mg for rivaroxaban. 
 
Statistical analysis 
A descriptive analysis was performed regarding the number of packs and counting units sold, 
and by DDD. Oral anticoagulants were globally evaluated as well as their both groups: VKA 
and NOACs. There were no demographic or clinical details about the patients that used the 
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drugs, the setting for the prescription. Linear regression parameters were estimated in order to 
retrieve the direction and significance of variations. Results were considered statistically 
significant if p<0.05. We also performed an analysis exclusive for prescriptions from August 




The prescription of oral anticoagulants in Portugal increased significantly (p for trend <0.05) 
in the last 6 years, according to the INFARMED data. The number of oral anticoagulant 
packs sold yearly increased from 579600 to 1405200 (relative increase of 242%) (Figure 11). In 
2010 the mean number of DDD was 52121 and there was an increase of 2.3-fold over these 6 
years (first trimester 2016 DDD: 120726).  
 
 
Figure 11: Yearly sold packs of oral anticoagulants. Source: INFARMED. 
 
 
Until 2014 this increase was obtained through both VKA and NOACs, mostly by the latter. 
There was an increase of VKA (129% packs; 130% DDD) and NOACs (8682% packs; 
13886% DDD) (Figure 11 and Figure 12). 
 




Figure 12: DDD of oral anticoagulants used in Portuguese outpatient setting. Source: INFARMED 
 
 
In 2015, the prescription of oral anticoagulants remained with an increased trend compared 
with the previous years. There was though a small decrease in the prescription of VKA 
compared with 2014 (relative decrease 7.7%). In opposition to VKA, NOACs kept their 
prescription trends in a way that packs sold were greater than VKA since 2015 (51.3% of the 
market of oral anticoagulants in 2015, and 58.4% in the first trimester of 2016). Considering 








2010 2011 2012 2013 2014 2015 2016* 
Packs 0.8% 3.6% 13.1% 25.3% 36.5% 51.3% 58.4% 
DDD 0.3% 1.7% 8.2% 17.0% 26.6% 43.0% 51.1% 
DDD: Defined daily dose; NOACs (Non-vitamin K antagonist oral anticoagulants). 
* January to March 2016. Source: INFARMED. 
 
The analysis of data provided by the IMS Health was overall similar to that provided by the 
INFARMED. Linear regression of the data of the last 4 years (February 2012 to February 
2016) showed that the prescription of anticoagulants remains increasing linearly, mostly due to 
NOACs, while VKA prescription did not change significantly (p value for trend 0.053). 
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NOACs dominance in the market of oral anticoagulants in terms of packs and counting units 
was firstly established in May 2015 and remains linearly increasing (Figure 13). 
 
 
Figure 13: Packs and counting units sold by month. Source: IMS Health. Dots are the monthly estimates 
and the solid lines are the linear regression lines 
 
 
The impact of reimbursement for atrial fibrillation 
As all NOACs were reimbursed for non-valvular AF in August 2014. A linear regression 
analysis was performed in order to evaluate whether reimbursement changed the pattern of 
prescription. The analysis showed that the prescriptions of OACs and NOACs after the 
reimbursement were still increasing (p-value for trend <0.001), while VKA showed a tendency 
to decrease (p=0.06). When the rates of growth of oral anticoagulants use (slope analysis) were 
compared before and after August 2014, the data was significant a greater growth of OACs 
prescription (p=0.005), due to a further increase in the NOACs prescription (p<0.001). The 
prescription of VKA was not significantly different from the period before August 2014 
(p=0.12) and there was a trend towards a decrease in the prescription of VKA. 
 





The Portuguese national outpatient prescription data showed that the prescription of oral 
anticoagulants is increasing, mostly due to NOACs, while VKA prescriptions were overall 
kept overtime. 
Between 2010 and the first trimester of 2016, the number of packs sold increased significantly. 
Confounding factors such as pack sizes, doses and posologies, were adjusted through the 
prescribed DDD of oral anticoagulants which increased 2.3-fold along the referred timeframe.  
In August 2014, all NOACs were reimbursed for atrial fibrillation. The rate prescriptions 
growth increased significantly after this period, while VKA prescriptions look unchanged, but 
a negative trend was observed. Due to the non-significant variation of VKA, it is plausible that 
only a small proportion of patient changed from VKA to NOACs. in the oral anticoagulants. 
Although not detailed nor conclusive, data are suggestive that the increase of NOACs 
prescription comes mainly from new prescriptions of oral anticoagulants instead of changes in 
oral anticoagulants. 
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2.4. Chapter discussion and conclusions 
 
 
Until recently, the proportion of patients eligible for receiving oral anticoagulant treatment 
was unacceptably low. The presented systematic review with meta-analysis estimated that only 
40% of the patients were treated accordingly. The international scenario is very 
heterogeneous. Only the Italian ISAF study showed a proportion similar to the presented 
study (ISAF 46% vs. Caldeira et al. 40%) 80. Other studies such as the international 
prospective GARFIELD registry (62%) 81, the German primary care ATRIUM registry (75%) 
82, and the international (seven European countries) PREFER in AF registry (85%) 83 showed 
higher proportions of anticoagulated patients. 
 
Another flaw related to the anticoagulant treatment, particularly in VKA, relies on the absence 
of adequate control of the INR. Until recently, it was unknown how Portuguese patients were 
controlled in terms of Time in Therapeutic Range (TTR), a standardized method to 
benchmark and compare centres and countries. 
In this chapter are published the results of the first Portuguese study, outside the clinical trials 
setting, which characterized the Time in Therapeutic Range through the Rosendaal method in 
a large number of patients. This retrospective study appraised more than 350 patients and 
their INRs for a mean of 1.3 years. The mean TTR of the sample was 60.3%, the median was 
63%, and 44% of these patients had a TTR<60%. As a title of example, an effective stroke 
risk reduction is only obtained when TTR>65-70%15,84. The results obtained in this study were 
similar to those seen in Portuguese patients included in the RE-LY trial (TTR 61%), and were 
in accordance to those reported in the literature71,85. 
 
There were, then, 2 major problems identified: the low rate of oral anticoagulants prescription; 
and in those who were anticoagulated, the overall control of INR was suboptimal and a 
significant proportion of patients had a TTR<60%. 
 
These unmet medical needs were fulfilled by NOACs as seen in the Portuguese national 
outpatient prescription data. Prescription of oral anticoagulants is increasing, mostly due to 
NOACs, while VKA prescriptions were overall kept overtime. The increase in the 
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prescription of oral anticoagulants is also explained by the reimbursement of NOACs, which 
are at least as efficacious as VKA,86 and more convenient.  
 
Besides the absolute increase of oral anticoagulants prescription, NOACs also bring the 
advantage of anticoagulation control due to the predictability of the anticoagulant effect. 
Applying the presented data to those retrieved from randomized controlled trial, in centres 
with TTR of 61%, NOACs tend to be safer and/or more effective than VKA. In RE-LY, all 
dosages (110 mg and 150 mg bid) had a significant lower risk of intracranial bleeding, with a 
similar risk major bleeding, while in the prevention of thromboembolic events only the dosage 
of 150 mg showed a significant risk reduction compared to warfarin. The efficacy of 
rivaroxaban was not statistically different from warfarin but there was a trend towards 
rivaroxaban in the prevention of thromboembolic complications (HR 0.70; IC95% 0.48-1.03). 
Apixaban was safer in terms of major bleeding with an efficacy likely to be better than 
warfarin (HR 0.73; IC95% 0.53-1.00). 
 
The prescription of oral anticoagulants was low and treated patients did not have an adequate 
control (low TTR). The paradigm in Portugal is changing towards an improvement of oral 
anticoagulants prescription, mostly due to NOACs, that do not have the previously mentioned 
control issues.  
Between 2010, when dabigatran (the first NOAC) was firstly marketed, and first trimester of 
2016, the number of packs sold increased significantly. Confounding factors such as pack 
sizes, doses and posologies, were adjusted through the prescribed DDD of oral anticoagulants 
which increased 2.3-fold along the referred timeframe. Interestingly, the DDD analysis shows 
that in 2016, the mean daily sells of oral anticoagulants correspond to 120000 individual doses. 
Interestingly the extrapolation the AF prevalence of 2.5% in individuals with more than 40 
years-old to the overall Portuguese population suggests that in Portugal there are about 
121000 patients with AF. 
 
Limitations 
In the systematic review and meta-analysis evaluating the proportion of AF patients treated 
with oral anticoagulants, it should be considered that clinical heterogeneity from the inclusion 
of studies with different populations, different settings (hospital vs. community) which used 
different methods to prescribe the anticoagulation to the thromboembolic risk (use of 
DISCUSSION AND CONCLUSIONS OF CHAPTER II 
 
 67 
CHADS2 or CHA2DS2-VASc) must be acknowledged as limitation. The expected statistical 
heterogeneity also limits the conclusions. 
 
The other two studies of this chapter (TTR evaluation and prescription of oral anticoagulants 
in Portuguese outpatients) had a retrospective design.  
 
The TTR evaluation was a retrospective cohort of patients anticoagulated with VKA followed 
in the Cardiology Anticoagulation Consultation of a single-centre. The data presented does 
not account for INR values registered in other facilities, such as in the emergency room or 
during hospitalizations. These reasons may limit the conclusions of this study.  
We did not focus on other patients with very high thrombotic risk such as those carrying 
mechanical heart valves (because INR target is 2.5-3.5). So the data here presented cannot be 
extrapolated to such subgroup. 
 
Its known that the use of oral anticoagulants is not disease-specific, i.e. these drugs are not 
indicated exclusively for patients with atrial fibrillation (the reference condition). 
However, it is estimated that AF corresponds to the largest proportion of patients treated with 
these drugs. It is also possible that prescription for venous thromboembolism treatment 
(VTE), or VTE prevention in elective hip or knee arthroplasty could have contributed for the 
increase of the prescriptions, but these are mostly candidates for a limited anticoagulation 
period. Furthermore, VTE preventions doses are inferior to the DDD actually considered, 
which limits the impact of these indications in the cumulative data of all these years. AF 
patients are candidates for life-long anticoagulation, unless they have a low thromboembolic 
risk or formal contra-indication. 
 
CONCLUSIONS 
It was estimated that in Portugal about 60% of patients with AF were not treated with oral 
anticoagulants. This single-centre retrospective study showed that oral anticoagulation with 
VKA has a suboptimal control with a mean TTR of 61%.  
Since the introduction of NOACs in the Portuguese market, the number of pack and DDD of 
oral anticoagulants prescribed significantly increased, due to NOACs. Currently the NOACs, 
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3.1. Methodology: systematic review and meta-
analysis 
 
The systematic reviews presented in this dissertation followed the Preferred Reporting Items 
for Systematic Reviews and Meta-Analyses (PRISMA) guidelines87.  
 
Eligibility criteria 
The eligibility criteria must comply with the focus/question of the review. In order to 
endeavor the objective nature of the systematic reviews, all of them followed the PICOS 
acronym to establish the question. 
 
PICOS acronym is the guide to define the Population/patients, the Intervention to be 
studied, the Comparisons/comparators, the Outcomes evaluated, and the Study designs that 
more reliably answer to the question of the review. The approach to each one of these points 
is detailed ahead. 
 
Population/patients 
All studies had to include patients with prothrombotic conditions requiring anticoagulant 
drugs.  
 
For bleeding risk evaluation, the length of therapy / follow-up period are important factors88. 
Although many major bleeding events occur in the first weeks of anticoagulant treatment it is 
possible that the process may be related to previous established structural prone areas. 
Following the patients for longer periods captures more events and helps to establish more 
robustly the safety profile. AF usually requires life-long anticoagulation and VTE often 
requires anticoagulation for a period of at least 3 months, with the duration based on the 
benefits and risk of therapy. Therefore, bleeding risk appraisal was performed in AF or VTE 
patients requiring oral anticoagulation with NOACs or VKA (with or without an initial stage 
with low-molecular-weight heparin) (Table 11). 
 
For non-bleeding adverse events assessment, other conditions (and comparators) rather than 
AF and VTE were allowed when the baseline conditions and comparisons were not expected 
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a priori to influence the outcome (e.g. drug-induced liver injury), in order to increase the power 
of the analysis (Table 11). 
 
For assessment of tolerability and acceptability of NOACs, only AF patients were included as 
trials in this condition are longer and capture more reliably differences in the adherence to 
treatment along time (Table 11). Tolerability represents the degree to which overt adverse 
effect can be tolerated by the subject. In other words, evaluates the seriousness of adverse 
events and the potential impact on drug discontinuation (acceptability). While VTE treatment 
or prevention may require only temporary anticoagulant treatment89,90, stroke prevention in 
AF demands life-long treatment. Therefore, the potential clinical benefits of anticoagulants are 
only outweighed if drug-related harms and their adherence profile are at least similar to their 
comparators in trials that are long enough to reflect potential differences in tolerability and 
acceptability/drug discontinuation. 
Thus, tolerability and acceptability are essential components of safety. 
 
Intervention and Comparators 
All RCTs evaluating NOACs (oral IIa inhibitors: dabigatran; oral Xa inhibitors: apixaban, 
edoxaban, or rivaroxaban) were included.  
Only phase III RCTs were considered to avoid bias in risk estimation due to statistical effects 
of rare events and the impact of small size underpowered studies on meta-analysis results91-94. 
Furthermore, we were interested in determining the risk associated with the NOACs doses 
transposed to phase III trials. Therefore, phase II RCTs (such as the previously mentioned 
RE-ALIGN40) were excluded. 
 
Regarding bleeding risk, tolerability and acceptability evaluations, NOACs were compared to 
VKA (with or without initial treatment with LMWH) (Table 11). 
 
In the assessment non-bleeding adverse events, NOACs were allowed to be compared with 
any control (VKA, LMWH, acetylsalicylic acid, placebo, mechanical thromboprophylaxis or 
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Table 11: Conditions and controls evaluated with NOACs phase III trials according to the outcome of 
interest. 
Outcomes Conditions Controls 
Bleeding  
adverse events 




All (AF, VTE, VTE 
prevention, ACS…) 
VKA, LMWH, ASA, 
Placebo, Mechanical VTE 
prevention 
Tolerability and acceptability AF VKA 
ACS: Acute coronary syndrome; AF: Atrial fibrillation; ASA: Acetylsalicylic acid; LMWH: Low-molecular-weight 
heparin; VKA: Vitamin K Antagonists; VTE: Venous thromboembolism. 
 
Outcomes 
Bleeding risk assessment followed the standardized major bleeding criteria for clinical 
investigations among non-surgical patients established by the International Society of Thrombosis 
and Haemostasis (ISTH)95. Accordingly, we have evaluated the following types of major bleeding: 
o Major bleeding and bleeding related mortality, which included the evaluation of 
overall major bleedings (according to the ISTH definition), fatal bleedings, Major 
bleeding case-fatality rate (defined as the ratio between fatal bleeding and major 
bleeding events), and all-cause mortality in major bleeding survivors; 
o Major gastrointestinal bleeding, which is the most frequent site of bleeding in 
anticoagulated patients; 
o Intracranial hemorrhage, the bleeding site that mostly results into death or severe 
disability; 
o Other major bleeding sites that can impair quality of life such as intraocular 
bleeding, or other rare but potentially lethal such as pericardial bleeding. 
 
The evaluated non-bleeding adverse events were related to the potential pharmacokinetics of 
the anticoagulants, or to unexpected findings in trials, observational studies, or in anecdotal 
case report letters. The following outcomes were assessed: 
o Drug-induced liver injury (DILI), defined as increases in serum levels of 
transaminases above three times the upper limit of normal (ULN) and total 
bilirubin above two times the ULN. According to Hy’s law, the outcome defined 
above is the most specific predictor of potential severe hepatotoxicity96. Other 
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hepatic outcomes studied were incidence of transaminases elevation >3x ULN, 
and incidence of bilirubin elevation >2x ULN. 
o Renal failure was defined primarily as events requiring dialysis or reported renal 
failure as treatment-emergent serious adverse event by investigators. Other 
outcome definitions were also explored. 
o Insomnia was evaluated as an adverse event as reported by trials’ investigators. 
o Overall infections, post-surgery infection and urinary tract infection adverse events. 
 
The overall tolerability and acceptability were evaluated in patients with AF compared with 
VKA. 
o Tolerability was indirectly evaluated by determining the incidence of any serious 
adverse event (SAE1), as reported by investigators and/or adjudicated by committees. 
Whenever possible, treatment-emergent SAEs were retrieved. 
o Acceptability97 was split in drug-related (also associated to the tolerability profile) and 
patient-related treatment discontinuation. Discontinuations due to adverse events were 
considered to be drug-related, and discontinuations due to patients’ own decisions 




Randomized controlled trials have the best methodology to properly evaluate the comparative 
efficacy and/or safety of two or more therapeutic interventions. In the systematic reviews here 
presented only phase III RCTs were included. The reasons for this option is related to the 
small studies bias risk, rare events and NOACs doses. 
 
Information sources and search method 
Records of potentially eligible studies were identified through an electronic search of 
bibliographic databases, usually MEDLINE (using OVID interface), CENTRAL at Cochrane 
Library, and Web of Science. Other databases could be searched according to the purposes of 
the systematic review. No language restrictions were applied. Systematic reviews and meta-
analyses evaluating the topic, as well as reference lists of reports of potential eligible studies 
were comprehensively searched. 
                                                 
1 Fatal or life-threatening events, disabilities, or situations that require or prolong hospitalizations. 
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The search strategy was exhaustively discussed and determined with accordance with 
methodologists in order to pursue the balance of a highly sensitive search with an adequate 
specificity. Full methods for search are detailed in the Appendix and are explained in the full 
text of each published article. 
 
 
Study selection and data collection process 
Titles and abstract of records obtained in the search process were screened by two 
investigators. Doubts and disagreements were solved by consensus or. Whenever needed a 
third element was consulted. Selected studies were assessed in full-text to determine its 
appropriateness for inclusion. Data from included studies were independently extracted by 
two authors to an electronic form. Retrieved data items were: study design, year of 
publication, patients’ characteristics, and drugs used, studies’ outcomes, data of required 
outcomes and estimates adjustments.  
Studies included in the review are briefly characterized in the Appendix. 
 
Data analysis 
RevMan sotware (The Nordic Cochrane Centre, The Cochrane Collaboration, 2014) was used 
to derive forest plot showing the results of individual studies and pooled analysis.  
All the outcomes were summarized as dichotomous data.  
The estimate measures were reported as Risk Ratio (RR) or Odds Ratio (OR) with their 95% 
confidence intervals (95%CI). Relative risk measures, such RR/OR (in opposition to risk 
difference which is an absolute risk measure) are more similar across studies with different 
designs, populations and lengths of follow-up compared to absolute measures, such as risk 
difference 98.  
Random effects model was used independently of the existence (I2≥50%) or not of substantial 
heterogeneity between studies’ results because included studies had different characteristics. 
Furthermore, this method provides more conservative estimates. 
Heterogeneity measured as the percentage of total variation between studies due to 
heterogeneity was assessed through the I2 tests99.  
When significant differences were found an absolute risk measure was determined: Number 
Needed to Treat (NNT) or Harm (NNH), or the number of events avoided/caused per 1000 
treated-patients. 
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3.2. Bleeding adverse events 
Bleeding events bring concerns for patients taking anticoagulant drugs and for healthcare 
professionals who support them. The annual major bleeding rates for patients treated with the 
classical Vitamin K Antagonists (VKA) ranges from 1.3% to 3.4% 100,101. These events usually 
require long hospitalizations and relevant resource use102. Major bleedings usually require 
transitory interruption of anticoagulant drugs. Their unavoidable suspension in patients with 
high thrombotic risk may be fatal. Bleedings events are then associated with significantly 
increased risk of mortality 103, due to the direct effects of the bleeding or due to thrombotic 
events. 
 
Many bleeding risk prediction models have been developed in order to detect these clinical 
relevant events in patients with atrial fibrillation (Figure 14), mainly based in patients naïve 
regarding anticoagulant drugs or treated with VKA. 
HAS-BLED is a simple tool and seems to perform well compared to the other in terms of the 
sensitivity of the high-risk category. However, its sensitivity is about 50% in both AF and 
VTE patients 104. This area requires, therefore, further improvements and faces new challenges 
with NOACs arrival. 
 
Figure 14: Pooled sensitivity and specificity of tools used for major bleeding risk prediction in AF. 
*Data from 4 studies evaluating HAS-BLED and ATRIA in the same population. **Data from 5 studies evaluating HAS-
BLED and HEMORR2HAGES in the same population. Adapted from Caldeira et al. J Interv Card Electrophysiol 2014. 
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Independently of all characteristics considered in the mentioned bleeding-risk tools, the length 
of therapy as well as the follow-up period are important factors to evaluate these adverse 
events88. Although many major bleedings occur in the first weeks of anticoagulant treatment it 
is possible that the process may be related to previous established structural prone areas, while 
following patient for longer periods captures more events and helps to establish more robust 
safety profile of studied drugs.  
Therefore, for bleeding risk evaluation, NOACs were compared with VKA in patients 
requiring medium or long-term anticoagulation. Pragmatically, this includes all trials evaluating 
patients with non-valvular AF and VTE. As occurs in the clinical practice VKA was 
complemented with a low-molecular-weight heparin in the initial phase, but it was not 
detrimental for the analysis. 
 
The definition of major bleeding has been controversially discussed because each condition 
has its own peculiarities. In cardiovascular trials have used many definitions, as defined by the 
Thrombolysis in Myocardial Infarction (TIMI) or the The Global Use of Strategies to Open 
Occluded Arteries (GUSTO) 105. 
 
In 2005, the International Society of Thrombosis and Haemostasis (ISTH) established a 
standardized major bleeding criteria for clinical investigations among non-surgical patients 95 
(Table 12). Major bleeding was here defined according to the ISTH definition.  
 
Table 12: ISTH Major Bleeding definition: (required to have at least one of the following criteria) 
Fatal bleeding 







Intramuscular with compartimental syndrome 
Bleeding causing a fall in hemoglobin level of 20 g/L (1.24 mmol/L) or more, or leading to 
transfusion of two or more units of whole blood or red cells 
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The profile of NOACs seems to exceed other antithrombotic drugs, namely vitamin K 
antagonists (VKA), in the predictability of the dose-response relation, lack of coagulation 
monitoring and dose adjustments needs, and fast onset of action19. However, the inexistence 
of an antidote for NOACs for emergent hemorrhagic events is considered by many as one of 
the main drawbacks of this group of drugs and argues against their routine use 106-108. 
 
To evaluate the risk of hemorrhagic-related fatalities associated with NOACs in comparison 
with vitamin K antagonists (VKA) a systematic review with meta-analysis was performed. 
Major bleeding and fatality cases, directly or indirectly related to the major bleeding events, 
reported in randomized controlled trials (RCTs) of patients requiring medium or long-term 
anticoagulation were analysed. 
 
METHODS 
This was a systematic review and meta-analysis of randomized controlled trials (full 
methodology detailed the published version of the article and briefly explained in the Section 
3.1) comparing NOACs, against VKA or sequential treatment of LMWH and VKA in patients 
with atrial fibrillation (AF) or venous thromboembolism (VTE). 
 
The objective was to evaluate the risk of major bleeding, and overall mortality directly or 
indirectly associated with major bleeding events. Therefore, the main outcomes were: 
incidence of major bleeding, fatal bleeding; major bleeding case-fatality rate; and all-cause 
mortality in major bleeding survivors. 
Fatal bleeding events were defined as events in which the cause of death was a direct 
consequence of a major bleeding event. Major bleeding case-fatality rate was defined as the 
ratio between fatal bleeding and major bleeding events. In patients who survived to a major 
bleeding event, all-cause mortality was also evaluated. 
 
 




Twelve studies70,109-120 were included for analysis: 5 studies on AF70,109-112 and 7 studies on 
VTE113-120.  
 
A total of 102790 patients were enrolled (71.0% with AF) with a mean age of 71 years for AF 
patients and 56 years for VTE patients. Mean follow-up period ranged from 1 to 2.8 years for 
AF trials, and most of VTE patients had a 6 months’ follow-up.  
 
Major bleeding risk analysis 
NOACs were significantly associated to a decreased risk of overall major bleeding both in AF 
and VTE. With exception of rivaroxaban in ROCKET AF110, all trials showed at least a trend 
towards major bleeding risk reduction.  
In AF trials, NOACs were associated with a 20% risk reduction in major bleeding (RR 0.80, 
95%CI 0.66-0.96). The NNT to avoid one major bleeding in AF patients was 82 (95%CI: 48 
to 410), which means that NOACs are likely to avoid 12 major bleedings (95%CI: 2.4 to 20.8) 
per 1000 treated patients.  
In VTE studies, a 39% major bleeding risk reduction was noticed (RR 0.61, 95%CI 0.46-0.80). 
Compared with VKA, there was a significant 28% major bleeding risk reduction with NOACs 
(RR 0.72, 95% 0.61 to 0.85) in these patients. The NNT to avoid one major bleeding in VTE 
patients was 148 (95%CI: 107.1 to 289.1). NOACs are therefore likely to avoid 7 major 
bleedings (95%CI: 3.5 to 9.3) per 1000 treated VTE patients. 
Overall, NOACs showed to reduce significantly the risk of major bleeding compared to VKA. 
There was a significant 28% of major bleeding risk reduction (RR 0.72, 95%CI: 0.61 to 0.84; 
I2=77%). However, the analysis is limited by substantial heterogeneity which may be related to 
the characteristics of individual NOACs and populations. Overall, the NNT to avoid one 
major bleeding was 77 (95%CI: 55.2 to 134.4). The number of major bleeding events avoided 
per 1000 patients treated with NOACs was 13 (95%CI: 7.4 to 18.1). 
Figure 15 shows the forest plots of the analyses. 




Figure 15: Forest plot of major bleeding risk associated with NOACs compared to VKA. 
 
Fatal bleeding risk analysis 
In AF patients, NOACs were associated with a 47% risk reduction in the risk of fatal bleeding 
(RR 0.53, 95%CI: 0.42 to 0.68; I2=0%). The NNT to prevent one fatal major bleeding was 419 
(95%CI: 339.2 to 615.0), and the number of fatal bleeding events avoided per 1000 patients 
treated with NOACs was 2 (95%CI: 1.6 to 2.9) in a period of 1 to 2.8 years. 
In VTE patients, NOACs were also associated with a significant 64% risk reduction in the risk 
of fatal bleeding (RR 0.36; 95%CI: 0.16 to 0.81; I2=0%). The number of fatal bleeding events 
avoided per 1000 patients treated with NOACs was 1 (95%CI: 0.3 to 1.3), and the NNT was 
1013 (95%CI: 772.0 to 3413.0) for an average period of 6 months.  
Overall, NOACs showed a significant risk reduction in fatal bleeding risk with a RR of 0.52 
(95%CI: 0.41 to 0.65; I2=0%). NNT for global analysis was 533 (95%CI: 434.2 to 731.9), and 
events spared for each 1000 patients treated with NOAC were 2 (95%CI: 1.4 to 2.3). 
Figure 16 shows the forest plot for this outcome. 
 




Figure 16: Forest plot of fatal bleeding risk associated with NOACs compared to VKA. 
 
Major bleeding case-fatality rate analysis 
Case-fatality rate was lower for AF patients treated with NOACs. Pooled analysis showed a 
significant 30% risk reduction (RR 0.70, 95%CI: 0.51 to 0.95; I2=33%) (Figure 17). For each 
40 patients (95%CI: 24 to 240) experiencing a major bleeding event with NOACs, one 
bleeding fatality is avoided compared to VKA. Regarding VTE, NOACs did not significantly 
reduced major bleeding case-fatality rate (RR 0.57; 95%CI: 0.26 to 1.27; I2=0%) (Figure 17). 
Overall, considering all trials, NOACs were associated with a 33% risk reduction of major 
bleeding case-fatality rate (RR 0.67, 95%CI: 0.53 to 0.84; I2=0%). Globally, one fatal bleeding 
was avoided for each 36 patients (95%CI: 25.3 to 74.4) experiencing a major bleeding event 
with NOACs compared to VKA. 
 
 




Figure 17: Forest plot of major bleeding case-fatality risk associated with NOACs. 
 
Post-major bleeding all-cause mortality risk analysis 
Only AF studies presented data for all-cause mortality following major bleeding events. RE-
LY (dabigatran vs. VKA)70 and ARISTOTLE (apixaban vs. VKA)109 provided 30-days post 
major bleeding mortality, while ROCKET AF (rivaroxaban vs. VKA)110 data were not limited 
to the 30-days post-index event. Except for ROCKET AF, data were adjusted for multiple 
variables.  
Pooled analysis of these trials was taken using odds ratio in order to preserve the original 
estimates obtained after adjustment to potential confounders. NOACs showed a significant 
43% odds reduction in the risk of all-cause mortality in major bleeding survivors (OR 0.57, 
95%CI: 0.45 to 0.73; I2=0%) (Figure 18). Adjusting the data to the 30-days mortality rate 
reported by Majeed and colleagues121, 78 deaths (95%CI: 63 to 98) would have been avoid per 
1000 patients surviving to a major bleeding event treated with NOACs compared to VKA. 
 




Figure 18: Forest plot of meta-analysis evaluating the mortality after a major bleeding events with 
NOACs and VKA. 
 
 
Outcome results according to NOAC 
NOACs were comparable in terms risk of major bleeding risk and fatal events associated with 
major bleeding, either for AF, VTE or overall. The risk reductions for all the above presented 


















Pooled analysis from randomized controlled data shows that NOACs significantly decreased 
the risk of fatal bleeding in patients with AF and VTE compared to VKA (with or without an 
initial stage with LMWH). In patients with AF these drugs were also associated with a 
significant decreased risk of all-cause mortality in major bleeding survivors. Major bleeding 
case-fatality was also significantly reduced in this context. Despite the absence of specific 
antidotes, NOACs did not show an increased risk of mortality associated to the bleeding 
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Gastrointestinal (GI) bleeding is the most frequent cause of major bleeding accounting for 30-
40% of the overall major bleeding events 121-124 and some studies have shown an increased risk 
of GI bleeding among NOAC treated patients 70,110. A previously published systematic review 
have also associated NOACs with an increased GI major and clinically-relevant non-major 
bleeding risk 125. However, the overall severity of this ‘class effect’ is not known and requires a 
comprehensive evaluation of major GI bleeding events, rather than clinically relevant 
bleedings. Therefore, the risk of major GI bleeding associated to NOACs was evaluated, 
through a systematic review with meta-analysis of randomized controlled trials (RCTs). 
 
METHODS 
This was a systematic review and meta-analysis of randomized controlled trials (full 
methodology detailed the published version of the article and briefly explained in the Section 
3.1) reporting data for GI bleeding events comparing NOACs, against VKA (with or without 
an initial stage with concomitant LMWH in patients with atrial fibrillation (AF) or venous 
thromboembolism (VTE). 
Primary outcome was major GI bleeding, as defined by the International Society on 




Twelve studies with 102790 patients were analysed70,109-120: 5 RCTs with AF patients,70,109-112 and 
7 studies with VTE patients.113-120.  
Mean follow-up period ranged from 1 to 2.8 years for AF trials, and most of VTE patients 
had a 6 months of follow-up.  
 
Major GI bleeding risk analysis 
Five RCTs evaluated 72961 patients with AF, comparing NOACs with VKA.70,109-112 
Compared to VKA, NOACs were not associated with an increased risk of major GI bleeding 
(RR 1.08; 95%CI: 0.85 to 1.37, I2=78 %, Figure 20) 




Seven RCTs evaluated a total of 29829 patients with VTE and compared NOACs with VKA 
(with or without initial treatment with LMWH) 113-120. Major GI bleeding risk was not different 
between NOACs and VKA (RR 0.77, 95%CI: 0.49 to 1.21, I2=43 %, Figure 20). 
 
Overall, NOACs were comparable to VKA (± LMWH) in 12 RCTs enrolling 102790 patients 
with AF or VTE, as no differences were found in the pooled major bleeding risk (RR 0.97, 




Figure 20: Forest plot of major GI bleeding risk associated to NOACs compared with VKA. 
 
Figure 20 shows the results of the pooled analysis of major GI bleeding risk of NOACs 
compared to VKA, and Figure 21 shows the risk of major GI bleeding with each individual 
NOAC. None of the NOACs individually were associated with an increased risk of major GI 
bleeding, and there were no significant differences among them. 
CHAPTER III: SAFETY AND TOLERABILITY OF ORAL ANTICOAGULANTS 
 
 91 




The main conclusion of this systematic review is that NOACs, overall, did not increase the 
risk of major GI bleeding. Even with the established proneness to GI bleeding associated to 









Anticoagulants pose an increased risk of bleeding 126. Amongst the many possible different 
bleeding events, both in terms of location and severity, intracranial hemorrhage (ICH) is by far 
the most feared due to the increased morbidity and lethality 127,128. In RCTs, NOACs risk of 
major bleeding events has been heterogeneous 129,130, and uncertainty exists regarding a 
putative “protective” effect of NOACs in comparison to other antithrombotic drugs through 
all indications, as well as the clinical relevance of this effect. Therefore, NOACs ICH risk was 
analysed through a systematic review of RCTs. 
 
METHODS 
This was a systematic review and meta-analysis of randomized controlled trials (full 
methodology detailed the published version of the article and briefly explained in the Section 
3.1) reporting data for ICH comparing NOACs, against VKA or sequential treatment of 
LMWH and VKA in patients with atrial fibrillation (AF) or venous thromboembolism (VTE). 
The outcome of interest was intracranial hemorrhage (ICH), a component of major bleeding 
according to the International Society of Thrombosis and Haemostasis.95 
 
RESULTS 
Overall 11 RCTs (99346 patients) reporting data about ICH, and comparing NOACs with 
VKA, were included: 5 trials evaluating AF (72961 patients) patients70,109-112, and 6 trials with 
VTE patients (26385 patients)113-119. 
 
Intracranial hemorrhage risk analysis 
Pooled analysis of AF trials showed a significant 56% ICH risk reduction (RR 0.44, 95%CI: 
0.35 to 0.55), with moderate statistical heterogeneity (I2=49%) (Figure 22). NNT to avoid 1 
ICH was 123 (95%CI: 105.8 to 152.8), and the ICH events saved per 1000 patients treated with 
NOACs were 8 (95%CI: 6.5 to 9.5). 
In VTE patients the comparison of NOACs with VKA (with or without the sequential 
treatment with LMWH), showed with a significant 69% risk reduction of ICH risk with 
NOACs (RR 0.37, 95%CI: 0.18 to 0.74), without statistical heterogeneity (I2=0%) (Figure 22). 
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NNT to prevent one ICH compared to VKA was 714 patients (95%CI: 615.2 to 888.6) during 
an average of 7 months. This means that 1 ICH event (95%CI: 1.1 to 1.6) is avoided per 1000 
patients treated with NOACs compared to VKA. 
 
Globally NOACs significantly reduced the risk of ICH by 57% (RR 0.43, 95%CI: 0.36 to 0.51) 
compared to VKA. In terms of absolute risk assessment, NOACs owe a NNT of 162 patients 
(95%CI: 143.9 to 188.0) and 6 patients without ICH (95%CI: 5.3 to 6.9) per 1000 treated with 
NOACs. 
The forest plot with the pooled analysis of ICH risk associated with NOACs is illustrated in 
Figure 22. Figure 23 shows that the ICH risk reduction is transversal to all NOACs. 
 
 
Figure 22: Forest plot with risk of intracranial hemorrhage with NOACs in comparison to VKA. 
 
 






Intracranial hemorrhage is a well-known and lethal complication of anticoagulant drugs 131,132. 
Knowing that this the bleeding site most commonly associated to disability and mortality, the 
results here obtained are of paramount importance. It is not well established the reason for 
NOACs superiority, however it is known that cerebral vessels hemostasis is likely to be highly 
dependent on the tissue factor/factor VIIa interaction to primarily initiate the coagulation 
process. Unlike VKA, which block the carboxylation process and inhibit the production of 
functional factor VII, among other coagulation factors, NOACs directly and selectively inhibit 
factor IIa or Xa without interfering with the primary hemostatic mechanism of cerebral 
vessels. 
In conclusion, for patients requiring anticoagulation treatment, the risk of ICH is about half 
with NOACs in comparison to VKA (with or without LMWH). 
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Intraocular and pericardial hemorrhages are quite important due to their potential 
consequences.  
Although rare 19, substantial intraocular hemorrhages can cause severe visual acuity 
impairment  and, in some cases, surgery is needed for complete resolution 133. 
Pericardial hemorrhages with NOACs have been seldom reported, but their consequences can 
be lethal 134. 
Therefore, to better estimate the risk of these clinically-relevant bleedings (event defined by 
default as a major bleed according to the ISTH definition95) with NOACs, a systematic review 
and meta-analysis of RCTs was performed. 
 
METHODS 
This was a systematic review and meta-analysis of randomized controlled trials (full 
methodology detailed the published version of the article and briefly explained in the Section 




Ten RCTs (91106 patients) were included with data for intraocular bleeding 70,109-119, and 6 
trials (79083 patients) reported pericardial bleeding70,109,110,112,115,119. 
 
Intraocular hemorrhage risk analysis 
No difference was identified between NOACs and VKA among both AF (RR 0.84, 95%CI: 
0.59 to 1.19, I2=35%) and VTE patients (RR 0.67, 95%CI: 0.37 to 1.20, I2=0%) (Figure 24).  
The overall analysis confirmed the absence of evidence for increased risk of substantial 
intraocular bleeding was associated with NOACs (RR 0.79, 95%CI: 0.61 to 1.03; I2=8%) 
(Figure 24). 
 




Figure 24: Forest plot with results of pooled analysis regarding intraocular bleeding. 
 
Pericardial bleeding risk analysis 
Pooled results also did not show an increased risk of pericardial bleeding with NOACs in AF 
setting (RR 1.06, 95%CI: 0.37 to 3.06), VTE patients (RR 0.26, 95%CI: 0.03 to 2.31), or in the 
overall analysis (RR 0.81; 95%CI: 0.31 to 2.11) (Figure 25). No heterogeneity was noticed 
across studies estimates (I2=0%).  
 
 
Figure 25: Forest plot with the results of the pooled analysis regarding pericardial bleeding. 
 




As expected, due to the rare frequency of these events, individual NOACs were not associated 
to an increased or decreased risk of intraocular or pericardial bleeding.  
The Figure 26 shows the estimated for each individual NOAC. 
 
 





These results highlight the absence of evidence about differences in the risk of intraocular and 
pericardial hemorrhages between NOACs and VKA (with or without LMWH). 
For intraocular hemorrhage, only substantial events such as hyphema, vitreous hemorrhage, 
subretinal hemorrhage and suprachoroidal hemorrhage were considered as major bleeding 
events. This definition respects the criteria established by ISTH 95, excluding minor 
uncomplicated bleedings, such as subconjunctival hemorrhages. 
Pericardial hemorrhages are very rare, but potentially, life-threatening clinically events. Based 
on the best available evidence, no safety alert can be raised for an increased risk of pericardial 
or intraocular bleeding with NOACs. 
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3.3. Non-bleeding adverse events 
 
While most of the safety issues regarding antithrombotic drugs mainly rely on the clinical 
assessment of the pharmacodynamics consequences, such as bleeding (reported the previous 
section), other pharmacokinetics-related adverse events or other possible off-target effects can 
arise and must be scrutinized in order ensure the safety of drugs. 
Liver and kidneys are the main organs for overall drug metabolism and excretion.  
All oral anticoagulants, with exception of dabigatran, are metabolized by liver cytochrome 
P450. Furthermore, the recent history of ximelagatran (an oral direct thrombin inhibitor) post-
marketing withdrawal due increased risk of liver injury51, increases the need of safety 
reassurance regarding the hepatic safety of NOACs. 
All oral anticoagulant drugs (NOACs and VKA) are at least in some extent excreted in the 
urine. Acute kidney injury episodes related to anticoagulant treatment was recently described 
and deemed to have a prognostic impact135.  
For the reasons previously mentioned, drug-induced liver injury and renal dysfunction risks of 
NOACs were assessed in this section. 
Other outcomes evaluated in this section, such as insomnia and infections, were elicited by the 
unexpected findings in trials or observational studies, and anecdotal case report letters. 
As none of the mentioned outcomes are expected to be related to specific conditions or other 
known anticoagulant drugs, to further increase the power of the analysis, other conditions and 
comparator (other than AF and VTE; and VKA, respectively), were considered for the 
analysis of the risk of non-bleeding adverse events. 
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3.3.1. Drug-induced liver injury 
 
BACKGROUND 
Drugs are frequently metabolized in the liver 136. Drug-induced liver injury (DILI) includes a 
broad clinical and pathologic spectrum of hepatotoxicity, and many genetic and non-genetic 
patient characteristics have been proposed as risk factors for DILI from medications 137,138. In 
recent years, safety alerts have been made warning for the risk of DILI, including life-
threatening liver failure, caused by cardiovascular drugs. For example, dronedarone, an 
antiarrhythmic drug, can cause serious liver injury 139, and ximelagatran, an oral direct 
thrombin (IIa) inhibitor, has been withdrawn from the market in 2004 due to the risk of DILI 
51. These safety warnings only emerged with post-marketing experience because hepatic 
adverse drug reactions due to cardiovascular drugs are relatively uncommon, but potentially 
serious, and premarketing clinical trials are underpowered to detect differences between 
treatment arms. These recent high profile cases of serious liver adverse reactions associated 
with cardiovascular drugs have amplified the need for careful pre-marketing analysis of DILI 
risk associated safety. 
Therefore, a systematic review and meta-analysis of randomized controlled trials was 




This was a systematic review and meta-analysis of randomized controlled trials (full 
methodology detailed the published version of the article and briefly explained in the Section 
3.1). All RCTs were considered for inclusion irrespective of patients’ disease, comorbidities, 
background therapy, NOAC treatment duration or follow-up. Only trials reporting hepatic 
data as a pre-specified outcome were included to avoid selective reporting. Trials had to 
provide laboratory data for transaminases and bilirubin. 
Primary outcome was DILI, defined as increases in serum levels of transaminases above three 
times the upper limit of normal (ULN) and total bilirubin above two times the ULN. 
According to Hy’s law, the outcome defined above is the most specific predictor of potential 
severe hepatotoxicity 96. Secondary outcomes were incidence of transaminases elevation >3x 
ULN, and incidence of bilirubin elevation >2x ULN.  
 





For DILI analysis, 26 studies enrolling 161800 patients were included39,70,109-115,117-120,140-151. 
About 90912 of these patients were treated with NOACs. The NOACs evaluated were 
apixaban (7 RCTs; 45122 patients) 39,109,140-144, dabigatran (7 RCTs; 31670 patients) 
70,113,118,119,145,146, edoxaban (2 RCTs; 28848 patients)112,117, and rivaroxaban (10 RCTs; 56160 
patients)110,111,114,115,120,147-151.  
Patients’ mean age varied between 55 and 71 year-olds across trials. About 30% (43 130 
patients) of the patients had AF. The weighted mean follow-up was 16.6 months (range, 2 
weeks to 2.8 years). 
Low-molecular weight heparin (LMWH) was the most common control group as it was 
included in 39% of the studies. 
 
For transaminases elevation analysis, 25 trials with 145164 patients were 
included39,70,109,111,113,114,116,118,120,140-142,144-147,149-154: 7 RCTs with apixaban (47838 patients) 39,109,116,140-
142,144, 8 RCTs with dabigatran (31670 patients) 70,113,118,145,146,152,153, 2 RCTs with edoxaban (28848 
patients) 112,117, and 8 RCTs with rivaroxaban (33519 patients)111,114,120,147,149-151,154. 
 
Bilirubin elevation was studied in 9 RCTs including 41692 patients70,116,118,140-142,147,150,151. These 
trials evaluated the following NOACs: apixaban (4 RCTs; 16723 patients)116,140-142, dabigatran 
(2 RCTs; 19476 patients)70,118, and rivaroxaban (3 RCTs; 5493 patients)147,150,151. 
 
Risk of DILI (transaminases >3x ULN with total bilirubin >2x ULN) analysis 
Pooled analysis of 26 studies showed that NOACs does not increase the risk of DILI 
(transaminases >3x ULN with total bilirubin >2x ULN). The RR was 0.93 (95%CI: 0.75 to 
1.15). Individually, none of the NOACs increased the risk of DILI and no differences were 
found between NOACs (p=0.31) in the risk of DILI against control. There was no 
heterogeneity among studies results (I2=0%). Figure 27 shows the detailed results for this 
outcome 
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Figure 27: Forest plot with results of DILI (elevation of transaminases >3x ULN and of total 




Risk of transaminases elevation (3x ULN) analysis 
Interestingly, NOACs were less likely than controls to have transaminase elevations >3x ULN 
(RR 0.81; 95%CI: 0.72 to 0.91) (Figure 28). Moderate heterogeneity (I2=47%) was found 
between studies. This “protective” effect was apparently higher among LWMH-controlled 
studies. Therefore, an exploratory analysis according to the control group of the trials was 
performed.  




Figure 28: Forest plot of transaminases elevation (3x ULN) risk associated to NOACs. 
 
 
Pooled results from LMWH-controlled trials showed a 29% risk reduction (RR 0.71; 95%CI: 
0.59 to 0.85; data not shown in figures) of transaminases elevations among NOAC treated 
patients in comparison to LWMH, with low-to-moderate heterogeneity (I2=27%). Pooled 
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Risk of bilirubin elevation (2x ULN) analysis 
In terms of bilirubin elevation, NOACs were similar to controls with a RR 0.98 (95%CI: 0.61 








The main findings of this systematic review are that NOAC are not associated with an 
increased risk of DILI, based on pooled estimates from large RCTs. Globally, DILI is an 
uncommon event from a population perspective with an annual incidence rate of 1-2 events 
per 1000 patients155. Due to the potential severity of this adverse event it is important to 
estimate the risk of DILI in the most possible precise way and as soon as possible during the 
early phase of drug development and before massive post-marketing use. Meta-analysis 
increases the power to detect group differences. In the case of NOAC, the present meta-
analysis included data from more than 150 000 patients, more than half exposed to NOAC 
treatment during a mean duration of 16 months. 
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All NOACs (with different extensions) are somehow excreted by the kidneys, meaning that in 
patients with severe renal dysfunction the concentration of anticoagulant and its effects 
increase. Safety in this setting is not assured as pivotal clinical studies did not include patients 
with estimated glomerular filtration rate <25 mL/min.  
Furthermore, the recent description of acute kidney injury episodes associated to 
anticoagulant treatment deserved the attention of the scientific community135. Therefore, to 
adequately evaluate NOACs in terms of renal failure, which by itself may impose important 
changes in the pharmacokinetics (or in the indication of use), a systematic review and meta-
analysis of RCTs was performed. 
 
METHODS 
This was a systematic review and meta-analysis of randomized controlled trials (full 
methodology detailed the published version of the article and briefly explained in the Section 
3.1). All RCTs were considered for inclusion irrespective of patients’ disease, comorbidities, 
background therapy, NOAC treatment duration or follow-up. Trials had to provide data about 
renal dysfunction or laboratory markers of kidney function. 
Primary outcome was renal failure reported by investigators as an adverse event (or serious 




Eleven trials reported the outcome of interest70,109-112,118,119. These trials enrolled overall 90768 
patients. Seven of these were VKA-controlled trials (with or without an initial stage with 
concomitant LMWH): 5 AF RCTs70,109-112 and 2 VTE RCTs118,119, with overall 78385 patients. 
The remaining were rivaroxaban LMWH-controlled trials with patients that underwent 
orthopedic surgery149-151,154.  The mean age of patients included in RCT ranged from 55 to 73 
years. Follow-up varied between 1 month (post-orthopedic surgery thromboprophylaxis 






Renal failure as increase of serum creatinine was the outcome sought in three studies109,118,119, 
treatment-emergent adverse event (TE AE) for one study111, and treatment-emergent serious 
adverse events (TE SAE) for 3 studies70,110,112.  
For RECORD (1-4) studies149-151,154, a series of trials evaluating rivaroxaban versus low-
molecular weight heparin (LMWH) in patients undergoing orthopedic surgery, 2 outcomes of 
interest were available: overall TE SAE acute renal failure for all the 4 trial together; and 
high/increase of serum creatinine, separately for RECORD1-2149,154, and RECORD3-4150,151.  
 
Renal failure risk analysis 
Data from 10 RCTs with 75100 patients were included for analysis (40507 treated with 
NOACs).  
 
Primary analysis of renal failure as a treatment-emergent serious adverse event (TE SAE) did 
not associate NOACs to this outcome (RR 0.93; 95%CI: 0.82 to 1.05; I2=0%), among 65837 
patients (Figure 30). 
 
 
Figure 30: Forest plot with evaluation of NOACs risk of renal failure as treatment-emergent SAE. 
 
The use of other outcomes was remarkable in RECORD1-2 (increase of serum creatinine) for 
an increase of renal failure risk in rivaroxaban arm compared to LMWH (RR 1.29, 95%CI: 
1.11 to 1.50). Nevertheless, the analysis of the primary outcome (TE SAE renal failure), 
ensures safety and does not confirm this proneness in terms of severity in a larger population. 
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Analysis according to renal failure definition was performed (Figure 31).  
J-ROCKET that was the only study reporting TE AE renal impairment and significant 
increased risk of this adverse event was noticed in this trial (Figure 31). The pooled results of 




Figure 31: Risk of renal dysfunction with NOACs according to the outcome definition. AE: Adverse 




NOACs did not show an increased risk of serious renal failure compared to other 
anticoagulants drugs. Rivaroxaban showed an increased risk of creatinine elevation in trials of 
thromboprophylaxis after hip or knee surgery. Surveillance should be warranted in order to 










Insomnia is common sleep disorder characterized by difficulty to initiate or maintain sleep156. 
This condition can lead to impaired life quality and inability to adequately perform many tasks 
of daily living activities157,158.  
Darexaban, is an anti-Xa oral anticoagulant discontinued in the clinical development stage due 
to the lack of partnerships for large clinical development and commercialization159. In a phase 
III randomized mechanical prophylaxis-controlled trial, darexaban showed high rates of 
insomnia, although it was not different than the proportion of insomnia reported in patients 
with mechanical thromboprophylaxis160. Insomnia is known to be an important adverse event 
associated to mechanical thromboprophylaxis161, and similar rates of insomnia obtained 
between darexaban and thromboprophylaxis were not expected. However, since the trial had 
an open-label design, the perception of adverse events by patients and/or physicians may have 
been biased162. Furthermore, insomnia related adverse events may be reported in a subjective 
manner163.  
These reasons support the aim of the systematic review of RCTs, in order to reassure the 




This was a systematic review and meta-analysis of randomized controlled trials (full 
methodology detailed the published version of the article and briefly explained in the Section 
3.1). All RCTs were considered for inclusion irrespective of patients’ disease, comorbidities, 
background therapy, NOAC treatment duration or follow-up. Trials had to provide data about 
the adverse event insomnia as reported by investigators. 
Beyond the considered NOACs (apixaban, dabigatran, edoxaban, rivaroxaban), darexaban’s 
trial (Sakon et al160; despite of the discontinuation in the development) was included because 








Seven phase RCTs reported the frequency of insomnia as an adverse event140,144,146,149,150,153,160. 
Overall these trials included 23023 patients.  
 
Insomnia risk analysis 
Overall, the meta-analysis showed that NOACs did not increase the risk of insomnia, RR 0.94 
(95%CI 0.83-1.08; I2=0%), and no differences were found between each of these drugs 
(p=0.97). Figure 32 shows the forest plot of the meta-analysis. 
 
 
Figure 32: Pooled risk of insomnia with NOACs, including darexaban. 
 
 
One of the purposes of this review was to evaluate whether the study design (open label vs. 
blinded studies) had an impact in the risk of insomnia. In blinded studies, NOACs were not 
associated to increased risk of insomnia (RR 0.94, 95%CI 0.83-1.08; I2=0%). 
 
CONCLUSIONS 
This systematic review did not show increased risk of insomnia with NOACs. This question 
was driven by the results of a RCT comparing darexaban with mechanical prophylaxis in the 
prevention of venous thromboembolism in patients undergoing major abdominal surgery160. 
One of the points of interest of this trial was its open-label design, with the reported incidence 
of insomnia being high despite the absence of differences among the interventions. The risk 
of insomnia with mechanical thromboprophylaxis was expected to be higher compared to 
darexaban, and study design was hypothesized explain differences in the estimates. The results 
of this meta-analysis showed that NOACs were also not associated to insomnia in blinded 









There is a bilateral relationship between inflammation and coagulation164,165. Inflammation is 
an important component of the innate immune system. Acute inflammation as arises in 
systemic infections (sepsis) is known to activate the coagulation system being possible to 
occur disseminated intravascular coagulation, a potentially lethal complication of sepsis. It is 
generally accepted that there are 3 mechanisms for this prothrombotic complication: cytokine-
induced tissue factor expression; the downregulation of activated protein C (a endogenous 
anticoagulant; see Chapter I); and decreased fibrinolysis164. Inversely, coagulation may prompt 
to or enhance the immune response. Coagulation factors such as thrombin and factor Xa can 
activate protease-activated receptors (PARs), increase the endothelial adhesion and chemotaxis 
of leucocytes, and the production of cytokines166.  
Considering the role of thrombin and factor Xa in the immune response, some doubts were 
raised concerning the role of the NOACs in the proneness to infections167. In fact some have 
elicited this link based on observational studies (higher rate of wound complications after 
orthopedic surgeries168, and anecdotal case reports connecting NOACs to infections 
(particularly urinary tract infections)169. 
To further clarify this link, a systematic review and meta-analysis of RCTs with data about 




This was a systematic review and meta-analysis of randomized controlled trials (full 
methodology detailed the published version of the article and briefly explained in the Section 
3.1). All RCTs were considered for inclusion irrespective of patients’ disease, comorbidities, 
background therapy, NOAC treatment duration or follow-up. Trials had to report data about 










Twelve RCTs reporting outcomes of interest were included39,70,109,110,112,115,144,146,149-151,154. 
 
Infection risk analysis 
Pooled analysis of 8 RCTs (with 66186 patients) showed that NOACs did not increase the 
risk of infection (RR 0.98, 95%CI: 0.96 to 1.01; I2=0%) (Figure 33) 
 
Post-surgery/wound infection risk was not increased with NOACs with a RR 0.93 (95%CI: 
0.59 to 1.46; I2=0%) in a meta-analysis with 5 RCTs with 14196 patients (Figure 33).  
 
Unexpectedly, NOACs showed a significant 6% risk reduction of urinary tract infection 
rate (RR 0.94, 95%CI: 0.88 to 0.999; I2=15%) in a meta-analysis with 78998 patients 
enrolled with 5 trials (Figure 33). The NNT to prevent one patient to have urinary tract 
infection with NOACs was 281 (95%CI: 140.6 to >1000000), and 4 events (95%CI: 0 to 
7.1) prevented for each 1000 patients treated with NOACs, according to the presented data. 
 
 
Figure 33: Forest plot with pooled risks of all infections, post-surgery infection and urinary tract 





Each of the NOACs was individually assessed and none was associated with an increased risk 









Despite the potential link between anticoagulants and immunity, this systematic review did not 
find any association between NOACs and increased risks of overall infection or post-
orthopedic surgery. Conversely, NOACs showed to reduce significantly the risk of urinary 
tract infections, mostly due to the results of dabigatran in RE-LY trial70. Even with this 
dimension of the sample size, none of the trials were not designed to assess the infectious risk 
of interventions. Accordingly, the putative ‘protective’ effect is very small, and it is not 
warranted. Furthermore, this analysis is limited by the selective reporting bias (opportunistic 
reporting of infectious adverse events) as the outcomes were not predefined. Pooling the 
results at study-level also increases the risk of bias particularly when different populations are 
included in the analysis. 
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The success and effectiveness of any chronic treatment, anticoagulation included, depends on 
patients’ tolerability and adherence to the medication. While venous thromboembolism 
treatment or prevention may require only temporary anticoagulant treatment 89,90, stroke 
prevention in AF demands life-long treatment. 
NOACs have overcome many limitations of VKAs, namely the variability in dose response 
and the convenience related to absence of frequent coagulation monitoring and dose 
adjustments.  
However, life-long potential clinical benefits seen in RCTs and meta-analysis are only 
outweighed if the adverse reactions’ and medication adherence profile are at least similar to 
that experienced by patients treated with VKAs. In this systematic review, tolerability and 





This was a systematic review and meta-analysis of randomized controlled trials (full 
methodology detailed the published version of the article and briefly explained in the Section 
3.1) comparing NOACs and VKA in patients with AF. 
The outcomes of interest were tolerability and acceptability of NOACs. 
Tolerability was indirectly evaluated by determining the incidence of any serious adverse event 
(SAE), as reported by investigators and/or adjudicated by committees. Whenever possible, 
treatment-emergent SAEs were retrieved. 
Acceptability was split in drug-related (also associated to the tolerability profile) and patient-
related treatment discontinuation97. Discontinuations due to adverse events were considered 
to be drug-related, and discontinuations due to patients’ own decisions (consent withdrawal 
and treatment discontinuation) were considered to be patient-related. Whenever possible, the 
denominator of these outcomes was the safety population of each arm (i.e. patients that took 
the drug). 
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Due to the expectation of inclusion of both open-label and blinded RCTs, and considering the 
possible influence of these characteristics in the analysed outcomes, a prespecified sub-group 
analysis according to the blinding status of included trials was planned170. Despite the 
distinctive pharmacokinetic and pharmacodynamic properties of individual NOAC drugs, it 
was hypothesized that these drugs could have a class effect compared to VKAs.  
 
RESULTS 
Five RCTs were included in the systematic review evaluating four NOACs70,109-112: apixaban109, 
dabigatran70, edoxaban112, and rivaroxaban (two studies with rivaroxaban110,111). 
Altogether, these trials enrolled 72 720 patients with AF under oral anticoagulant treatment, 
59% of them treated with NOACs. All trials had a double-blinded scheme with the exception 
of RE-LY which had an open-label design70. 
 
Tolerability and acceptability analysis 
NOACs were associated with a small yet significant 4% risk reduction of SAE in patients with 
NVAF (RR 0.96; 95%CI: 0.94 to 0.98; Figure 35 upper panel). The results were consistent 
across studies, without any statistical heterogeneity (I2=0%). NNT with NOACs to expect the 
prevention of 1 SAE compared to VKA was 74 (95%CI: 49 to 148) for an average period of 
1.7 years. For each 1000 patients treated with NOACs instead of VKA, it is expected that 14 
SAE (95%CI: 7 to 20) would be prevented for an average period of 1.7 years. 
Drug discontinuation rate due to adverse events was similar between NOACs and VKAs (RR 
1.03; 95%CI: 0.88 to 1.21; Figure 35 mid panel). This analysis was remarkable for significant 
statistical heterogeneity (I2=93%)  
Patient-related drug discontinuation was also similar between NOACs and VKAs (RR 0.99; 








Figure 35: Forest plots with NOACs pooled risks of SAE (upper panel), drug-related discontinuation (mid 
panel), and patient-related discontinuation (bottom panel). 
 
Subgroup analysis according to study design 
RE-LY study (dabigatran versus VKA) was the only open-label trial70. The risk reduction of 
SAE was not different between blinded and open-label RCTs (p=0.49) (Figure 36).  
For both drug- and patient-related treatment discontinuations, the results for dabigatran versus 
VKA (derived from the open-label RE-LY trial) were significantly different compared to the 
pooled results for the other NOACs (p<0.0001 and p=0.0001, respectively) (Figure 36).  
 
Dabigatran was associated with a significant increase of both drug- and patient-related 
treatment discontinuations, while pooled results for the other NOACs showed a reduction in 
the risk of discontinuation due to patients’ own decisions (Figure 36). The level of 
heterogeneity in pooled estimates for discontinuation due to drug- and patient-related causes 
decreased when RE-LY trial was removed from the analysis (I2=67% and I2=0%, 
respectively). 
 




Figure 36: Pooled risks of tolerability and acceptability outcomes according to the trials design (open-
label vs. double-blinded). * p-value for interaction <0.0001; ** p-value for interaction =0.0001. 
 
A further exploratory analysis was performed by adding both drug- and patient-related 
treatment discontinuations into a single outcome. As expected, overall NOACs did not reduce 
the incidence of this outcome (RR 1.00; 95%CI: 0.88 to 1.14; data not shown in the figures), 
with high heterogeneity (I2=95%), mostly due to RE-LY (RR 1.25; 95%CI: 1.18 to 1.32). 
Without RE-LY, NOACs showed a 5% reduction of drug discontinuation risk (RR 0.95; 




Overall, NOACs were associated with a significant 4% reduction in the risk of SAE. NOACs’ 
drug-related and patient-related acceptability profiles were similar to VKA. At this level 
NOACs did not show a clear drug-class effect.  
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3.5. Chapter discussion and conclusions 
 
NOACs have been proven to be at least as efficacious as other alternative treatment 
options, in particular VKA, with a more favorable pharmacological profile. As seen the 
number of patients treated with NOACs is increasing overtime.  
In this chapter the safety and tolerability profiles of NOACs were evaluated. The main 
findings were: 
1) NOACs have a favorable safety profile with decreased risk of major bleeding, 
bleeding-related mortality and ICH; 
2) NOACs are not more frequently associated with non-bleeding adverse events 
(including hepatic and renal function).  
3) NOACs have a favorable tolerability profile, with a decreased risk of overall serious 
adverse events and patient-related drug discontinuation (except for dabigatran). 
 
Bleeding adverse events 
According to findings presented in this dissertation, NOACs were not associated with an 
increased risk of major bleeding, or bleeding-related mortality. In fact, based on published 
random controlled data, NOACs decrease the risk of fatal events directly or indirectly 
related to major bleeding, particularly in AF patients.  
 
Concerns have been raised against NOACs due to the absence of an antidote to reverse 
anticoagulation in patients with major bleeding events171.  In an individual patient the lack 
of an antidote may interfere with the clinician’s perception of available therapeutic rescue 
options. However, most of the studies show that the majority of major bleeding events are 
managed solely with supportive therapy or red cell transfusion70,121,122. Putting all data into 
context, NOACs appear to be safer than VKA, even in the absence of specific antidotes 
for these drugs. 
 
Some of these findings may be tightly related to the decreased risk of ICH with NOACs in 
patients with AF and VTE requiring medium or long-term effective anticoagulation. 
Taking into consideration that ICH is commonly associated with important disability and 
mortality, these results are of paramount importance. Also according to the presented 
findings, the safer risk profile of NOACs also applies to other conditions with other 
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standard comparators, such as patients requiring anticoagulation after hip or knee 
arthroplasty usually treated with LMWH 79. 
It is not well established the reason for this safer profile, however it is known that cerebral 
vessels hemostasis is likely to be highly dependent on the tissue factor/factor VIIa 
interaction to primarily initiate the coagulation process172. Unlike VKA, which block the 
carboxylation process and inhibit the production of functional factor VII, among other 
coagulation factors, NOACs directly and selectively inhibit factors IIa or Xa without 
interfering with the primary hemostatic mechanism of cerebral vessels172. 
As for GI bleeding risk, it is known that to NOACs have an oral route of administration 
and, with the exception of dabigatran, all of them may have their anticoagulant effect 
directly in the mucosa of the gut. Dabigatran etexilate is a prodrug, and is converted into 
the active metabolite by esterases present in the gut, plasma and liver.173 Moreover, 
dabigatran’s oral route bioavailability is 7% and the remainder may act locally in the 
absorption site. Therefore it is not surprising that overall NOACs encompass an increased 
risk of GI bleeding,125 but these data shows that this increased risk is not due to severe 
events (major bleeding). 
NOACs also did not increased the risk of pericardial and intraocular bleeding, which are 
important causes of bleeding-related mortality and disability, respectively. 
Despite these encouraging safety results, the prescription act of any antithrombotic drug is 
the net result of balancing the risk of ischemic and hemorrhagic events for an individual 
patient. Unfortunately, clinical trials still have no standardized measures for net clinical 
benefit evaluation174.  
 
Non-bleeding adverse events 
Ximelagatran, the first approved NOAC, was later withdrawn from the market in 2004 
following the detection of an increased risk of severe liver injury51. The hepatic risk profile 
of this drug was not noticed in short term studies (i.e. less than one month of follow up). 
In long term trials, the increase in serum levels of ALT (> 3x ULN) was 7-fold higher with 
ximelagatran compared to warfarin.  
This prompted the attention of pharmacovigilance among the newer NOACs studies in 
respect to hepatic events.  
Due to the potential severity of this adverse event it is important to estimate the risk of 
DILI in the most possible precise way and as soon as possible during the early phase of 
drug development and before massive post-marketing use. The resuls were robust in terms 
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of cumulative sample size and follow-up, and failed to find an increased risk of liver injury 
with NOACs.  
Unexpectedly, NOACs in general, and dabigatran in particular (which is not metabolized in 
the liver), were also less likely to increase transaminases compared to controls. 
Interestingly, this putative “protective” effect of NOACs was more evident in studies 
which had as control group LMWH. Therefore, one can hypothesize that these results are 
not due to a true “protective” effect of NOAC, but rather due to LMWH-associated 
hepatotoxicity. In fact, hepatotoxicity has been reported to occur in up to 5-10% of 
LMWH-treated patients175. Despite all, it is unlikely that these results have clinical 
significance and, therefore, no claims can be made to change the current clinical practice 
based on these results. Furthermore, there were no differences between NOAC and 
LMWH regarding the elevation of transaminases and bilirubin, which is a more sensitive 
measurement of DILI risk. 
 
Overall, NOACs were also not associated with an increased risk of renal failure compared 
to VKA, particularly serious acute renal failure, although some studies reported a higher 
incidence of creatinine increase with rivaroxaban176.  
Darexaban was another NOAC which have not reached the market159. In the pivotal phase 
III trial, it was with surprise that the risk of insomnia was similar between darexaban and 
mechanical thromboprophylaxis160. Therefore, it was hypothesized that NOACs, as a drug-
class, could have an increased risk of insomnia. These findings failed to confirm this 
hypothesis  
As for infection risk, despite the potential link between anticoagulants (particularly those 
targeting thrombin or Xa, such as NOACs) and immunity, no associations were found 
between NOACs and the risk of overall infection, post-orthopedic surgery wound 
infection or urinary tract infection.  
 
 
Tolerability and acceptability 
NOACs were associated with a small, yet clinical significant decrease in the risk of SAE 
when compared to VKA, without differences between individual NOACs, suggesting a 
drug-class effect regarding this outcome. These results reflect differences in the tolerability 
profile, with lower risk of events with NOACs.  
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Acceptability analysis (whether drug-related or patient-related) returned heterogeneous 
results. In terms of drug-related discontinuation, and with the exception of dabigatran, 
NOACs showed an acceptability overlapping that of VKA. In RE-LY study, patients 
treated with dabigatran had higher discontinuation rates. The knowledge about the 
treatment assigned in RE-LY can, at least partially, explain these findings because patients 
who know that they are being treated with a new active drug may be more prone to 
discontinue in the setting of an adverse event. However, the discontinuation rate in 
dabigatran group due to adverse events was also significantly higher compared to standard 
anticoagulation in the double-blinded double-dummy RE-COVER trial that enrolled 
patients with VTE 113. Gastrointestinal symptoms, namely dyspepsia, were the main reason 
for premature dabigatran discontinuation. 
Concerning patient-related discontinuation (acceptability), no differences were found 
between NOACs and VKA. However, excluding the RE-LY trial from analysis because of 
the above mentioned reasons (open-label design) resulted in a small, yet significant 
reduction of patient-related discontinuation risk with NOACs. It should be empathized 
that there are no obvious reasons for the higher rate of patient-related discontinuation 
among dabigatran-treated patients. In fact, data from RE-COVER trial (double-blind 
design) on patients with VTE does not support it113. 
It is worth noting that, according to previous publications, drug discontinuation or switch 




Systematic reviews with meta-analysis are limited by methodological issues associated to 
meta-analysis and individual studies. The results of the meta-analyses were based on study-
level data and not on individual patients’ data. 
Included studies were powered for their primary outcomes and not to detect differences 
with respect to most of outcomes evaluated individually. Data here presented were derived 
from secondary outcomes of included trials and most of them were of very low frequency. 
 
The analyses included a wide range of conditions, however these findings are mostly valid 
for patients with non-valvular AF potentially suitable for VKA as these were included in all 
analyses (bleeding events, non-bleeding events, tolerability and acceptability). Patients with 
valvular AF (particularly significant mitral stenosis and mechanical heart valves) were not 
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included in any of the studies considered 40. Patients with non-valvular AF unsuitable for 
VKA were only analysed in the AVERROES trial (apixaban versus acetylsalicylic acid) and 
considered for evaluation in non-bleeding adverse events only 39. Despite the differences in 
the clinical characteristics of AF and VTE patients, data from trials including these 
conditions were pooled together in bleeding risk evaluation, based on the assumption that 
the relative risk of interventions would not be different among the diverse prothrombotic 
diseases using the same control127. For non-bleeding risk events, the analysis was performed 
irrespectively of the conditions and controls, as none of these were deemed to influence 
the outcomes.  
 
NOACs are a group of anticoagulant drugs composed by oral thrombin and Xa inhibitors. 
The objective was to evaluate the overall drug-related harms of NOACs, and therefore 
drugs such as dabigatran and edoxaban were evaluated irrespectively of their higher or 
lower dose (data were merged). Despite the pharmacodynamic and pharmacokinetic 
differences among NOACs, these drugs were analysed together under the assumption of a 
class effect due to NOACs similarities in opposition to VKA, particularly, in bleeding 
adverse events, tolerability and acceptability. 
 
At outcome level, all bleeding events were pre-defined in the included trials and followed 
the ISTH definition. However, there is a risk of selective reporting bias for major bleeding 
case-fatality outcome because NOACs and VKA bleeders have different clinical 
characteristics and pooled data were not adjusted to those and other possible differences. 
Hepatic safety data were mainly based on laboratorial results. To be more accurate, other 
causes of hepatic injury and cholestasis should also be evaluated, but data were too scarce. 
Renal safety, insomnia, and infections data were essentially based on the subjective report 
of these events by investigators. None of the outcomes were pre-defined, comprehensively 
searched, or independently adjudicated. Therefore, potential selective reporting bias should 
be considered. 
Nevertheless, and despite these limitations, the results are reasoned to be robust enough to 









In the pooled safety data from phase III RCTs, NOACs were associated with a decreased 
risk of major bleeding, fatal bleeding and ICH compared to the AVK. Regarding the risk of 
major gastrointestinal bleeding, intraocular and pericardial, there was no significant increase 
in these events. 
The NOACs are not associated with liver injury or severe renal impairment. Similarly, there 
was no increased risk of infections or insomnia. 
The overall risk of serious adverse events was significantly decreased by NOACs compared 
to VKA. The results for acceptability (drug discontinuation) were heterogeneous. However, 
for most NOACs the risk of treatment discontinuation due to drugs-related or patient-










Pharmacovigilance of  oral 
anticoagulants 
 
CHAPTER IV: PHARMACOVIGILANCE OF ORAL ANTICOAGULANTS 
 
 125 
4.1. Oral anticoagulants data from the national 





In the last years many changes have been observed in the management of prothrombotic 
conditions due to the arrival of new antithrombotic drugs178,179. The already marketed new oral 
anticoagulants or Non-vitamin K antagonist oral anticoagulants (NOACs) (apixaban, 
dabigatran, edoxaban and rivaroxaban) showed to be at least as efficacious as Vitamin K 
Antagonists (VKA) for the prevention of stroke and systemic embolism associated to non-
valvular atrial fibrillation and for the treatment of venous thromboembolism (VTE). These 
drugs were also effective in the prevention of VTE in patients with hip or knee arthroplasty179. 
Clinical trials are majorly designed for efficacy evaluation. The reduced exposure of new drugs 
during clinical trials before marketing may result in the arising of some unknown adverse drug 
reactions (ADRs) during the post marketing phase. The knowledge of treatments harms is 
essential in order to improve the practice towards an effective and safer level.  Thus post-
marketing drug safety surveillance should complement safety evaluations from clinical trials. 
Hereby, the frequency of reported manifestations of ADRs associated to all oral 





This observational pharmacovigilance study had a retrospective design and evaluated the 
spontaneous notifications of adverse events in the Portuguese National Competent Authority 
Pharmacovigilance Database180,181. 
All oral anticoagulant-related spontaneous notifications of adverse events reported to the 
pharmacovigilance centres of the Portuguese National Authority of Medicines and Health 
Products (INFARMED) were assessed. The first NOAC to be commercialized was dabigatran 
etexilate, in 2010 (according to INFARMED data). Thus, the presented analysis was restricted 
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to the period of January 2010 to April 2015, for the three available NOACs – apixaban, 
dabigatran and rivaroxaban182. 
The incidence of anticoagulant-related ADRs, based on the spontaneous notifications, was 
estimated using nationwide exposures as counting units (CU) and the defined daily dose 
(DDD) of anticoagulants according to the World Health Organization183. Such data was 
provided also by the Portuguese National Authority of Medicines and Health Products 
(INFARMED). The incidences were calculated using ADRs/100 000 CU (national oral 
anticoagulants sells are at this order of magnitude) and ADRs/million of DDD (national oral 
anticoagulants sells are at the dozens of millions of DDD).  
To be eligible, spontaneous notifications had to report the patients’ data (demographics, 
suspected drugs and adverse events) and the professional group of the reporting person 
(physician, pharmacist, nurse, other health professional or user)184. 
Oral anticoagulant drugs were searched and characterized according to their World Health 
Organization (WHO) Anatomical Therapeutic Chemical Code (ATC) Classification System: 
B01AA03 for warfarin, B01AA07 for acenocoumarol, B01AE07 for dabigatran etexilate, 
B01AF01 for rivaroxaban, and B01AF02 for apixaban185. Warfarin and acenocoumarol (these 
are the only VKA commercialized in Portugal) were grouped into VKA class. Dabigatran 
etexilate, rivaroxaban and apixaban were further grouped into NOACs class. Parenteral 
anticoagulants were excluded from this analysis. 
Each report refers to a single ADR case and the whole cases were characterized in terms of 
age and gender distribution, the concomitant use of other relevant non-anticoagulant drugs, as 
well as the seriousness of the suspected ADRs. According to criteria present in international 
guidelines, which are also the ones adopted by the Portuguese System of Pharmacovigilance, 
serious ADRs are those resulting in death, life-threatening events, requiring inpatient 
hospitalization or prolongation of existing hospitalization, resulting in persistent or significant 
disability/incapacity or congenital anomaly/birth defect, or any other medical event deemed 
to be important due to major clinical consequences and/or due to the requirement of any 
medical intervention to reverse it184. 
Spontaneous reports contained at least one potential ADR which was considered a suspected 
ADR. Each event was isolated and classified according to a standardized medical terminology 
that is used in the Medical Dictionary for Regulatory Activities (MedDRA), version 18.0, 
under the System Organ Class (SOC) and the Preferred Term (PT) levels, determined by the 
International Conference of Harmonisation186. 
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The suspected ADRs were also analysed according to the PT, SOC and use of anticoagulant 
drug. Due to the multiaxial properties and classification of MedDRA, thrombotic and bleeding 
events are distributed along the different SOCs. These outcomes are of special interest for 
patients treated with oral anticoagulants as they represent absence of efficacy (thrombotic 
events) and hemorrhagic toxicity (bleeding events). Suspected ADRs were scrutinized and 
classified by two investigators as thrombotic or hemorrhagic according to the Standardised 
MedDRA Queries (SMQ) terms. SMQs are validated, standard sets of MedDRA terms, used 
to support signal detection and monitoring. Broad terms SMQs were used to increase the 
sensitivity of searches. For thrombotic events, PT terms related to venous thromboembolism 
were identified using the SMQ “Embolic and thrombotic events, venous” terms, while stroke 
or systemic embolism, and myocardial infarction were identified and classified using the SMQ 
“Embolic and thrombotic events, arterial” terms. For bleeding events related with 
gastrointestinal system all terms included in the SMQ “gastrointestinal haemorrhage” were 
comprehensively searched. For those related with central nervous system bleeding events the 
SMQ used was “hemorrhagic central nervous system vascular conditions”. For the other 
bleeding events the SMQ terms “haemorrhage” were appraised.  
Potential interactions in the reported hemorrhagic cases were appraised according to the 
concomitant use of certain drugs, that were searched in the database according to their WHO 
ATC code: B01AC for antiplatelet drugs, B01AB for heparins, M01A for non-steroidal anti-
inflammatory drugs (NSAIDs), N06A and N06C for antidepressants, N03A for 
anticonvulsant drugs and D06, A01AB, A02BD, A07A, D01, D07C, D09AA, D10AF, G01, P, 
R02AB, R05X, S01, S02, S03 and J for anti-infective drugs. The use of such medication may 
increase bleeding proneness, as established in some bleeding risk stratification tools76,187. 
The Microsoft Excel® 2010 software was used for the analysis of data. IBM SPSS Statistics 23 
software and R-3.2.2 software were used to perform the statistical tests. 
The study was approved by the Ethics Committee Board of the Faculty of Medicine, 













Oral anticoagulant-related ADRs: absolute number and incidence by yearly sells 
From January 2010 to April 2015, 794 suspected ADRs from 270 cases fulfilling the inclusion 
criteria were retrieved from the Portuguese pharmacovigilance database (Figure 37).  
 
 
Figure 37: Flowchart of ADR cases and ADRs. 
 
In the period 2010-2014 the yearly number events reported associated with oral anticoagulants 
increased significantly from 14 to 371 (Figure 38).  




Figure 38: Absolute number of ADRs according to the oral anticoagulant from January 2010 until 
April 2015. 
 
However, the incidence according to drugs exposure had a peak in 2012 (19 ADRs per million 
of DDD, and 61 ADRs per 100 000 CU) mostly due to reports of events related to NOACs. 
NOACs had then 400 spontaneously reported ADRs per 100 000 of CU (Figure 39A), and 
145 ADRs per million of DDD (Figure 39B). The following years showed a decrease of the 
reporting incidence related to overall oral anticoagulants and NOACs. The incidence VKA-
related spontaneously reported ADRs was low but their peak was reached in the year 2014 and 
the first four months of 2015 (12 ADRs per 100 000 CU, and 4 ADRs per million of DDD) 
(Figure 39). 
 




Figure 39: The yearly incidence of ADRs related to all oral anticoagulants (green solid line), VKA 
(blue solid line), and NOACs (red solid line) per 100 000 CU and million of DDD. 
 
 
Overall characterization of patients, ADRs, and notifiers. 
About 96% of the suspected ADRs (764 events) complied with seriousness criteria, and 13% 
of the patients (35 patients) had a lethal outcome. Overall, NOACs (apixaban, dabigatran and 
rivaroxaban) were suspected to be related to 78% of the oral anticoagulants ADRs. The 

















Table 13: Characteristics of patients, notifiers and suspected ADRs. 
 Overall VKA NOACs 
Patients 
n (%) 271 62 (23%) 209 (77%) 
Mean age 71 71 71 
Male (% in each group) 125* (46%) 32 (52%) 92 (44%) 
Lethal events (%) 35 (13%) 5 (8%) 30 (14%) 
Suspected ADRs 
N 794 174** 622** 
Seriousness 763 159** 606** 
Notifier body 
Physician 539 (67,5%) 50 (32,1%) 456 (74,9%) 
Pharmacist 141 (17,7%) 73 (46,8%) 68 (11,2%) 
Nurse 1 (0,1%) 1 (0,6%) 0 (0,0%) 
Patient or other non-
healthcare professional 
31 (3,9%) 0 (0,0%) 31 (4,9%) 
Dentist 67 (8,4%) 32 (20,5%) 35 (5,7%) 
Others  19 (2,4%) 0 (0,0%) 19 (3,1%) 
NOACs, non-vitamin K antagonist oral anticoagulants; VKA, vitamin K antagonists. 
*No data for some ADRs 
**There are two ADRs related to patients that were exposed to both VKA and NOACs  
 
The mean age of patients with reported adverse events was 71 years old. There were not any 
significant differences between NOACs and VKAs, regarding mean age, gender and the 
proportion of patients with a lethal outcome (Table 13). 
Physicians were the professional group that most frequently reported ADRs, accounting for 
67.5% of the ADRs. There are 7 patients whose reports were done by 2 or more reporting 
groups. In VKA group, pharmacists were the top reporting group (46.8 %), while other 
NOACs ADRs were reported by physicians (74.9 %). It should be emphasized that dentists 
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Evaluation of ADRs according SOCs among NOACs and VKA 
The evaluation according SOCs showed that the most frequently reported ADRs are 
associated with “gastrointestinal disorders”, “nervous system disorders” and “general 
disorders and administration site conditions”. NOACs had a higher proportion of ADRs 
reported by SOCs, with the exception of the SOC “Investigations”, which was mostly 
reported in association with VKA. The NOAC responsible for the majority of the cases was 
expectedly dabigatran because it was the first NOAC commercialized. The VKA with more 
notifications is warfarin, which can be explained by its widespread use in Portugal compared 
with acenocoumarol. Figure 40 depicts the absolute number of ADRs stratified oral 
anticoagulant class and according to each SOC.  
 
 
Figure 40: Proportion of suspected ADRs associated to oral anticoagulants according to SOC. 
 
 
Evaluation of thromboembolic and hemorrhagic ADRs among NOACs and VKA 
Aggregating ADR data into clinically meaningful SMQs, 49 arterial thromboembolic events, 
13 venous thromboembolic events, and 200 hemorrhagic events were reported.  
Among the reported 63 thromboembolic events (there was one case of atrial thrombosis that 
did not allow to classify as arterial or venous thromboembolism), 60 of these occurred with 
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NOACs (95%). The reported proportion of arterial or venous thromboembolic events 
(among the ADRs of the same drug class) was numerically higher with NOACs (Table 14).    
Considering all the reported hemorrhagic events, 84% (168 events) arose with NOACs, and 
the relative proportion of reported hemorrhagic events (either global, gastrointestinal or 
intracranial hemorrhages) according to each drug class among the global ADRs was 
numerically higher with NOACs (Table 14). The 57 GI hemorrhagic events associated with 
NOAC represented 54% of the NOACs Gastrointestinal (SOC) ADRs (57 of 105), and 51 of 




Table 14: ADRs classified according to SMQ terms. 
ADRs VKA NOACs 
Arterial thromboembolism (SMQ)* 3 (1,7%) 46 (7,4%) 
Venous thromboembolism (SMQ)* 0 (0,0%) 13 (2,1%) 
Hemorrhage (SMQ) 32 (18,4%) 168 (27,0%) 
Gastrointestinal hemorrhage (SMQ) 10 (5,7%) 57 (9,2%) 
Intracranial hemorrhage (SMQ) 2 (1,1%) 22 (3,5%) 
Other hemorrhages 20 (11,5%) 89 (14,3%) 
Percentages are expressed as proportion of SMQ among all ADRs with the same drug class. 
NOACs, non-vitamin K antagonist oral anticoagulants; PT, preferred term; SMQ, Standardised MedDRA 
Queries; VKA, vitamin K antagonists. 




The concomitant use of oral anticoagulants with other drugs known to increase the 
hemorrhagic risk (heparins, NSAIDs, and antiplatelet drugs) corresponded solely to 11% of 
the hemorrhagic reports (Figure 41). Yet among VKA-reported hemorrhagic events, about 
30% took concomitantly other relevant drugs, specially heparins (17%) or NSAIDs (9%) 
(Figure 41). Concerning NOACs-reported hemorrhagic events only 5% used other drugs that 
increase the bleeding risk (Figure 41). There were no bleeding events reported in patients 
exposed concomitantly to oral anticoagulants and anticonvulsants, antidepressants or anti-
infective drugs. 
 




Figure 41: Proportion of concomitant use of heparin, NSAID and antiplatelet drugs in the reported 
hemorrhagic events. NSAIDs: Non-steroidal anti-inflammatory drugs; NOACs: non-vitamin K antagonist 




Evaluation of ADRs by PT terms 
Looking individually to drugs and ADRs by PT terms, most of the reported events associated 
to NOACs were related to the ineffectiveness of oral anticoagulants (Table 15). Ischemic 
stroke was the most reported event related to the use of dabigatran while for rivaroxaban the 
most frequent suspected ADR was deep vein thrombosis. On the other hand, the adverse 

















Table 15: The most frequent suspected ADRs by PT terms according to each oral anticoagulant class 
and drug. 
Drug MedDRA PT term Frequency 
VKA International normalized ratio increased 31 
Drug monitoring procedure incorrectly performed 20 
Drug interaction 7 
Dermatitis acneiform 5 
Thrombocytopenia 5 
NOACs Ischemic stroke 29 
Anemia 22 
Gastrointestinal hemorrhage 11 
Hematochezia 11 
Rectal hemorrhage 10 
Warfarin International normalized ratio increased 22 
Drug monitoring procedure incorrectly performed 11 
Thrombocytopenia  5 
Dermatitis acneiform 5 
Drug interaction 5 
Acenocoumarol Drug monitoring procedure incorrectly performed 9 
International normalized ratio increased 9 
Drug ineffective 3 
Drug interaction 2 
Vasculitis 2 





Rivaroxaban Deep vein thrombosis 4 
Rectal haemorrhage 4 
Uterine haemorrhage 3 
Blot blister 3 
Chest pain 3 
Apixaban Somnolence 1 
Platelet count decreased 1 
Fatigue 1 
Gastrointestinal haemorrhage 1 
Epistaxis 1 
NOACs, non-vitamin K antagonist oral anticoagulants; PT, preferred term; VKA, vitamin K 
antagonists. 





The study about the oral anticoagulants-related adverse events reported to the Portuguese 
pharmacovigilance centres concluded that the absolute number of reported events was 
increasing, and that ADRs reports were more often associated with NOACs than with 
VKA, reflecting their novelty. The reporting incidence peak (taking into account the annual 
sell of CU and DDD) was in 2012. Since 2012 the incidence of NOACs-related ADRs has 
been decreasing. Both increased experience with NOACs and the increasing scientific 
evidence about key outcomes in patients treated with this class of drugs could have 
contributed decisively. Physicians were the healthcare professionals that most frequently 
notified adverse events with NOACs, possibly reflecting the careful and watchfulness of 
the reporters as prescribers of a new drug. 
Dabigatran was the first NOAC to be commercialized, followed rivaroxaban, and more 
recently apixaban. The timing for commercialization, and thus exposure, largely influenced 
the proportion of ADRs associated to NOACs: higher with dabigatran, lower with 
rivaroxaban, an even lower with apixaban. Gastrointestinal (GI) signs/symptoms were the 
most frequently reported manifestations associated with NOAC (16.9%) with 9.2% of 
NOACs ADRs being related to GI bleeding. The GI tract is the most common site 
associated to major bleeding events. NOACs have been associated with increased risk of 
GI bleeding125, even though it is known that the increase of bleeding risk is usually not 
associated with severe events as previously shown (Chapter IV)188. Thromboembolic events 
accounted for almost 10% of the overall NOACs reported ADRs while haemorrhage was 
responsible for 27% of them. Thromboembolic event reports associated with VKAs 
accounted for 1.7% while hemorrhages were present in 27% of the ADRs. In randomized 
controlled trials NOACs were at least as efficacious as VKA concerning stroke and 
systemic embolism86. NOACs were also associated with decreased risks of major bleeding 
and fatal bleeding86,189. Therefore, the differences in the proportions may not reproduce the 
population incidences of these adverse events but rather reflect the unexpectancy of the 
reporter of the ADRs regarding these outcomes, considering the best available evidence. 
Other adverse events previously studied, such as infections or hepatic adverse events190,191, 
also showed low proportions in both drug classes. Warfarin and acenocoumarol reported 
events were mostly based on impaired international normalized ratios (INR) and 
pharmacists took an important role on reporting. Dabigatran and rivaroxaban’s top 
suspected ADRs were ischemic stroke and deep venous thrombosis, respectively. Despite 
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the potential risk reduction of these events with NOACs, all RCTs showed that a residual 
thrombotic risk exists and patients may have thrombotic events in such conditions.  It is 
worth noting that VKAs have their efficacy and safety dependent on keeping the INR into 
therapeutic ranges. Portugal is a country with overall low percentages of time in therapeutic 
range with VKA71,182,192,193, which would preclude high rates of reported ADRs. However, as 
the act of reporting depends on the sensibility of the notifiers, it is possible that the years 
of experience with VKA harms incorrectly desensitizes patients and/or healthcare 
professionals from reporting the ADRs to the pharmacovigilance centres, otherwise, the 
small number of ADRs found in the present study would be contradictory compared to the 
data found in RCTs194. Even in the presence of a low number of VKA-related ADRs, their 
incidence (using either CU or DDD exposures) recently reached its maximum. It can be 
speculated that the licensing of NOACs and the current scientific discussions has increased 
the watchfulness of the community (particularly pharmacists and nurses, which are 
healthcare professionals involved in INR measurements) around the safety of these drugs. 
In the other hand, the nature of the most common ADRs are laboratorial, are expected (do 
not introduce novelty), and may reflect the standardized procedures of a healthcare 
professionals’ cluster that actively report ADRs. 
 
Limitations 
The pharmacovigilance study about the ADR related to oral anticoagulants was limited by 
the context of spontaneous reporting. It is important to notice that in Portugal the 
consumers are allowed to report ADR since July 2012. With 62 reports (about 4%) sent by 
these stakeholders, the number of reported ADRs increased slightly. 
Causality, which is an important feature in pharmacovigilance was not reported because an 
important share of the ADRs did not have this parameter in the database. Therefore, as for 
any data mining study, the robustness of the conclusions depends on the database 












The incidence of oral anticoagulant-related ADRs, considering the sells by DDD or CU, 
has reached its peak in 2012 and have been decreasing since then. However, the absolute 
number of ADR reports associated with oral anticoagulants has increased overtime. The 
majority of reports and ADRs were related to NOACs. These were usually reported by 
physicians and involve the GI tract or nervous system manifestations. Among VKA, most 
of the ADRs were related to laboratorial parameters and pharmacists more frequently 
reported the ADRs of this class of oral anticoagulants. One quarter of the reported 
NOACs ADRs were hemorrhagic and 10% were related to thromboembolic events (lack of 
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Atrial fibrillation (AF) is the most common sustained arrhythmia. It was estimated in 2010 
that 33.5 million individuals worldwide,195 and nearly nine million individuals in the 
European Union (EU),196 had AF; the number in the EU is predicted to double to nearly 
18 million by 2060.  
Against this background, it is important to assess the economic impact and burden and 
cost of illness of AF in Portugal, which is the aim of the present study. 
The purpose of studies on cost of illness is to measure the impact of a disease or risk factor 
in terms of use of economic resources and reduction in economic activity due to associated 
disability. Studies on burden and cost of illness are not strictly speaking economic 
evaluations, since they do not address specific interventions or compare alternative 
interventions; rather, they seek to describe accurately the status of a particular health 
problem and its magnitude. 
 
METHODS 
Burden of disease 
Burden of disease is estimated by means of disability-adjusted life years (DALYs), a 
measure of the years of health lost due to disease or premature death. It includes two time-
based indicators: years of life lost, the difference between age at death and standard life 
expectancy for that age; and years lost due to disability.197 Disability is assigned a severity 
weight between 0 (no disability; perfect health) and 1 (total disability or death). These 
weights were originally defined by expert panels at the World Health Organization (WHO), 
and were re-estimated for the Global Burden of Disease Study 2010 through a large-scale 
empirical investigation.198 The formula used is: 
 
where: 
a – age of onset, 
L – duration of disability or time lost due to premature mortality, 
D – disability weight (between 0 and 1), 
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C – age-weighting correction constant (0.04), 
e – expectation of life, 
x – age (ranging between a and a+L), 
¿ – parameter from the age-weighting function (0.1658), and 
r – discount rate (3%). 
The discount rate used in this calculation is 3%, and the calculation includes different 
weighting for different age-groups, with the middle age-group (20–50 years), the years 
when people tend to be raising children, being assigned greater weight.197  
Whenever direct evidence about the duration of diseases is not available (an information 
which is needed to calculate DALYs), the DisMod II model (developed by Barendregt et al. 
for the WHO199) was used. This exploits the causal relations between the variables that 
describe a disease process by age-group and gender: incidence, prevalence, remission, case 
fatality, mortality, relative risk (RR) for mortality, and duration. 
The model was calibrated using data from the Portuguese Institute of Statistics on the 
resident population and mortality in Portugal for 2010, as well as the findings of the FAMA 
study (on AF prevalence) and the Rotterdam Study (on AF incidence).54,200,201  The 
remission rate of AF was assumed to be zero. It should be mentioned that AF can often be 
asymptomatic, and that the reported incidence and prevalence may be underestimated.145,202 
In order to calculate DALYs due to disability, the degree of disability attributable to a given 
health problem must be specified. The weighting factors used to characterize the relevant 
conditions in this study were those published in the Global Burden of Disease Study 
2010.198
The calculations were based on population and mortality statistics from the WHO for 
2010, hospital data from 2011 and official NHS prices for 2013. Data on mortality from 
AF and stroke in Portugal were taken from the WHO's European Detailed Mortality 
Database (http://data.euro.who.int/dmdb/). Most deaths from stroke in this database are 
not specified as ischemic or hemorrhagic, so on the basis of the DRGs and in the opinion 
of the expert panel, it was assumed that 30% in women and 40% in men are hemorrhagic. 
Cost of illness 
The first step in the analysis was to identify the conditions that are related to AF as well as 
the disease itself. The main complications of AF are heart failure and ischemic stroke, the 
latter being the most serious.203,204 The relation between AF and stroke is unequivocal: 
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patients with AF have an age-adjusted risk that is five-fold higher than the general 
population, and stroke in AF patients is more likely to lead to severe disability.205 With 
regard to intracranial hemorrhage, the risk is similar to that of the general population, but it 
is higher in AF patients under anticoagulant therapy.205,206  
The conditions considered in the analysis were AF and ischemic stroke, identified by the 
International Classification of Diseases, Ninth Edition, Clinical Modification (ICD 9-CM) 
codes 427.31 (Atrial fibrillation), 427.32 (Atrial flutter), 433 (Occlusion and stenosis of 
precerebral arteries [with cerebral infarction]) and 434 (Occlusion of cerebral arteries [with 
cerebral infarction]). 
The second step was to establish the quantitative relation between AF and stroke by 
estimating the fraction of the cost and burden of stroke that statistically is due to AF, using 
the epidemiological concepts of RR and population attributable fraction (PAF). RR in this 
case is the ratio between the risk of suffering stroke in a population with AF and the risk in 
a population without AF. The values for RR used in this study, taken from Kannel et al.,207 
based on data from the Framingham Study and recently updated by Ball et al-,208  
The PAF is the proportion of cases that would not occur in a population if the risk factor 




 PAF – population attributable fraction, 
 P – prevalence of AF, and 




Direct costs attributable to atrial fibrillation 
As well as the burden of disease, AF is also responsible for costs to society and to the 
NHS, considered as direct costs attributable to atrial fibrillation, which in this study are 
divided between inpatient and outpatient care. 
The centrally managed database of diagnosis-related groups (DRGs) of the Portuguese 
NHS for 2011 was used to estimate resource use for inpatient care, including other 
interventions covered by the DRGs such as outpatient surgery and day hospital sessions 
arising from AF and associated conditions. 
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Hospitalizations were identified on the basis of a primary diagnosis of AF or of ischemic 
stroke in accordance with the ICD 9-CM. 
The unit costs used in the analysis were taken from Order in Council 163/2013, which 
defines the prices associated with DRGs and other health interventions. The costs of AF- 
and stroke-related admissions were calculated by summing the product of the number of 
patients in each DRG and the price of the corresponding DRG. 
Outpatient costs include direct medical costs (consultations, emergencies, diagnostic and 
therapeutic interventions, drugs, physiotherapy sessions, etc.), and direct non-medical costs 
(urgent and non-urgent patient transportation and institutionalization). 
Resource use was estimated on the basis of the literature and on the findings of a panel of 
experts from various medical specialties convened to define resource use in patients with 
AF and ischemic stroke. 
 
Indirect costs of atrial fibrillation 
In calculating the indirect costs of AF, only costs associated with lost production due to the 
disease were included (excluding losses due to premature death). 
The absenteeism due to ischemic stroke attributable to AF must be taken into account as 
well as that of AF itself. Calculation of the indirect costs of stroke directly attributable to 
AF requires use of the PAF. Absenteeism related to AF and ischemic stroke may have 
different reasons but given the nature of AF, it is only ischemic stroke that leads to 





Burden of disease 
Disability-adjusted life years due to death 
The first step in quantifying the burden of disease arising from mortality attributable to AF 
is to calculate the number of deaths and DALYs due to diseases associated with AF., and 
that in 2010 there were 813 deaths from AF (303 men and 510 women) and 9316 deaths 
from ischemic stroke. 
It was estimated that in 2010 33753 DALYs were lost from deaths due to AF and stroke. 
The burden of stroke attributable to AF in Portugal in 2010 is estimated at 4070 deaths 
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(3.8% of all deaths) and 10521 DALYs due to death (1.7% of all DALYs from premature 
death). Figure 42 shows the distribution of deaths for men and for women by age-group. 
 
 
Figure 42: Mortality attributable to atrial fibrillation by age-group and gender. AF: atrial 
fibrillation. 
 
Figure 43 shows the distribution of DALYs due to death attributable to atrial fibrillation by 
age-group and gender. Stroke was responsible for the majority of life years lost due to 
premature death attributable to AF in both sexes. 
 
 




Figure 43: Disability-adjusted life years due to death attributable to atrial fibrillation by age-group 
and gender. AF: atrial fibrillation. 
 
 
It can also be seen in Figure 43 that the distribution of burden of disease at more advanced 
ages differs markedly between men and women, mainly due to differences in the number 
of men and women in older age-groups. Thus, there are more DALYs due to death 
attributable to AF per 100000 individuals in men up to the age of 79 (437 vs. 304 for 
women), but this pattern is reversed over the age of 80 (928 for men vs. 1446 for women). 
 
Disability-adjusted life years due to disability 
The severity weight for disability due to AF is 0.145. For stroke, two representative cases – 
moderately severe stroke with long-term sequelae (weight 0.076) and moderately severe 
stroke with long-term sequelae and cognitive deficit (weight 0.312) – were considered and 
the mean of the two (0.194) was adopted for this study. 
It is estimated that 14% of AF patients in Portugal have suffered stroke. Calculation of the 
severity weight in these patients entails adding to the mean weight for AF (0.145) a part of 
the corresponding disability weight for stroke. The mean RR of stroke for the population 
with AF is 3.71. The proportion of stroke attributable to AF is (RR-1)/RR, hence the 
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fraction of strokes in AF patients attributable to AF itself is 73.05%. Considering that 14% 
of AF patients have suffered stroke, the mean disability weight of AF is 
(0.145+0.14*0.7305*(0.194−0.145))=0.15. On this basis, AF caused a loss of 12563 
DALYs due to disability in 2010, over 5000 for men and over 7000 for women. 
Adding DALYs due to premature death and due to disability gives a total burden of disease 
attributable to AF of 23084 DALYs (Figure 44), of which DALYs due to disability account 
for around 54%. 
Figure 44:  Total disability-adjusted life years attributable to atrial fibrillation by age-group and 
gender. 
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Cost of illness 
Direct costs 
Costs of inpatient care 
Table 16 summarizes the total costs of inpatient care attributable to AF. The total cost of 
inpatient care (including outpatient DRGs) attributable to AF is €34503800. The data 
shown in Table 16 reveal that the cost of hospitalization for AF itself accounts for 55% of 




 Table 16: Costs of inpatient care attributable to atrial fibrillation. 
Disease No. of episodes Total cost (€) PAF (%) Attributable cost (€) 
Inpatient DRGs 
AF  6339 17569100 100 17569100 
Ischemic stroke  20903 113310028 14 15523595 
Outpatient DRGs 
AF  259 1410227 100 1410227 
Ischemic stroke  4 6409 14 878 
Subtotal 
AF  6598 18979327 100 18979327 
Ischemic stroke  20907 113316437 14 15524473 
Total     34503800 
AF: atrial fibrillation; DRG: diagnosis-related group; PAF: population attributable fraction. 
 
Costs of outpatient care 
Based on the resource use estimated by the expert panel and on unit costs, the outpatient 
costs attributable to AF and ischemic stroke were calculated for the year of the diagnosis or 
event and following years (Table 17). The total cost of outpatient care attributable to AF is 
around €22 million in the year of the diagnosis or event and €59 million for patients 
diagnosed in previous years. The outpatient cost attributable to AF accounts for 45.2% of 
the total costs attributable to AF. 
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Table 17: Outpatient costs attributable to atrial fibrillation. 









in previous years 
Total (€) 
AF 10960 72160 7140340 37229346 44369687 
Stroke  2171 16097 15185149 21431089 36616238 
Total 22325489 58660435 80985925 
AF: atrial fibrillation. 
The total direct costs attributable to AF are €115.5 million, made up of €34.5 million for 
inpatient care (Table 16) and €81 million for outpatient care (Table 17). Ischemic stroke is 
responsible for 45% of all direct costs attributable to AF. 
Indirect costs 
Indirect costs of atrial fibrillation without stroke 
When estimating the indirect costs of AF without stroke it was assumed that the disease's 
impact is only in terms of absenteeism, without early retirement. 
Table 18 shows the estimates of number of working days lost per year for each disease due 
to consultations, exams, hospitalizations and convalescence. Length of hospital stay was 
estimated on the basis of DRGs. It was assumed that convalescence time for AF was equal 
to length of hospitalization. The employment rate of AF patients (low given the fact that 
many are past retirement age) was taken into account when calculating mean costs. 
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2.17 1.66 1.68 1.3 6.5 
Cost per 
patient (€) 





571335 2876961 436026 2227050 661444 
Total (€)    6772816 
The total indirect costs arising from hospitalizations due to AF were calculated by 
multiplying the indirect costs of days spent in hospital and convalescing by the number of 
admissions. Adding all these estimates, an overall indirect cost of AF without stroke of 
€6.77 million was obtained. 
Indirect costs of atrial fibrillation with stroke 
Estimating the indirect costs of AF with stroke is more complicated, since there are 
different subgroups of patients depending on the consequences of the stroke and the need 
for rehabilitation after the event. The findings of the expert panel were used to identify 
possible scenarios following stroke and the proportion of patients in each scenario, each of 
which involves different levels of absenteeism resulting from physiotherapy sessions and 
differences in ability to return to work.  
According to the expert panel, 12% of patients who suffer stroke attributable to AF are 
unable to return to work, 52% need six months of physiotherapy after hospitalization and 
22% need 12 months, leading to absenteeism of six and nine months, respectively, 
assuming that after six months of physiotherapy the patient loses half a working day for 
each physiotherapy session for the following six months. 
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The expert panel also calculated that only 0.83% of patients with stroke attributable to AF 
are unable to work for a period of less than three months. As for those with AF-related 
stroke AF in previous years, 12% have still not returned to work, while 23% are absent 
from work for the equivalent of one and a half months a year. 
The estimates in Table 19: Indirect costs of stroke attributable to atrial fibrillation. show 
that the indirect costs of ischemic stroke attributable to AF amount to almost €20 million. 
Thus, considering all aspects of the indirect costs of ischemic stroke, the total indirect costs 
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This analysis showed that 4070 deaths can be attributed to AF in 2010 in Portugal, 
corresponding to 3.8% of all deaths, and that the total burden of disease attributable to AF 
is 23084 DALYs. The overall cost of illness is estimated at €140.7 million, around 0.08% of 
Portugal's gross domestic product. The results are a clear statement of the seriousness of 
AF in Portugal. Stroke is highly disabling and frequently results in early retirement; as well 
as the costs involved, the burden of AF reflects the fact that stroke in AF patients is 
particularly lethal and, for those who survive, disabling. These picture confirms the 
importance of AF, but at the same time they make it clear that this is an area in which 
significant health gains can be made 
CHAPTER V: THE SOCIO-ECONOMIC IMPACT OF AF AND ORAL ANTICOAGULANTS 
 
 157 





NOACs are considered to be at least as effective as VKAs, with lower risk of intracranial 
hemorrhage 79 and with no need for laboratory monitoring of international normalized 
ratio (INR). Three of these NOACs have been approved to date for reimbursement under 
the National Health Service (NHS) for AF patients in Portugal: apixaban, dabigatran and 
rivaroxaban. These three drugs have different mechanisms of action, pharmacokinetics and 
dosage regimens, and thus offer different therapeutic options for individual patients 
according to renal dysfunction, age, bleeding risk, history of coronary artery or peripheral 
arterial disease, and stroke risk. 
Although these drugs are more expensive than VKAs, studies on dabigatran and 
rivaroxaban compared to warfarin for AF patients in Portugal indicate that they are cost-
effective in clinical practice.210,211 Since August 2014, these NOACs have been reimbursed 
by the NHS for the prevention of thromboembolic events in patients with non-valvular 
AF. Against this background, it is important for decision-makers to be aware of the health 
gains and associated costs of the different NOACs. The aim of this study was thus to 
estimate the cost-effectiveness of NOACs, particularly apixaban (the most recent to have 





A Markov model of cost-effectiveness and cost-utility was used, with a six-week cycle 
length, the minimum period in which changes in health (or disease) state would be 
expected, following a cohort of 1000 patients over a lifetime horizon. The model, details of 
which were recently published by Lip et al.212, was programmed in Excel using Visual Basic 








Figure 45: Markov model decision tree. AC: anticoagulants; ASA: aspirin; CRNM: clinically relevant 
non-major; HS: hemorrhagic stroke; ICH: intracranial hemorrhage; IS: ischemic stroke; NVAF: non-
valvular atrial fibrillation; NVAF subsequent ASA: NVAF patients on second-line aspirin. Reproduced 




In the model, the natural history of the disease is represented by 11 mutually exclusive 
health states: non-valvular AF; mild, moderate or severe non-fatal ischemic stroke; mild, 
moderate or severe non-fatal hemorrhagic stroke; systemic embolism; myocardial infarction 
(MI); non-valvular AF with discontinued first-line anticoagulation; and death. After six 
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weeks the patient can enter, remain in, or transition to another state according to the 
corresponding transition probability, defined as the likelihood of an event occurring within 
that period. 
The risk of ischemic stroke is calculated according to the patient's CHADS2 score
213 (the 
method for estimating thromboembolic risk in use at the time of the clinical trials of the 
drugs under analysis) and the level of anticoagulation for patients treated with warfarin as 
determined by time in therapeutic range (TTR) of the international normalized ratio (INR). 
The likelihood of stroke, MI, intracranial bleeding and other major and non-major bleeding 
increases with age. The model also considers the long-term impact of MI and systemic 
embolism on mortality, reflected in higher hazard ratios (HR). For patients in the state of 
non-valvular AF who discontinue first-line anticoagulation, the model structure remains the 
same but the transition probabilities differ. 
Severity of stroke (ischemic or hemorrhagic) is classified according to the modified Rankin 
scale (mRS)214: mild, 0–2; moderate, 3–4; severe, 5; and fatal, 6. All patients with fatal stroke 
transition to the state of death in the following cycle, while non-fatal stroke is modeled as a 
tunnel state from which patients can only transition to recurrent stroke or death. Patients 
can only experience one recurrent stroke in the model, from which the transition is to 
stroke of the same or greater severity. The model does not allow recurrent MI or systemic 
embolism, patients either remaining in the same health state or transitioning to death. 
At the end of each cycle health care costs, quality-adjusted life years (QALYs) and life years 
gained are calculated. Levels of health-related quality of life (utilities), clinical outcomes and 
mortality rates vary according to stroke severity. In accordance with the Portuguese 
Ministry of Health's guidelines for economic evaluation studies of drugs,215 published by 




In the model's base-case scenario, the characteristics of the population are those of patients 
enrolled in trials of apixaban, specifically ARISTOTLE,109 in terms of median age (70 









The results of treatment with apixaban 2.5–5 mg twice daily are compared with (1) 
dabigatran 150 mg twice daily in patients aged ≤80 years and 110 mg twice daily in patients 
aged >80 years with high bleeding risk and those treated with verapamil (the dabigatran 
group) and (2) rivaroxaban 15–20 mg once daily. 
 
Relative effectiveness of the new oral anticoagulants: indirect comparisons 
Economic evaluations of new health technologies such as drugs analyze their effectiveness 
and the associated costs compared to existing options. Assessment of the relative 
effectiveness of the NOACs is thus one of the central aims of this study. There have to 
date been no head-to-head studies between the NOACs, so their effectiveness in AF must 
be estimated by indirect analysis using a common comparator, in this case warfarin. 
It is therefore essential to assess the reliability of the estimates of effectiveness used in the 
model. Therefore, a systematic review of the literature was carried out to identify indirect 
comparisons between NOACs that provide data on their effectiveness in AF, searching the 
MEDLINE and Cochrane Library databases in September 2014 using the search 
terms meta-analysis, indirect comparison, Bayesian, network, apixaban, dabigatran, rivaroxaban and 
atrial fibrillation. Ten studies were identified, six frequentist 212, 216-220 and four Bayesian 
(network meta-analyses).221-224 The estimates for the various outcomes in these publications 
are consistent and are similar to those used in the base-case scenario in the economic 
model.212 Given the aim of the present study, Lip et al.212 (frequentist indirect comparison 
using the method of Bucher et al.225) and Mitchell et al.222 (Bayesian network meta-analysis) 
probably give the best estimates of the relative effectiveness of the three NOACs in AF, 
since they use only data from phase III clinical trials and establish associations using HRs, 
which takes the time factor into account and respects the primary statistical analysis of each 
trial.  
The event rates in the base-case scenario are derived from the HRs reported by Lip et al.212 
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Costs 
The study adopts the perspective of the NHS and therefore does not analyze indirect costs. 
Three main types of costs are identified in the model: costs arising from vascular events, 
costs of anticoagulant therapy, and costs of monitoring and/or routine consultations. 
Costing is based on (1) Order in Council 20/2014109 for unit costs of consultations, 
diagnostic exams and diagnosis-related groups (DRGs); (2) analysis of the database of NHS 
hospitalizations (DRGs) in 2013226; (3) the Portuguese Ministry of Health's drug database 
(Infomed) for prices of medications, consulted on January 2, 2015227; and (4) estimates 
outpatient care resource use by a geographically representative expert panel of various 
specialists. For the health states of non-fatal ischemic or hemorrhagic stroke, MI and 
systemic embolism, costs were divided into acute and long-term maintenance, the acute 
phase including the first two weeks of hospital stay and the first three months of 
rehabilitation. The model assumes that the maintenance stage will continue until death and 
according to the expert panel, includes costs of consultations, emergencies and transport, 
diagnostic exams, medication and technical assistance. It was not possible to estimate the 
costs of stroke according to severity (mild, moderate or severe), since there are no data on 
costs according to the mRS in Portugal. For the other health states only the costs of 
hospitalization (acute phase) were included. 
Overall costs per event, treatment costs and costs of monitoring and routine care are 
shown in Table 21. 
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Table 21: Costs arising from vascular events, anticoagulant therapy and monitoring and routine 
consultations. 
Events Costs (€) 
Acute 
(per episode) 
Long-term (per month) 
Non-fatal ischemic stroke (weighted mean)  8653.26 44.57 
Fatal ischemic stroke  6381.20 – 
Non-fatal hemorrhagic stroke (weighted mean) 13779.62 41.07 
Fatal hemorrhagic stroke  10419.64 
Other intracranial hemorrhage  7932.21 – 
GI bleeding  8798.64 – 
Non-intracranial and non-GI bleeding  2090.04 – 
CRNMB  2514.98 42.32 
Systemic embolism  3937.93 – 
MI  4560.10 53.61 
Other CV hospitalizations  2081.64 – 
Source: b.databases of Centro Hospitalar Lisboa Central and Hospital Fernando da Fonseca; c.Order in 
Council 20/2014 109; d.expert panel. 
a. Drug prices do not include value-added tax.
CRNMB: clinically relevant non-major bleeding; CV: cardiovascular; GI: gastrointestinal; MI: myocardial 
infarction. 
Mortality 
The probabilities of death associated with vascular events in the model are those observed 
in the trials of the NOACs, with the exception of the fatality rate in MI, which was 
obtained from Scarborough et al.228 The model assumes that these probabilities are 
independent of treatment. For the period corresponding to the duration of the 
ARISTOTLE trial, mortality from non-vascular causes is assumed to be the same for all 
three NOACs, and the figures in the ARISTOTLE trial (3.08% for apixaban and 3.34% for 
warfarin) was used in the model. Mortality after the period analyzed in the clinical trials was 
estimated on the basis of Portuguese life tables,229 multiplied by the HRs associated with 
the population with AF estimated by Friberg et al. to take into account the increased risk of 
this population.230 Specifically, the parameters of a Gompertz survival function were 
calculated by age-group (<75 years and ≥75 years) and by gender. The model includes 
adjustments to mortality risk to account for the increased mortality associated with AF and 
different degrees of stroke severity. 
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Health-related quality of life weights or utilities 
The mean values for utilities and disutilities associated with different health states were 
taken to be the same as those estimated for the UK population by Sullivan et al.231 There 
are also disutilities associated with warfarin therapy (unlike the NOACs) and with other 
vascular events. The model assumes that these disutilities are cumulative. Table 
22 summarizes the utilities and disutilities used in the model. 
Table 22: Mean utilities and disutilities for the population in the model. 
Utility considered in the model for each health state a 
AF (baseline utility) 0.7270 




Systemic embolism 0.6265 
MI 0.6098 





Other ICH (excluding hemorrhagic stroke) 0.1511 (6 weeks) 
Other major bleeding (excluding ICH) 0.1511 (14 days) 
CRNMB 0.0582 (2 days) 
Other CV hospitalizations 0.1276 (6 days) 
Source: aSullivan et al.231; bGage et al.232 
c. While under treatment with anticoagulants.
AF: atrial fibrillation; CRNMB: clinically relevant non-major bleeding; CV: cardiovascular; ICH: intracranial
hemorrhage; MI: myocardial infarction; NOACs: new oral anticoagulants.
Sensitivity analysis 
One-way sensitivity analyses were performed to assess the robustness of the results in 
terms of the following parameters: (1) use of the HRs estimated by Mitchell et al. (Bayesian 
network meta-analysis) instead of those estimated by Lip et al.212; (2) anticoagulation levels 
as reported in the clinical trials, instead of those obtained in Portuguese patients; (3) 
duration of the acute phase of hospitalization taken to be six rather than two weeks; (4) 
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different costs of stroke depending on severity, with weighting calculated on the basis of 
UK figures, instead of a uniform cost for stroke of any severity; (5) the same distribution of 
stroke of similar severity for all NOACs (based on the distribution in the case of apixaban); 
(6) the same treatment discontinuation rates for non-vascular causes for all comparators as
for apixaban (13.2%/year) from the beginning of treatment, instead of the rates reported in 
the clinical trials; (7) mortality rates after the period covered by the trials taken to be the 
same as for the general population, thus underestimating mortality; (8) use of different 
utilities associated with each health state, as estimated in a previous study by Sullivan et 
al.,233 and used in other studies of the cost-effectiveness of NOACs234-236; and (9) a discount 
rate for costs and utilities of 0% or 3% instead of 5%. 
A probabilistic sensitivity analysis using 2000 Monte Carlo simulations incorporating 
second-order uncertainty was also performed.237 The results are presented as the probability 
of apixaban being cost-effective compared to the other therapeutic options based on a 
threshold of €20000/QALY, the limit usually taken to be acceptable for funding new 
health technologies in Portugal. 
RESULTS 
Event rates and costs 
   Table 23 shows the number of vascular events associated with each anticoagulant in a 
cohort of 100000 patients according to the rates derived from the model. The number of 
vascular events and event-related deaths was lower with apixaban except for hemorrhagic 
stroke. The difference was greatest for ischemic stroke, other major bleeding, clinically 
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Table 24 and Figure 46 present the breakdown of costs associated with the different 
therapeutic options over a lifetime horizon. Warfarin has the lowest mean cost per patient 
and rivaroxaban the highest. The total mean cost of apixaban is between these two, with 
the lowest clinical costs (due to its low vascular event rate) and lowest costs of monitoring 
and routine care. Although the daily cost of apixaban is lower than dabigatran and 
rivaroxaban, lifetime costs are greater because the duration of treatment tends to be longer 
due to its lower discontinuation rate. 
Table 24: Total mean cost per patient for each therapeutic option over a lifetime horizon. 
Costs (in €) Warfarin Apixaban Dabigatran Rivaroxaban 
Clinical events 5467.29 4989.03 5244.03 5386.30 
Therapy 214.42 3754.35 3015.69 3463.96 
Monitoring and routine care  3252.29 1254.77 1311.27 1278.31 
Total  8934.16 9998.14 9570.99 10128.56 
Figure 46: Breakdown of mean total costs per patient for each therapeutic option over a lifetime 
horizon. 
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Cost-effectiveness of apixaban compared to the other therapeutic options 
Table 25 and Figure 47 show the results of the cost-effectiveness analysis of apixaban 
compared to the other therapeutic options. As suggested in the literature238,239 for multiple 
comparisons, the results are presented as a graph in which the x-axis represents the 
differences in QALYs and the y-axis the differences in cost between the comparators and 
the reference therapy (in this case warfarin). The red line linking the points on the graph 
represents the efficient frontier. The frontier consists of three segments: its slope 
corresponds to €4367/QALY when it joins the points representing warfarin and 
dabigatran, €9163/QALY when it joins the points representing dabigatran and apixaban, 
and is vertical above apixaban because no therapy is more effective. Rivaroxaban is 
dominated because it is to the left of the cost-effectiveness frontier, presenting greater 
costs and fewer QALYs than other therapies on the frontier. Rivaroxaban is also 
dominated by apixaban when analyzed in isolation. 
 
 
Table 25: Cost-effectiveness analysis of apixaban compared to the other therapeutic options in the 
base-case scenario. 
  Apixaban compared to 
  Warfarin  Dabigatran  Rivaroxaban  
Incremental costs  €1063.98  €427.15  –€130.42  
Life years gained  0.19  0.05  0.04  
Incremental QALYs  0.19  0.05  0.03  
 
ICER 
Cost per life year gained  €5708.44  €7926.91  Dominant  
Cost per QALY gained  €5529.05  €9162.77  Dominant  








Figure 47: Effectiveness (measured in quality-adjusted life years) and incremental costs of NOACs 
relative to warfarin (represented by the coordinates 0,0). The red line represents the efficient 
frontier; the slope of each segment corresponds to the incremental cost-effectiveness ratio between 




The results of the one-way and probabilistic sensitivity analyses confirm the robustness of 
the study's findings. In the one-way analysis of the nine parameters specified in the 
Methods section, which reflect a range of alternate scenarios, apixaban is always dominant 
compared to rivaroxaban. Compared to the other therapeutic options, apixaban presents 
ICERs well below €20000/QALY, ranging between €4909 and €6741/QALY compared to 
warfarin and between €5162 and €12016/QALY compared to dabigatran. If it is assumed 
that discontinuation rates for non-vascular causes remain the same from the beginning of 
treatment, the costs of apixaban are less than either rivaroxaban or dabigatran. In this case, 
apixaban is dominant compared to rivaroxaban and, for a threshold of €20000/QALY, is 
cost-effective compared to warfarin and dabigatran. The results of the sensitivity analyses 
are summarized in Table 26. 




Table 26: Summary of results of sensitivity analyses. 







Use of the HRs estimated by Mitchell et 
al.222 
5590.52 10599.93 737.27 
Anticoagulation levels as reported in the 
clinical trials 
6740.70 8229.74 874.30 
Duration of the acute phase of hospitalization 
6 weeks 
5531.95 9160.65 730.37 
Costs of stroke depending on severity, based 
on UK figures) 
5559.85 8449.95 723.18 
The same distribution of stroke of similar 
severity for all comparatorsb 
5601.85 12016.36 564.64 
The same treatment discontinuation rates for 
non-vascular causes for all comparators from 
the beginning of treatmentb 
5313.84 5161.81 679.93 
Mortality rates after the trial period the same 
as for the general population 
5234.19 8444.37 767.13 
Utilities estimated by Sullivan et al. 233 5125.67 7926.91 746.79 








ICUR: incremental cost-utility ratio. 
a Based on a willingness to pay of 20 000€/QALY. 
b Based on the results of the apixaban arm of the ARISTOTLE trial. 
 
In the probabilistic sensitivity analysis, the probability of apixaban being cost-effective for a 
threshold of €20000/QALY is 96%, 87% and 95% compared to warfarin, dabigatran and 
rivaroxaban, respectively. If all the comparators are considered together, apixaban is the best 
alternative from a threshold of €8000/QALY. In this scenario, for a willingness to pay of 
€20000/QALY, the probability of apixaban being cost-effective is 70% (Figure 48). 
 




Figure 48: Cost-effectiveness acceptability curves showing the percentage of simulations for each 
willingness-to-pay value that are cost-effective for each treatment, enabling simultaneous comparison 
between all the therapeutic options. Apixaban is the best alter alternative from €8000/QALY. For a 
willingness to pay of €20000/QALY, the probability of apixaban being cost-effective compared to all the 





The results of the present study show that apixaban is cost-effective compared to warfarin and 
dabigatran (ICERs of €5529/QALY and €9163/QALY, respectively) and dominant compared 
to rivaroxaban. The probability of apixaban being cost-effective compared to all the other 
therapeutic options is 70% for a threshold of €20000/QALY. These conclusions were robust 
in all the sensitivity analyses performed. This information is useful for healthcare decision-
makers when selecting the best option for the individual patient. 
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5.3. Chapter discussion and conclusions 
 
Considering the previous chapters, one should agree that anticoagulation is increasing due to 
NOACs, and that no safety problems were observed nor any abnormal pattern of adverse 
events in the pharmacovigilance. Seems reasonable to assume that NOACs bring health 
advantages that should be weighed against the limited resources available, taking into account 
the high price of NOACs and the recent economic restrains. 
In order to evaluate the impact of NOACs in the Portuguese society and economy, first the 
reference condition – AF – was characterized in terms of cost and burden, and then NOACs 
were evaluated in terms of relative effectiveness, taking VKA as the common comparator. 
  
AF is an important public health issue, because it is the most common sustained arrhythmia in 
the clinical practice, and it is a risk factor for stroke, a significant cause of morbidity and 
mortality in Portugal 43. The risk of stroke is five times higher in patients with AF, increasing 
with age 32. Over 15% of strokes are due to AF and they are generally more severe than those 
not associated with AF 33,35. Stroke attributable to AF is associated with a 30-day mortality of 
25% and one-year mortality of 50% 30. These patients have longer hospital stays and greater 
use of health resources 32,33.  
According to the FAMA study, the prevalence AF in Portugal was estimated to be 2.5% in the 
population aged 40 and over, and more than 10% in those aged 80 and over; only 60% of 
cases were previously diagnosed and acknowledged. As in other countries, the prevalence of 
AF in Portugal is increasing, probably due to aging populations and better diagnosis. As an 
example of this trend, there were 4678 admissions with a primary diagnosis of AF in NHS 
hospitals in Portugal in 2008, while the corresponding figure for 2012 was 6765, an increase of 
45%. 
The burden of AF in terms of DALYs and costs to society are a clear statement of the 
seriousness of this condition in Portugal. Stroke is highly disabling and frequently results in 
early retirement; as well as the costs involved, the burden of AF reflects the fact that stroke in 
AF patients is particularly lethal and, for those who survive, disabling. 
The total burden of disease attributable to AF is 23084 DALYs. The overall cost of illness is 
estimated at €140.7 million, around 0.08% of Portugal's gross domestic product. 
Compared to other diseases/risk factor studied in Portugal, hypercholesterolemia, which is an 
ominous risk factor (for stroke, coronary artery disease and peripheral artery disease) was 
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estimated to be related to a loss of 43.773 DALYs while alcoholic beverages consumption 
retrieved a similar value (41.257 DALYs).25,34 From all conditions addressed, the tobacco 
smoking seems to have the greatest burden for society with 145.801 DALYs.23 
All the referred disease, with exception of AF, are risk factor for multiple diseases. In this 
analysis, for methodological reasons, the cost and burden of the disease only focused atrial 
fibrillation and its attributable fraction in stroke. The estimates are very likely to 
underestimated, because the results do not consider bleeding episodes, including intracranial 
hemorrhage, a major complication of the anticoagulant therapy. Even though the impact in 
the society is very important, holding important annual costs (more than €140 million). 
 
Having AF such a significant socio-economic impact in Portugal, it is essential to use the best 
available resources to address health care in AF patients. Nowadays, considering the known 
economic restrains, health care resources should be managed thoughtfully, because an increase 
in the expenses in a certain field will require a decrease in the investment in other areas. Using 
a cost-effectiveness and cost-utility approach  
There were few therapeutic options for this purpose for several decades, when warfarin was 
the reference treatment, but the development of NOACs has changed the picture. Since the 
NHS began reimbursing these drugs the number of patients using them has increased 
significantly, and it is likely that NHS spending on outpatient anticoagulation therapy 
(currently 4.5%, corresponding to more than €50 million in 2014) will rise further.240 In the 
light of this situation, it is important for health decision-makers to have access to estimates of 
the cost-effectiveness of these NOACs for stroke prevention in AF. 
Several cost-effectiveness studies have been published in which a specific NOAC was 
compared with warfarin. Without exception these studies, carried out in both Europe and the 
USA, have shown that the NOACs are cost-effective compared to warfarin.241 However, the 
results of these studies cannot be used for naive indirect cost-effectiveness comparisons, and 
they certainly do not reflect the situation in Portugal. An economic evaluation was, therefore, 
performed based on a previously published model212 which compared the three NOACs 
(available in Portugal until the first half of 2016: apixaban, dabigatran and rivaroxaban) to each 
other, which was adapted for the clinical setting. 
The results of the present study show that apixaban is cost-effective compared to warfarin and 
dabigatran (ICERs of €5529/QALY and €9163/QALY, respectively) and dominant compared 
to rivaroxaban. The probability of apixaban being cost-effective compared to all the other 
therapeutic options is 70% for a threshold of €20000/QALY. These results are in agreement 
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with those of studies in other European contexts, including Belgium,242 the Netherlands,234 the 
UK212,243 and France,244 in which apixaban was also cost-effective compared to warfarin and 
cost-effective or dominant compared to dabigatran and rivaroxaban. The fact that apixaban is 
the most cost-effective NOAC in these studies may be due to its greater effectiveness, which 
can be attributed to the lower rate of vascular events associated with its use, particularly 
ischemic stroke,212,244,245 major bleeding222 and event-related deaths.212,222 A logical consequence 
is that apixaban presents a lower event-related discontinuation rate and that patients remain 
under treatment for longer (and thereby benefit in terms of thromboembolic prevention). This 
lower discontinuation rate explains the higher total lifetime costs of apixaban therapy 
compared to the other NOACs. 
However, other studies have recently been published, in Norway235 and the UK,234,236 in which 
the results are different, with dabigatran being considered cost-effective compared to apixaban 
(both being superior to rivaroxaban). In these studies, incremental QALYs were 0.2%–1.3% 
higher with dabigatran than with apixaban, even though the numbers of vascular events used 
in the analysis were taken from the same clinical trials as those used in the present study. 
Various methodological differences may account for these conflicting results: (1) differences 
in modeling; (2) use of different non-event-related discontinuation rates; (3) modeling of 
mortality after the trial period; (4) use of different values for the utilities associated with each 
health state (the present study uses estimates based on Sullivan et al. in 2011,231 while the other 
studies were based on the values reported by the same group in 2006233); (5) different discount 
rates. 
All of these differences except the first were subjected to one-way sensitivity analysis in the 
present study that confirmed the robustness of the main results. Therefore, the differences 
between the studies cannot be explained by these parameters. They may thus be due to 
differences in modeling, including the ways in which the states of the Markov model are 
specified, different cycle lengths, the use of a single level of severity for stroke, and differences 
in cost estimates (which are influenced by the resources and characteristics of health care 
systems and the prices of drugs in each country). A quantitative analysis of these questions is 
beyond the scope of this study. 
Some studies have suggested that the cost-effectiveness of the NOACs depends on the level 
of anticoagulation control, in that they will tend to be more cost-effective when 
anticoagulation control is poor. In particular, it has been suggested that dabigatran is less cost-
effective in well-controlled patients.71,246 However, the results of sensitivity analysis for this 
parameter showed no significant differences 




In the study of cost and burden of AF, for methodological reasons, the results presented in 
this study underestimate the cost and burden of the disease. They do not consider bleeding 
episodes, including intracranial hemorrhage, a major complication of the anticoagulant therapy 
used as prophylaxis against stroke in AF patients. Heart failure associated to atrial fibrillation 
(e.g. tachymyopathy) was not accounted for the overall outpatients’ expenses, and loss of 
productivity. It is important to stress that the burden and cost shown could be lower because 
it is estimated that 40% of the patients are treated with oral anticoagulants. 
 
The cost-effectiveness study had limitations in terms of the data used, particularly for the 
number of events, since these were taken from clinical trials with short follow-up periods (2–3 
years), which may not reflect the actual effectiveness of each drug. Furthermore, in the 
absence of head-to-head comparisons between the NOACs, cost-effectiveness was estimated 
indirectly, using warfarin as a common comparator, and so it was not possible to control for 
differences in baseline patient characteristics, trial design, anticoagulation level or risk profile 
determined by CHADS2 score (although the results on the cost-effectiveness of apixaban are 
similar in the subpopulation with higher CHADS2 scores).
247 According to the literature review 
carried out by the authors of the present study, the estimates of effectiveness used in this 
study are consistent with those in published indirect comparisons and the results did not 
change when other estimates obtained by Bayesian methods were used.222  
In all studies of this chapter the consumption of resources in the outpatient care was 
estimated by a panel of experts from different regions and different specialties that handle 
with AF patients. 
In order to assess the robustness of the results obtained, a comprehensive sensitivity analysis 
for several factors was performed. The results are reassuring because qualitatively the results 
did not change, i.e. all NOACs remained in the cost-effectiveness quadrant, apixaban was 












NOACs shown to be cost-effective compared with VKA for the prevention of 
thromboembolic events in atrial fibrillation. In this model the apixaban showed to be cost-
effective compared to warfarin (ICER € 5529/ QALY) and dabigatran (ICER € 9163/ 
QALY), and dominant compared to rivaroxaban. This study considered an acceptability 
threshold for the payment of € 20000/QALY, and the likelihood of apixaban be cost-effective 
compared to the other options was 70%. Thus the NOACs may bring benefits in terms of 
health outcomes and resource utilization in a significant condition such as AF which leads 
yearly to the loss of 23,084 DALYs and has expenses of 141 million € (57% in direct costs and 
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AF is an important public health issue, particularly in Portugal, since it is a risk factor for 
stroke, a significant cause of morbidity and mortality in this country 43.  
About a third of Portuguese patients with AF are not aware of their condition. As AF can 
remain silent until complications occur55,56, clinical screening is indicated for individuals aged 
65 and over57. The main complications of AF are thromboembolic events, particularly stroke, 
which is among the most important causes of death and disability. Therefore, it is without 
surprise that AF holds an important impact, as shown in the cost of illness and burden of 
disease study. It was estimated that in 2013 AF was responsible for a cost of €140 million 
(about 0.08% of Portuguese gross domestic product) and 23084 DALYs 248.  Most of these 
DALYs and costs are related to stroke. The risk of stroke is five times higher in patients with 
AF, increasing with age32. Over 15% of strokes are due to AF and they are generally more 
severe than those not associated with AF 33,35. Stroke attributable to AF is associated with a 
30-day mortality of 25% and one-year mortality of 50% 30. These patients have longer hospital 
stays and greater use of health resources 32,33.  
 
It is well known that anticoagulation with VKA, such as warfarin, significantly decreases the 
risk of stroke and systemic embolism in these patients35. Nevertheless, according to the results 
presented in this dissertation78,192, the reported prevalence of anticoagulation in Portuguese AF 
patients is very low (40%) and the degree of anticoagulation control with VKA in those that 
are anticoagulated is suboptimal78,192. Thus, despite the evidence and the recommendations 
supporting the use of oral anticoagulants in AF patients, a significant proportion of the 
population at risk is not adequately anticoagulated. This scenario definitely contributes to the 
high AF associated mortality and morbidity. According to the estimates presented in this 
dissertation, the burden of disease attributable to AF in Portugal is about 23084 disability-
adjusted life years (DALYs). Therefore, there is still room for improvement and both 
prescription of oral anticoagulants and increased control of oral anticoagulation among AF 
patients is likely to have an important healthcare impact. 
 
NOACs have been proven to be at least as efficacious as other alternative treatment options, 
in particular VKA, with a more favorable pharmacological profile. As shown the use of 
NOACs is rising continuously. As known, individual RCTs are designed for efficacy outcomes 




analysis of phase III RCTs, in the absence of specific antidotes, support that NOACs 
(apixaban, dabigatran, edoxaban, rivaroxaban) are associated to a significantly decreased risk 
of major bleeding and fatal bleeding events compared to VKA. Intracranial hemorrhage risk is 
also lower, however the incidence of major GI, intraocular and pericardial bleeding events is 
comparable to VKA. Possible concerns about severe liver and renal adverse events, as well as 
insomnia risk and immunity issues (and infection risk) associated to NOACs are not 
supported by the data presented in this dissertation. The overall tolerability profile (serious 
adverse events) was more favorable with NOACs in comparison to VKA. Acceptability results 
(discontinuation risk) were heterogeneous, but the overall drug-related discontinuation risk 
was lower with NOACs in comparison to VKA. 
 
In Portugal, three of these NOACs have been reimbursed and widely available, following the 
published cost-effectiveness studies210,211, including the cost-effectiveness study presented in 
this dissertation182. NOACs are cost-effective interventions for the Portuguese reality. 
Therefore, taken into consideration the efficacy, safety, convenience and cost-effectiveness of 
NOACs, as well as the high incidence and prevalence of the target clinical indications (in 
particular AF), the rise of oral anticoagulants due to an increase of NOACs prescription is is 
expected as it follows a rational drug prescription. Following steps in the improvement of the 
use of oral anticoagulants/NOACs are related to specific prothrombotic indications or 
circumstances, to the optimal management of major bleeding events, including the use the 
new specific antidotes adequately, and keeping pharmacovigilance on track. It is critical to 
stress that the pharmacologic similarities of NOACs and VKA are minimal and that rules for 
VKA discontinuation should not be immediately extrapolated for NOACs249. In the other 
hand, the anticoagulant properties of NOACs are likely to be as effective as standard peri-
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6.1.1. Implications for research and clinical 
practice 
Research 
The results retrieved in this thesis showed that the proportion of patients previously 
anticoagulated was low and that the number of oral anticoagulants prescribed is increasing 
overtime. It remains unknown whether this prescription pattern owes mostly to the new 
diagnosed cases or to a change in the physicians’ attitude regarding patients with 
prothrombotic conditions, namely AF. A contemporary cross-sectional study of the 
prevalence of oral anticoagulation in AF patients in Portugal is mandatory in order to 
assess these data.  
It is important to mention that prescription data does not consider other important 
elements of successful drug therapy delivery: the compliance and persistence 251. In this 
field, antithrombotic drugs are critical as most of the studies show a low rate of persistence 
(<50%) including studies with NOACs252,253, which strongly suggests that this area should 
be improved. 
The use of antithrombotic drugs in prothrombotic conditions requires regular clinical 
supervision. Nowadays, is clear that in almost situations, the use of anticoagulants is 
recommended in diseases such as AF, despite the increased risk of bleeding with these 
drugs. Therefore, the critical question that requires to be research is which oral 
anticoagulant provides a better net clinical benefit174. This outcome is defined 
heterogeneously, as it results from different perceptions in how different outcomes should 
be combined. Despite all it seems extremely important to standardize the definition in 
order to proceed homogeneously with investigations, as previously recalled174. 
Despite the safety data presented in this dissertation, other potential safety issues such as 
the risk of myocardial infarction associated to NOACs should be addressed in the near 
future as uncertainty exists concerning some NOACs254-256. Trials are ongoing specifically 
designed to address NOACs safety in AF patients with coronary artery disease undergoing 
coronary stenting (RE-DUAL PCI NCT02164864; NCT02415400; NCT02334254). Rather 
than overviewing NOACs safety regarding myocardial infarction risk, they also aim to 
evaluate which may be the best combination of antithrombotic drugs in these patients 256.  
Another important remark concerns the observational studies (“real world data”) of 
patients treated with oral anticoagulants, particularly NOACs. These studies may be 
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hierarchically inferior to RCTs but have advantages concerning the absence of restrains in 
patients’ selection and well as the period of exposure to drugs which may be longer that 
RCTs and help to uncover potential long term adverse events. These studies are essential to 
ascertain the transferability of both efficacy and safety of trials towards effectiveness and 
population safety. National registries as occurs with acute coronary syndromes 
(NCT01642329) should be encouraged.  
 
Clinical practice 
The results presented show that NOACs have a good safety profile regarding bleeding and 
non-bleeding adverse events. Regarding bleeding events, in the absence of specific 
antidotes NOACs decreased the risk of major bleeding events (including fatal events). 
These results emphasize the safety of NOACs and that physician fears regarding the 
bleeding with these novel agents are not supported. Antidotes specific for NOACs are 
under development with promising results, in order to further improve healthcare and 
outcomes in bleeding patients21-25.  
With efficacy at least as similar to VKA and a good safety profile, the rise in the 
prescription of oral anticoagulants with NOACs, is likely to decrease the burden of AF in 
Portugal. There are still three important gaps in the care of these patients. The first is the 
development of a national guideline for atrial fibrillation, and second is the establishment 
of oral anticoagulant use as marker of healthcare quality in primary care setting and the 
third was the allowance of NOACs triplicate medical prescription to maintain long-term 
treatment. 
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6.2. Final remarks 
 
The proportion of patients treated with oral anticoagulants is increasing due to NOACs. 
These drugs overcame warfarin in term of prescriptions, improving a marker of quality in the 
management of some prothrombotic conditions such as AF, which was very low in Portugal 
where about 40% patients with AF were anticoagulated. NOACs also warrant a predictable 
anticoagulant effect without multiple drug-drug and drug-food interactions. The potential 
impact of this characteristic is inversely proportional to the degree of anticoagulation control 
with VKA, which was found to be low (TTR 61%). Therefore, NOACs may play an 
important role in the improvement of healthcare management of AF. This is particularly 
important because AF holds an important burden for society, and has important costs 
associated (0.08% of the GDP).  
 
Massive NOACs prescription, does not seem encompass any safety risks. The best available 
evidence from phase III RCTs supports that NOACs (apixaban, dabigatran, edoxaban, 
rivaroxaban) are associated to a significant decreased risk of major bleeding and fatal bleeding 
events compared to VKA. Intracranial hemorrhage risk is also decreased, however the 
incidence of major GI, intraocular and pericardial bleeding events is comparable to VKA. The 
other findings did not support the possible concerns about severe liver and renal adverse 
events, as well as insomnia risk and immunity issues (and infection risk) associated to NOACs. 
The overall tolerability profile (serious adverse events) was more favorable with NOACs in 
comparison to VKA. Acceptability results (discontinuation risk) were however heterogeneous, 
although the overall drug-related discontinuation risk was lower with NOACs in comparison 
to VKA. 
 
The number of spontaneously reported adverse events related to oral anticoagulants is 
increasing in Portugal. The number of ADRs weighted by the number of prescription has 
reached its peak in 2012 and has been decreasing since then. Although the majority of reports 
and ADRs were related to NOACs. One quarter of the reported NOACs ADRs were 
hemorrhagic and 10% were related to thromboembolic events (lack of efficacy), probably 






In the Portuguese scenario, all NOACs were cost-effective compared with VKA.  
In my opinion, NOACs are valuable therapeutic options under the right indications (such as 
non-valvular AF) and the data generated by the research projects presented in this dissertation 
support that the healthcare in the oral anticoagulation field has changed significantly towards 
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Search strategies for the systematic reviews 
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Search strategies for OVID/MEDLINE: 
3.2.1. Major bleeding, fatal bleeding events and major bleeding-
related mortality 
# Searches 
1 exp mortality/ 
2 exp Fatal outcome/ 
3 exp Hemorrhage/ 
4 (major adj2 (bleed* or hemorrhag* or haemorrhag*) adj3 (fatal or mortality or death)).af. 
5 1 or 2 
6 3 and 5 
7 4 or 6 












20 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 
21 randomized controlled trial.pt. 
22 controlled clinical trial.pt. 
23 randomized.ab. 




3.2.2. Major gastrointestinal bleeding 
# Searches 
1 exp Gastrointestinal Hemorrhage/ 
2 exp Hematemesis/ 
3 exp Melena/ 
4 exp Peptic Ulcer Hemorrhage/ 
5 gastrointestinal hemorrhage.af. 
6 Gastrointestinal haemorrhage.af. 
7 GI hemorrhage.af. 
8 gi haemorrhage.af. 
9 gastrointestinal bleed*.af. 
10 gi bleed*.af. 
11 Hematochezia.af. 
12 Haematochezia.af. 
13 (peptic ulcer* adj2 (bleed* or hemorrhage or haemorrhage)).af. 










28 21 or 22 or 23 or 24 or 25 or 26 or 27 
29 exp animals/ not humans.sh. 
30 28 not 29 
31 7 and 20 and 30 







26 new oral anticoagulant*.af. 
27 non-vitamin K oral anticoagulant*.af. 
28 non-vitamin K antagonist oral anticoagulant.af. 
29 savaysa.af. 
3.2.3. Intracranial hemorrhage 
# Searches 
1 (intracranial adj2 (bleed* or hemorrhag* or haemorrhag*)).af. 
2 exp Cerebral Hemorrhage/ 
3 exp Intracranial Hemorrhage, Hypertensive/ 
4 exp Intracranial Hemorrhage, Traumatic/ 
5 exp Subarachnoid Hemorrhage/ 
6 exp Hematoma, Epidural, Cranial/ 
7 exp Hematoma, Subdural/ 
8 1 or 2 or 3 or 4 or 5 or 6 or 7 
9 new oral anticoagulant*.af. 






16 9 or 10 or 11 or 12 or 13 or 14 
17 8 and 15 
18 randomized controlled trial.pt. 









26 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 
27 exp animals/ not humans.sh. 
28 25 not 26 
29 16 and 27 
3.2.4. Other major bleeding sites: intraocular hemorrhage 
# Searches 
1 exp eye hemorrhage/ 
2 intraocular hemorrhage.af. 
3 intraocular bleeding.af. 
4 Choroid Hemorrhage.af. 
5 Hyphema.af. 
6 Retinal Hemorrhage.af. 
7 Vitreous Hemorrhage.af. 
8 exp Choroid Hemorrhage/ 
9 exp Hyphema/ 
10 exp Retinal Hemorrhage/ 
11 exp Vitreous Hemorrhage/ 
12 hemovitreous.af. 













24 new oral anticoagulant*.af. 
25 non-vitamin K oral anticoagulant.af. 
26 non-vitamin K antagonist oral anticoagulant.af. 
27 darexaban.af. 
28 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 
29 13 and 28 
















15 new oral anticoagulant*.af. 
16 non-vitamin K oral anticoagulant.af. 
17 non-vitamin K antagonist oral anticoagulant.af. 
18 darexaban.af. 
19 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 
20 4 and 19 
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11 randomized controlled trial.pt. 
12 controlled clinical trial.pt. 
13 randomized.ab. 
14 placebo.ab. 




19 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 
20 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 
20 19 and 20 
*High sensitivity search, without considering the outcome








7 1 or 2 or 3 or 4 or 5 or 6 
APPENDIX 
423 
8 atrial fibrillation.ti,ab. 
9 exp atrial fibrillation/ 
10 8 or 9 
11 (renal adj2 disease).ti,ab. 
12 (renal adj2 failure).ti,ab. 
13 (renal adj2 dysfunction).ti,ab. 
14 (renal adj2 injury).ti,ab. 
15 (kidney adj2 disease).ti,ab. 
16 (kidney adj2 dysfunction).ti,ab. 
17 (kidney adj2 failure).ti,ab. 
18 11 or 12 or 13 or 14 or 15 or 16 or 17 
19 randomized controlled trial.pt. 
20 controlled clinical trial.pt. 
21 randomized.ab. 
22 clinical trials as topic.sh. 
23 randomly.ab. 
24 trial.ti. 
25 19 or 20 or 21 or 22 or 23 or 24 
26 exp animals/ not humans.sh. 
27 25 not 26 
28 7 and 10 and 18 and 27 
SEARCH STRATEGIES 
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11 randomized controlled trial.pt. 
12 controlled clinical trial.pt. 
13 randomized.ab. 
14 placebo.ab. 




19 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 
20 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 
20 19 and 20 
*High sensitivity search, without considering the outcome
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